<!DOCTYPE html>

<html id="htmlEl" lang="en">
<!-- NVCGPDQCancerInfoSummaryTemplate.aspx  -->

<head id="header">
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, user-scalable=no, initial-scale=1, maximum-scale=1, minimum-scale=1, shrink-to-fit=no"
    />
    <title>
        Bladder Cancer Treatment (PDQ®)—Health Professional Version - National Cancer Institute
    </title>
    <script src="//assets.adobedtm.com/f1bfa9f7170c81b1a9a9ecdcc6c5215ee0b03c84/satelliteLib-5b3dcf1f2676c378b518a1583ef5355acd83cd3d.js"></script>

    <link rel="apple-touch-icon" sizes="180x180" href="/publishedcontent/images/images/design-elements/icons/favicons/apple-touch-icon.png?v=oLa52veKe8"
    />
    <link rel="icon" type="image/png" href="/publishedcontent/images/images/design-elements/icons/favicons/favicon-32x32.png?v=oLa52veKe8"
        sizes="32x32" />
    <link rel="icon" type="image/png" href="/publishedcontent/images/images/design-elements/icons/favicons/favicon-16x16.png?v=oLa52veKe8"
        sizes="16x16" />
    <link rel="manifest" href="/publishedcontent/images/images/design-elements/icons/favicons/manifest.json?v=oLa52veKe8"
    />
    <link rel="mask-icon" href="/publishedcontent/images/images/design-elements/icons/favicons/safari-pinned-tab.svg?v=oLa52veKe8"
        color="#c0143c" />
    <link rel="shortcut icon" href="/publishedcontent/images/images/design-elements/icons/favicons/favicon.ico?v=oLa52veKe8"
    />
    <meta name="apple-mobile-web-app-title" content="Cancer.gov" />
    <meta name="application-name" content="Cancer.gov" />
    <meta name="msapplication-config" content="/publishedcontent/images/images/design-elements/icons/favicons/browserconfig.xml?v=oLa52veKe8"
    />
    <meta name="theme-color" content="#ffffff" />
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.1.1/jquery.min.js" type="text/javascript"></script>
    <script src="https://ajax.googleapis.com/ajax/libs/jqueryui/1.12.1/jquery-ui.min.js" type="text/javascript"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.9.3/headroom.min.js" type="text/javascript"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.touchswipe/1.6.18/jquery.touchSwipe.min.js" type="text/javascript"></script>
    <script src="/PublishedContent/js/cdeConfig.__v8917209c695fcb08fe4d652b341588b5.js" type="text/javascript"></script>
    <link href="/PublishedContent/Styles/nvcg.__vf22c303f1ae146123b7f57c66724b4fb.css" rel="stylesheet" />
    <script src="/PublishedContent/js/Common.__v0c0008cca6fece97c1aecd98d5e16507.js" type="text/javascript"></script>
    <script src="/PublishedContent/js/ContentPage.__v3e3221d75bd4a76e5be1f195d8e871a1.js" type="text/javascript"></script>
    <script src="/PublishedContent/js/PDQPage.__ve1272c34083e65ac22ef5b5b42736cb2.js" type="text/javascript"></script>
    <link rel="canonical" href="https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq" />
    <meta name="keywords" content="bladder cancer" />
    <meta name="description" content="Expert-reviewed information summary about the treatment of bladder cancer." />
    <meta name="content-language" content="en" />
    <meta name="english-linking-policy" content="/policies/linking" />
    <meta name="espanol-linking-policy" content="/espanol/politicas/enlaces" />
    <meta name="dcterms.type" content="pdqCancerInfoSummary" />
    <meta property="og:title" content="Bladder Cancer Treatment" />
    <meta property="og:description" content="Expert-reviewed information summary about the treatment of bladder cancer."
    />
    <meta property="og:type" content="Website" />
    <meta property="og:site_name" content="National Cancer Institute" />
    <meta property="og:url" content="https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq" />
    <meta name="twitter:card" content="summary" />
    <link rel="schema.dcterms" href="http://purl.org/dc/terms/" />
    <link href="https://www.cancer.gov/espanol/tipos/vejiga/pro/tratamiento-vejiga-pdq" hreflang="es" rel="alternate" />
    <link href="https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq" hreflang="en" rel="alternate" />
</head>

<body id="Body1" class="pdqcancerinfosummary" data-cde-contenttype="pdqcancerinfosummary" data-cde-pagetemplate="NVCGPDQCancerInfoSummaryTemplate"
    data-cde-templatetheme="default" data-cde-contentid="3394">
    <div class="skip">
        <a title="Skip to content" href="#main">Skip to content</a>
    </div>
    <!-- NOTIFICATION AREA -->


    <!-- END NOTIFICATION AREA -->

    <!-- HEADER -->
    <header class="push" role="banner">
        <div id="nvcgSlSiteBanner" class="row">
            <div class="contentid-911584 slot-item only-SI nci-logo-pages large-12 columns">

                <a href="/">
                    <!--[if gt IE 8]><!-->
                    <img src="/publishedcontent/images/images/design-elements/logos/nci-logo-full.svg" alt="National Cancer Institute">
                    <!--<![endif]-->
                    <!--[if lte IE 8]> <img class="nci-logo-IE-xl" src="/publishedcontent/images/images/design-elements/logos/nci-logo-xl.gif" alt="National Cancer Institute"> <img class="nci-logo-IE-desk" src="/publishedcontent/images/images/design-elements/logos/nci-logo-desk.gif" alt="National Cancer Institute"> <img class="nci-logo-IE-tab" src="/publishedcontent/images/images/design-elements/logos/nci-logo-tab.gif" alt="National Cancer Institute"> <img class="nci-logo-IE-phon" src="/publishedcontent/images/images/design-elements/logos/nci-logo-phon.gif" alt="National Cancer Institute"> <![endif]-->
                </a>
            </div>
        </div>
    </header>
    <!-- END HEADER -->
    <!-- Begin Page -->
    <div id="page">
        <!-- Global nav/utilit bar/language  -->
        <div class="fixedtotop">
            <div class="headroom-area">
                <!-- LANGUAGE BAR -->
                <div class="language-bar">
                    <div class="row sitewide-language">
                        <div id="LangList1" class="large-12 columns">
                            <ul>
                                <li>
                                    <a onclick="NCIAnalytics.ClickLink(this,&#39;Language Select Spanish&#39;);" href="/espanol/tipos/vejiga/pro/tratamiento-vejiga-pdq">Español</a>
                                </li>
                            </ul>
                        </div>
                    </div>
                </div>
                <!-- end "language-bar" -->
                <!-- END LANGUAGE BAR -->

                <!-- UTILITY NAV -->
                <div id="nvcgSlUtilityBar" class="utility-background hide-for-medium-down">
                    <div class="contentid-911757 slot-item only-SI row utility">
                        <div class="rawHtml">
                            <div class="large-12 columns utility">
                                <span>
                                    <a href="/contact">1-800-4-CANCER</a>
                                </span>
                                <span>
                                    <a href="https://livehelp.cancer.gov" onclick="window.open('https://livehelp.cancer.gov/', 'LiveHelp','scrollbars=yes,resizable=yes,menubar=yes,toolbar=yes,location=yes,width=650,height=600'); return false;">Live Chat</a>
                                </span>
                                <span>
                                    <a href="/publications">Publications</a>
                                </span>
                                <span id="utility-dictionary" class="link">
                                    <a href="/publications/dictionaries/cancer-terms">Dictionary</a>
                                </span>
                            </div>
                        </div>
                    </div>
                </div>
                <!-- END UTILITY NAV -->
            </div>
            <!-- end "headroom-area" -->
            <!-- BEGIN NAVIGATION -->
            <!-- Begin nav-search bar -->
            <div class="nav-search-bar gradient header">
                <div id="nvcgSlMainNav" class="row">
                    <div class="contentid-113330 slot-item first-SI">
                        <div class="navigation">
                            <div class="mobile-menu-bar">
                                <button type="button" class="open-panel nav-header menu-btn">Menu</button>
                                <a href="/global/contact" class="nav-contact">Contact</a>
                                <a href="/publications/dictionaries/cancer-terms" class="nav-dictionary">Dictionary</a>
                                <button type="button" class="nav-search">Search</button>
                            </div>
                            <nav id="mega-nav" role="navigation">
                                <ul class="menu nav-menu">
                                    <li class="nav-item lvl-1 has-children item-1">
                                        <div class="nav-item-title">
                                            <a href="/about-cancer">About Cancer</a>
                                        </div>
                                        <ul class="mobile-item">
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/about-cancer/causes-prevention">Causes and Prevention</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/causes-prevention/risk">Risk Factors </a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/causes-prevention/genetics">Genetics</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/causes-prevention/patient-prevention-overview-pdq">Cancer Prevention Overview</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/causes-prevention/research">Research</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/about-cancer/screening">Cancer Screening</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/screening/patient-screening-overview-pdq">Cancer Screening Overview</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/screening/screening-tests">Screening Tests</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/screening/research">Research</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/about-cancer/diagnosis-staging">Diagnosis and Staging</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/diagnosis-staging/symptoms">Symptoms </a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/diagnosis-staging/diagnosis">Diagnosis</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/diagnosis-staging/staging">Staging</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/diagnosis-staging/prognosis">Prognosis</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/diagnosis-staging/questions">Questions to Ask about Your Diagnosis</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/diagnosis-staging/research">Research</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/about-cancer/treatment">Cancer Treatment</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/treatment/types">Types of Cancer Treatment</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/treatment/side-effects">Side Effects</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/treatment/clinical-trials">Clinical Trials Information</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/treatment/drugs">A to Z List of Cancer Drugs</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/treatment/cam">Complementary & Alternative Medicine (CAM)</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/treatment/questions">Questions to Ask about Your Treatment</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/treatment/research">Research</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/about-cancer/coping">Coping with Cancer</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/coping/feelings">Feelings and Cancer</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/coping/adjusting-to-cancer">Adjusting to Cancer</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/coping/self-image">Self-Image & Sexuality</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/coping/day-to-day">Day-to-Day Life</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/coping/caregiver-support">Support for Caregivers</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/coping/survivorship">Survivorship</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/coping/questions">Questions to Ask About Cancer</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/coping/research">Research</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/about-cancer/advanced-cancer">Advanced Cancer</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/advanced-cancer/care-choices">Choices for Care</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/advanced-cancer/talking">Talking about Your Advanced Cancer</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/advanced-cancer/feelings">Coping with Your Feelings</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/advanced-cancer/planning">Planning for Advanced Cancer</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/advanced-cancer/caregivers">Advanced Cancer and Caregivers</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/advanced-cancer/questions">Questions to Ask about Advanced Cancer</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/advanced-cancer/research">Research</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/about-cancer/managing-care">Managing Cancer Care</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/managing-care/services">Finding Health Care Services</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/managing-care/track-care-costs">Costs & Medical Information</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/managing-care/advance-directives">Advance Directives</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/managing-care/using-trusted-resources">Using Trusted Resources</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/about-cancer/understanding">Understanding Cancer</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/understanding/what-is-cancer">What Is Cancer?</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/understanding/statistics">Cancer Statistics</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-cancer/understanding/disparities">Cancer Disparities</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                        </ul>
                                        <div aria-expanded="false" aria-haspopup="true" class="sub-nav-mega">
                                            <div class="sub-nav-group-wrapper">
                                                <div class="sub-nav-group-subwrapper">
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/about-cancer/understanding" class="sub-nav-group-header">Understanding Cancer</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/about-cancer/understanding/what-is-cancer">What Is Cancer</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/understanding/statistics">Cancer Statistics</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/understanding/disparities">Cancer Disparities</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/about-cancer/causes-prevention" class="sub-nav-group-header">Causes &amp; Prevention</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/about-cancer/causes-prevention/risk">Risk Factors</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/causes-prevention/genetics">Genetics</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/causes-prevention/patient-prevention-overview-pdq">Cancer Prevention Overview</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/about-cancer/screening" class="sub-nav-group-header">Screening</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/about-cancer/screening/patient-screening-overview-pdq">Cancer Screening Overview</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/screening/screening-tests">Screening Tests</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/about-cancer/diagnosis-staging" class="sub-nav-group-header">Diagnosis &amp; Staging</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/about-cancer/diagnosis-staging/symptoms">Symptoms</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/diagnosis-staging/diagnosis">Diagnosis</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/diagnosis-staging/staging">Staging</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/diagnosis-staging/prognosis">Prognosis</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/about-cancer/treatment" class="sub-nav-group-header">Treatment</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/about-cancer/treatment/types">Types of Treatment</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/treatment/side-effects/">Side Effects</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/treatment/clinical-trials">Clinical Trials</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/treatment/drugs">Cancer Drugs</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/treatment/cam">Complementary &amp; Alternative Medicine</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/about-cancer/coping" class="sub-nav-group-header">Coping</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/about-cancer/coping/feelings">Feelings &amp; Cancer</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/coping/adjusting-to-cancer">Adjusting to Cancer</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/coping/self-image">Self Image &amp; Sexuality</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/coping/day-to-day">Day to Day Life</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/coping/survivorship">Survivorship</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/coping/caregiver-support">Support for Caregivers</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/coping/questions">Questions to Ask About Cancer</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/about-cancer/advanced-cancer" class="sub-nav-group-header">Advanced Cancer</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/about-cancer/advanced-cancer/care-choices">Choices For Care</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/advanced-cancer/talking">Talking About Advanced Cancer</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/advanced-cancer/feelings">Coping With Your Feelings</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/advanced-cancer/planning">Planning for Advanced Cancer</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/advanced-cancer/caregivers">Advanced Cancer &amp; Caregivers</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/about-cancer/managing-care" class="sub-nav-group-header">Managing Cancer Care</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/about-cancer/managing-care/services">Finding Health Care Services</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/managing-care/track-care-costs">Managing Costs and Medical Information</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/managing-care/advance-directives">Advance Directives</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-cancer/managing-care/using-trusted-resources">Using Trusted Resources</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                </div>
                                            </div>
                                        </div>
                                    </li>
                                    <li class="nav-item lvl-1 contains-current has-children item-2">
                                        <div class="nav-item-title">
                                            <a href="/types">Cancer Types</a>
                                        </div>
                                        <ul class="mobile-item">
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/types/aya">Adolescents and Young Adults with Cancer</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/types/aya/research">Reports, Research, and Literature</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2">
                                                <div class="nav-item-title">
                                                    <a href="/types/by-body-location">Cancers by Body Location/System</a>
                                                </div>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/types/childhood-cancers">Childhood Cancers</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/types/childhood-cancers/late-effects-pdq">Late Effects of Childhood Cancer Treatment</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/types/childhood-cancers/pediatric-care-pdq">Pediatric Supportive Care</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/types/childhood-cancers/patient/unusual-cancers-childhood-pdq">Unusual Cancers of Childhood Treatment</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/types/childhood-cancers/pediatric-genomics-hp-pdq">Childhood Cancer Genomics</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/types/childhood-cancers/research">Study Findings</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/types/metastatic-cancer">Metastatic Cancer</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/types/metastatic-cancer/research">Metastatic Cancer Research</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2">
                                                <div class="nav-item-title">
                                                    <a href="/types/common-cancers">Common Cancer Types</a>
                                                </div>
                                            </li>
                                            <li class="lvl-2">
                                                <div class="nav-item-title">
                                                    <a href="/types/recurrent-cancer">Recurrent Cancer</a>
                                                </div>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/types/midline/patient-child-midline-tract-carcinoma-treatment-pdq">Midline Tract Carcinoma</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/types/midline/patient-child-midline-tract-carcinoma-treatment-pdq">Childhood Midline Tract Carcinoma Treatment</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/types/midline/hp-child-midline-tract-carcinoma-treatment-pdq">Health Professional</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                        </ul>
                                        <div aria-expanded="false" aria-haspopup="true" class="sub-nav-mega">
                                            <div class="sub-nav-group-wrapper">
                                                <div class="sub-nav-group-subwrapper">
                                                    <ul class="sub-nav-group cancer-types-border-container">
                                                        <li>
                                                            <a href="/types/common-cancers" class="sub-nav-group-header">Common Cancer Types</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/types/bladder">Bladder Cancer</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/types/breast">Breast Cancer</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/types/colorectal">Colorectal Cancer</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/types/kidney">Kidney (Renal Cell) Cancer</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/types/leukemia">Leukemia</a>
                                                                </li>
                                                            </ul>
                                                            <ul>
                                                                <li>
                                                                    <a href="/types/liver">Liver Cancer</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/types/lung">Lung Cancer</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/types/lymphoma">Lymphoma</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/types/pancreatic">Pancreatic Cancer</a>
                                                                </li>
                                                            </ul>
                                                            <ul>
                                                                <li>
                                                                    <a href="/types/prostate">Prostate Cancer</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/types/skin">Skin Cancer</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/types/thyroid">Thyroid Cancer</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/types/uterine">Uterine Cancer</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/types" class="sub-nav-group-header">All Cancer Types</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/types">A to Z List of Cancers</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/types/by-body-location">Cancers by Body Location</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/types/childhood-cancers">Childhood Cancers</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/types/aya">Adolescent &amp; Young Adult Cancers</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/types/metastatic-cancer">Metastatic Cancer</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/types/recurrent-cancer">Recurrent Cancer</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                </div>
                                            </div>
                                        </div>
                                    </li>
                                    <li class="nav-item lvl-1 has-children item-3">
                                        <div class="nav-item-title">
                                            <a href="/research">Research</a>
                                        </div>
                                        <ul class="mobile-item">
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/research/nci-role">NCI’s Role in Cancer Research</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/nci-role/intramural">Intramural Research</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/nci-role/extramural">Extramural Research</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/nci-role/bioinformatics">Bioinformatics and Cancer</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/nci-role/cancer-centers">NCI-Designated Cancer Centers</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/nci-role/fnlcr">Frederick National Laboratory for Cancer Research </a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/nci-role/partners-collaborators">Partners & Collaborators</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/nci-role/spotlight">Spotlight on Scientists</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/research/areas">Research Areas</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/areas/biology">Cancer Biology Research</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/areas/genomics">Cancer Genomics Research</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/areas/causes">Research on Causes of Cancer</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/areas/diagnosis">Cancer Diagnosis Research </a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/areas/prevention">Cancer Prevention Research </a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/areas/screening">Screening & Early Detection</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/areas/treatment">Cancer Treatment Research</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/areas/public-health">Cancer & Public Health</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/areas/disparities">Cancer Health Disparities</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/areas/childhood">Childhood Cancers</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/areas/clinical-trials">Clinical Trials</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/areas/global-health">Global Cancer Research</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/research/key-initiatives">Key Initiatives</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/key-initiatives/ras">The RAS Initiative</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/key-initiatives/moonshot-cancer-initiative">Cancer Moonshot℠</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/research/progress">Progress</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/progress/annual-report-nation">Annual Report to the Nation</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/progress/250-years-milestones">Milestones in Cancer Research and Discovery</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/progress/discovery">Stories of Discovery</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/research/resources">Research Tools, Specimens, and Data</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/resources/conducting">Conducting Clinical Trials</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/resources/statistical-tools">Statistical Tools and Data</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/resources/terminology">Terminology Resources</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/resources/data-catalog">NCI Data Catalog</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/research/resources/cryoem">Cryo-EM</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                        </ul>
                                        <div aria-expanded="false" aria-haspopup="true" class="sub-nav-mega">
                                            <div class="sub-nav-group-wrapper">
                                                <div class="sub-nav-group-subwrapper">
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/research/nci-role" class="sub-nav-group-header">NCI's Role in Cancer Research</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/research/nci-role/intramural">Intramural Research</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/research/nci-role/extramural">Extramural Research</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/research/nci-role/bioinformatics">Bioinformatics and Cancer</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/research/nci-role/cancer-centers">NCI-Designated Cancer Centers</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/research/nci-role/fnlcr">Frederick National Lab</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/research/nci-role/partners-collaborators">Partners &amp; Collaborators</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/research/nci-role/spotlight">Spotlight on Scientists</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/research/areas" class="sub-nav-group-header">NCI Research Areas</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/research/areas/biology">Cancer Biology</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/research/areas/genomics">Cancer Genomics</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/research/areas/causes">Causes of Cancer</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/research/areas/diagnosis">Diagnosis</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/research/areas/prevention">Prevention</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/research/areas/screening">Screening &amp; Early Detection</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/research/areas/treatment">Treatment</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/research/areas/public-health">Cancer &amp; Public Health</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/research/areas/disparities">Cancer Health Disparities</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/research/areas/childhood">Childhood Cancer</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/research/areas/clinical-trials">Clinical Trials</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/research/areas/global-health">Global Health</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/research/key-initiatives" class="sub-nav-group-header">Key Initiatives</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/research/key-initiatives/moonshot-cancer-initiative">Cancer Moonshot</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-nci/organization/ccg/research/computational-genomics/gdc">Genomic Data Commons</a>
                                                                </li>
                                                                <!--
			<li><a href="https://ncorp.cancer.gov/">NCI Community Oncology Research Program</a></li>
-->
                                                                <li>
                                                                    <a href="/research/areas/clinical-trials/nctn">National Clinical Trials Network</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/research/key-initiatives/ras">RAS Initiative</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/research/progress" class="sub-nav-group-header">Progress</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/research/progress/annual-report-nation">Annual Report to the Nation</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/research/progress/discovery">Stories of Discovery</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                        <br />
                                                        <br />
                                                        <li>
                                                            <a href="/research/resources" class="sub-nav-group-header">Research Tools, Specimens, and Data</a>
                                                        </li>
                                                    </ul>
                                                </div>
                                            </div>
                                        </div>
                                    </li>
                                    <li class="nav-item lvl-1 has-children item-4">
                                        <div class="nav-item-title">
                                            <a href="/grants-training">Grants & Training</a>
                                        </div>
                                        <ul class="mobile-item">
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/grants-training/grants-funding">Research Grants</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/grants-funding/funding-opportunities">Funding Opportunities</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/grants-funding/contacts">Research Program Contacts</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/grants-funding/funding-strategy">Funding Strategy</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/grants-training/policies-process">Grants Policies and Process</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/policies-process/overview">Introduction to Grants Process</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/policies-process/nci-policies">NCI Grant Policies</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/policies-process/legal">Legal Requirements</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/grants-training/apply-grant">Apply for a Grant</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/apply-grant/development">Step 1: Application Development & Submission</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/apply-grant/receipt">Step 2: Application Receipt & Assignment</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/apply-grant/peer-review">Step 3: Peer Review and Funding Outcomes</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/apply-grant/award-issuance">Step 4: Award Negotiation & Issuance</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/grants-training/manage-award">Manage Your Award</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/manage-award/contacts">Grants Management Contacts</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/manage-award/monitoring">Monitoring</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/manage-award/prior-approvals">Prior Approvals</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/manage-award/report-audit">Annual Reporting and Auditing</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/manage-award/grant-transfer">Transfer of a Grant</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/manage-award/grant-closeout">Grant Closeout</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/grants-training/training">Training</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/training/at-nci">Cancer Training at NCI</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/training/funding">Funding for Cancer Training</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/training/idwb">Building a Diverse Workforce</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/training/other">Other Fellowships and Internships</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/training/about">About Center for Cancer Training (CCT)</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/grants-training/training/contact">CCT Staff & Contact</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                        </ul>
                                        <div aria-expanded="false" aria-haspopup="true" class="sub-nav-mega">
                                            <div class="sub-nav-group-wrapper">
                                                <div class="sub-nav-group-subwrapper">
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/grants-training/grants-funding" class="sub-nav-group-header">Research Grants</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/grants-training/grants-funding/funding-opportunities">Funding Opportunities</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/grants-training/grants-funding/contacts">Research Program Contacts</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/grants-training/grants-funding/funding-strategy">Funding Strategy</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                        <br />
                                                        <li>
                                                            <a href="/grants-training/policies-process" class="sub-nav-group-header">Grants Policies &amp; Process</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/grants-training/policies-process/overview">Introduction to Grants Process</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/grants-training/policies-process/legal">Legal Requirements</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/grants-training/policies-process/nci-policies">NCI Policies</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/grants-training/apply-grant" class="sub-nav-group-header">Apply for a Grant</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/grants-training/apply-grant/development">Application Development &amp; Submission</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/grants-training/apply-grant/receipt">Receipt &amp; Assignment</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/grants-training/apply-grant/peer-review">Peer Review &amp; Outcomes</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/grants-training/apply-grant/award-issuance">Award Issuance</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/grants-training/manage-award" class="sub-nav-group-header">Manage Your Award</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/grants-training/manage-award/contacts">Grants Management Contacts</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/grants-training/manage-award/monitoring">Monitoring</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/grants-training/manage-award/prior-approvals">Prior Approvals</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/grants-training/manage-award/report-audit">Annual Reporting &amp; Auditing</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/grants-training/manage-award/grant-transfer">Grant Transfer</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/grants-training/manage-award/grant-closeout">Grant Closeout</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                        <br />
                                                        <li>
                                                            <a href="/grants-training/contracts-business" class="sub-nav-group-header">Contracts &amp; Small Business</a>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/grants-training/training" class="sub-nav-group-header">Training</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/grants-training/training/at-nci">Cancer Training at NCI (Intramural)</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/grants-training/training/funding">Funding for Cancer Training (Extramural)</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/grants-training/training/diversity-training">Building a Diverse Workforce</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/grants-training/training/other">Other Fellowships &amp; Internships</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/grants-training/training/contact">Training Program Contacts</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                </div>
                                            </div>
                                        </div>
                                    </li>
                                    <li class="nav-item lvl-1 has-children item-5">
                                        <div class="nav-item-title">
                                            <a href="/news-events">News & Events</a>
                                        </div>
                                        <ul class="mobile-item">
                                            <li class="lvl-2">
                                                <div class="nav-item-title">
                                                    <a href="/news-events/press-releases/2017">Press Releases</a>
                                                </div>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/news-events/media-resources">Resources for News Media</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/news-events/media-resources/contacts">Media Contacts</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/news-events/media-resources/multicultural">Multicultural Media Outreach Program</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/news-events/media-resources/reporting-fellowships">Cancer Reporting Fellowships</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/news-events/events">Events</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/news-events/events/scientific-meetings">Scientific Meetings & Lectures</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/news-events/events/conferences">Conferences</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/news-events/events/advisory-board-meetings">Advisory Board Meetings</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/news-events/events/social-media">Social Media Events</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2">
                                                <div class="nav-item-title">
                                                    <a href="/news-events/cancer-currents-blog">Cancer Currents Blog</a>
                                                </div>
                                            </li>
                                        </ul>
                                        <div aria-expanded="false" aria-haspopup="true" class="sub-nav-mega">
                                            <div class="sub-nav-group-wrapper">
                                                <div class="sub-nav-group-subwrapper">
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/news-events/press-releases/2017" class="sub-nav-group-header">All Press Releases</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/news-events/press-releases/2017">2017</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/news-events/press-releases/2016">2016</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/news-events/press-releases/2015">2015</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/news-events/press-releases/2014">2014</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/news-events/press-releases/2013">2013</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/news-events/press-releases/2012">2012</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/news-events/media-resources" class="sub-nav-group-header">Media Resources</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/news-events/media-resources/contacts">Media Contacts</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/news-events/media-resources/multicultural">Multicultural Media</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/news-events/events" class="sub-nav-group-header">Events</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/news-events/events/scientific-meetings">Scientific Meetings &amp; Lectures</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/news-events/events/conferences">Conferences</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/news-events/events/advisory-board-meetings">Advisory Board Meetings</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/news-events/events/social-media">Social Media</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/news-events/cancer-currents-blog" class="sub-nav-group-header">Cancer Currents Blog</a>
                                                        </li>
                                                    </ul>
                                                </div>
                                            </div>
                                        </div>
                                    </li>
                                    <li class="nav-item lvl-1 has-children item-6">
                                        <div class="nav-item-title">
                                            <a href="/about-nci">About NCI</a>
                                        </div>
                                        <ul class="mobile-item">
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/about-nci/overview">NCI Overview</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-nci/overview/history">History</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-nci/overview/contributing">Contributing to Cancer Research</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/about-nci/leadership">Leadership</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-nci/leadership/director">Director's Page</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-nci/leadership/nci-deputy-director">Deputy Director's Page</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-nci/leadership/previous">Previous NCI Directors</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2">
                                                <div class="nav-item-title">
                                                    <a href="/about-nci/organization">NCI Organization</a>
                                                </div>
                                            </li>
                                            <li class="lvl-2">
                                                <div class="nav-item-title">
                                                    <a href="/about-nci/advisory-boards">Advisory Boards and Review Groups</a>
                                                </div>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/about-nci/budget">Budget & Appropriations</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-nci/budget/about-annual-plan">About the Annual Plan & Budget Proposal</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-nci/budget/congressional-justification">NCI Congressional Justification</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-nci/budget/fact-book">NCI Budget Fact Book</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="lvl-2">
                                                <div class="nav-item-title">
                                                    <a href="/about-nci/careers">Careers at NCI</a>
                                                </div>
                                            </li>
                                            <li class="lvl-2">
                                                <div class="nav-item-title">
                                                    <a href="/about-nci/visit">Visitor Information</a>
                                                </div>
                                            </li>
                                            <li class="lvl-2 has-children">
                                                <div class="nav-item-title">
                                                    <a href="/about-nci/legislative">Legislative Activities</a>
                                                </div>
                                                <ul class="mobile-item">
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-nci/legislative/hearings">Hearings & Testimonies </a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-nci/legislative/current-congress">Current Congress </a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-nci/legislative/history">Legislative History</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-nci/legislative/committees">Committees of Interest</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-nci/legislative/resources">Legislative Resources</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-nci/legislative/recent-public-laws">Recent Public Laws</a>
                                                        </div>
                                                    </li>
                                                    <li class="lvl-3">
                                                        <div class="nav-item-title">
                                                            <a href="/about-nci/legislative/contact">Contact</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                        </ul>
                                        <div aria-expanded="false" aria-haspopup="true" class="sub-nav-mega">
                                            <div class="sub-nav-group-wrapper">
                                                <div class="sub-nav-group-subwrapper">
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/about-nci/overview" class="sub-nav-group-header">Overview &amp; Mission</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/about-nci/overview/history">History of NCI</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-nci/overview/contributing">Contributing to Cancer Research</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/about-nci/leadership" class="sub-nav-group-header">Senior Leadership</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/about-nci/leadership/director">Director</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-nci/leadership/nci-deputy-director">Deputy Director</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-nci/leadership/previous">Previous Directors</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/about-nci/organization" class="sub-nav-group-header">NCI Organization</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/about-nci/organization">Divisions, Offices &amp; Centers</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/about-nci/advisory-boards" class="sub-nav-group-header">Advisory Boards &amp; Review Groups</a>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/about-nci/budget" class="sub-nav-group-header">Budget &amp; Appropriations</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/about-nci/budget/">Current Year Budget</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-nci/budget/plan">Annual Plan &amp; Budget Proposal</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-nci/budget/congressional-justification">Congressional Justification</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-nci/budget/fact-book">NCI Budget Fact Book</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/about-nci/legislative" class="sub-nav-group-header">Legislative Activities</a>
                                                            <ul>
                                                                <li>
                                                                    <a href="/about-nci/legislative/hearings">Hearings &amp; Testimonies</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-nci/legislative/current-congress">Current Congress</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-nci/legislative/history">Legislative History</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-nci/legislative/committees">Committees of Interest</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-nci/legislative/resources">Legislative Resources</a>
                                                                </li>
                                                                <li>
                                                                    <a href="/about-nci/legislative/recent-public-laws">Recent Public Laws</a>
                                                                </li>
                                                            </ul>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/about-nci/careers" class="sub-nav-group-header">Careers</a>
                                                        </li>
                                                    </ul>
                                                    <ul class="sub-nav-group">
                                                        <li>
                                                            <a href="/about-nci/visit" class="sub-nav-group-header">Visitor Information</a>
                                                        </li>
                                                    </ul>
                                                </div>
                                            </div>
                                        </div>
                                    </li>
                                </ul>
                            </nav>
                        </div>
                    </div>
                    <div class="contentid-911752 slot-item last-SI">
                        <div class="rawHtml">
                            <div class="search" role="search">
                                <form action="/search/results" method="post" id="siteSearchForm" name="siteSearchForm" onsubmit="NCIAnalytics.SiteWideSearch(this);">
                                    <label class="hidden" for="swKeyword">Search</label>
                                    <input placeholder="search" class="searchString ui-autocomplete-input" id="swKeyword" maxlength="255" name="swKeyword" onblur="bSearchBoxBool=false;"
                                        onfocus="bSearchBoxBool=true;" value="" autocomplete="off" type="text" aria-autocomplete="list"
                                        aria-haspopup="true">
                                    <button class="searchSubmit" id="sitesearch" onclick="return siteSearchSubmit();" type="submit">
                                        <span class="hidden">Search</span>
                                    </button>
                                </form>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            <!-- End nav-search bar -->

            <!-- END NAVIGATION -->
        </div>
        <!-- END Global nav/utility bar/language -->

        <!-- Begin MAIN CONTENT AREA -->
        <div class="main-content" id="content" tabindex="0">
            <div class="row general-page-body-container collapse">
                <div class="large-12 columns">
                    <div class="row">
                        <div id="cgvSlBreadcrumb" class="medium-8 columns bcrumbs">
                            <div class="contentid-870117 slot-item only-SI">
                                <ul class="breadcrumbs">
                                    <li>
                                        <a href="/">Home</a>
                                    </li>
                                    <li>
                                        <a href="/types">Cancer Types</a>
                                    </li>
                                    <li>
                                        <a href="/types/bladder">Bladder Cancer</a>
                                    </li>
                                    <li class="last-breadcrumb">
                                        <a href="/types/bladder/hp">Health Professional</a>
                                    </li>
                                </ul>
                            </div>
                        </div>
                    </div>
                    <!-- END "row" -->
                </div>
                <!-- END "large-12 columns" -->
                <div class="row">
                    <!--    SECTION NAVIGATION -->
                    <div id="nvcgSlSectionNav" class="medium-3 columns local-navigation">
                        <div class="contentid-939869 slot-item only-SI">
                            <div class="section-nav">
                                <ul>
                                    <li class="level-0 has-children">
                                        <div>
                                            <a href="/types/bladder">Bladder Cancer</a>
                                        </div>
                                        <ul>
                                            <li class="level-1 has-children">
                                                <div>
                                                    <a href="/types/bladder">Patient</a>
                                                </div>
                                                <ul style="display:none;">
                                                    <li class="level-2">
                                                        <div>
                                                            <a href="/types/bladder/patient/bladder-treatment-pdq">Bladder Cancer Treatment</a>
                                                        </div>
                                                    </li>
                                                    <li class="level-2">
                                                        <div>
                                                            <a href="/types/bladder/patient/bladder-screening-pdq">Bladder Cancer Screening</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="level-1 contains-current has-children">
                                                <div>
                                                    <a href="/types/bladder/hp">Health Professional</a>
                                                </div>
                                                <ul style="display:block;">
                                                    <li class="level-2 contains-current">
                                                        <div class="current-page">
                                                            <a href="/types/bladder/hp/bladder-treatment-pdq">Bladder Cancer Treatment</a>
                                                        </div>
                                                    </li>
                                                    <li class="level-2">
                                                        <div>
                                                            <a href="/types/bladder/hp/bladder-screening-pdq">Bladder Cancer Screening</a>
                                                        </div>
                                                    </li>
                                                </ul>
                                            </li>
                                            <li class="level-1">
                                                <div>
                                                    <a href="/types/bladder/research">Research</a>
                                                </div>
                                            </li>
                                        </ul>
                                    </li>
                                </ul>
                            </div>
                        </div>
                    </div>
                    <!--    END SECTION NAV -->
                    <div class="medium-9 columns contentzone" id="main" tabindex="0" role="main">
                        <!-- ********************************* BEGIN Page Content ********************************** -->
                        <article>

                            <!-- PUBLIC ARCHIVE BANNER -->
                            <div id="cgvPublicArchiveBannerSl" class="row collapse">
                                <div class="contentid-172410 slot-item only-SI large-12 columns">

                                </div>
                            </div>
                            <!-- END PUBLIC ARCHIVE BANNER -->

                            <div class="resize-content">
                                <!-- Begin resizeable area -->

                                <!-- PAGE TITLE -->
                                <h1>
                                    <span>Bladder Cancer Treatment (PDQ®)–Health Professional Version</span>
                                </h1>

                                <!-- END PAGE TITLE -->



                                <!-- PAGE OPTIONS -->
                                <script type="text/javascript">
                                    var addthis_share = {
                                        title: "Bladder Cancer Treatment"
                                    }
                                </script>
                                <script type="text/javascript">
                                    var addthis_config = {
                                        ui_language: "en",
                                        ui_508_compliant: true
                                    }
                                </script>
                                <div id="PageOptionsControl1" class="page-options no-resize">
                                    <ul>
                                        <li class="po-font-resize">
                                            <a title="Resize font" href="#">
                                                <img alt="Resize font" src="/publishedcontent/images/images/spacer.gif" />
                                            </a>
                                        </li>
                                        <li class="po-print">
                                            <a title="Print" onclick="NCIAnalytics.PrintLink(this);" href="#">
                                                <img alt="Print" src="/publishedcontent/images/images/spacer.gif" />
                                            </a>
                                        </li>
                                        <li class="po-email">
                                            <a title="Email" href="/common/popUps/PopEmail.aspx?title=Bladder+Cancer+Treatment+(PDQ%c2%ae)%e2%80%93Health+Professional+Version&amp;docurl=%2ftypes%2fbladder%2fhp%2fbladder-treatment-pdq&amp;language=en&amp;a=-1076771V808&amp;b=a30153"
                                                onclick="NCIAnalytics.eMailLink(this); dynPopWindow(&#39;/common/popUps/PopEmail.aspx?title=Bladder+Cancer+Treatment+%28PDQ%c2%ae%29%e2%80%93Health+Professional+Version&amp;docurl=%2ftypes%2fbladder%2fhp%2fbladder-treatment-pdq&amp;language=en&amp;a=-1076771V808&amp;b=a30153&#39;, &#39;emailPopUp&#39;, &#39;height=525,width=492&#39;); return false;">
                                                <img alt="Email" src="/publishedcontent/images/images/spacer.gif" />
                                            </a>
                                        </li>
                                        <li class="po-facebook">
                                            <a class="addthis_button_facebook add_this_btn" title="Facebook" onclick="NCIAnalytics.BookmarkShareClick(this);"
                                                href="#">
                                                <img alt="Facebook" src="/publishedcontent/images/images/spacer.gif" />
                                            </a>
                                        </li>
                                        <li class="po-twitter">
                                            <a class="addthis_button_twitter add_this_btn" title="Twitter" onclick="NCIAnalytics.BookmarkShareClick(this);"
                                                href="#">
                                                <img alt="Twitter" src="/publishedcontent/images/images/spacer.gif" />
                                            </a>
                                        </li>
                                        <li class="po-googleplus">
                                            <a class="addthis_button_google_plusone_share add_this_btn" title="Google+" onclick="NCIAnalytics.BookmarkShareClick(this);"
                                                href="#">
                                                <img alt="Google+" src="/publishedcontent/images/images/spacer.gif" />
                                            </a>
                                        </li>
                                        <li class="po-pinterest">
                                            <a class="addthis_button_pinterest_share add_this_btn" title="Pinterest" onclick="NCIAnalytics.BookmarkShareClick(this);"
                                                href="#">
                                                <img alt="Pinterest" src="/publishedcontent/images/images/spacer.gif" />
                                            </a>
                                        </li>
                                    </ul>
                                </div>
                                <script async="async" src="//s7.addthis.com/js/250/addthis_widget.js#pubid=xa-4ed7cc9f006efaac"
                                    type="text/javascript">

                                    </script>
                                <!-- END PAGE OPTIONS -->

                                <div id="cgvBody">
                                    <div class="contentid-3394 slot-item only-SI">
                                        <div class="summary-sections">

                                            <section id="_1">
                                                <h2>General Information About Bladder Cancer</h2>
                                                <div id="_section_1" class="pdq-sections">
                                                    <div class="pdq-hp-patient-toggle">
                                                        <a href="/types/bladder/patient/bladder-treatment-pdq">Go to Patient Version</a>
                                                    </div>
                                                    <section id="_10">
                                                        <h3 id="_10_toc">Incidence and Mortality</h3>
                                                        <p id="_357" tabindex="-1">Bladder cancer is the sixth most common cancer in the United States
                                                            after lung cancer, prostate cancer, breast cancer, colon cancer,
                                                            and lymphoma. It is the third most common cancer in men and the
                                                            eleventh most common cancer in women. Of the roughly 70,000 new
                                                            cases annually, about 53,000 are in men and about 18,000 are
                                                            in women. Of the roughly 15,000 annual deaths, more than 10,000
                                                            are in men and fewer than 5,000 are in women. The reasons for
                                                            this disparity between the sexes are not well understood. </p>
                                                        <p id="_11" tabindex="-1">Estimated new cases and deaths from bladder cancer in the United
                                                            States in 2018:[
                                                            <a href="#cit/section_1.1">1</a>]</p>
                                                        <div class="pdq-content-list">
                                                            <ul id="_12">
                                                                <li>New cases: 81,190.</li>
                                                                <li>Deaths: 17,240.</li>
                                                            </ul>
                                                        </div>
                                                    </section>
                                                    <section id="_13">
                                                        <h3 id="_13_toc">Anatomy</h3>
                                                        <p id="_316" tabindex="-1">The urinary tract consists of the kidneys, the ureters, the bladder,
                                                            and the urethra. The urinary tract is lined with transitional
                                                            cell urothelium from the renal pelvis to the proximal urethra.
                                                            Transitional cell carcinoma (also referred to as urothelial carcinoma)
                                                            can develop anywhere along this pathway. </p>
                                                        <figure id="figure_497" class="image-center">
                                                            <a href="/images/cdr/live/CDR765031.jpg" target="_blank" class="article-image-enlarge">Enlarge</a>
                                                            <img id="_497" alt="Anatomy of the male urinary system (left panel) and female urinary system (right panel); two-panel drawing showing the right and left kidneys, the ureters, the bladder filled with urine, and the urethra. The inside of the left kidney shows the renal pelvis. An inset shows the renal tubules and urine.  Also shown are the prostate and penis (left panel) and the uterus (right panel)."
                                                                title="Anatomy of the male urinary system (left panel) and female urinary system (right panel); two-panel drawing showing the right and left kidneys, the ureters, the bladder filled with urine, and the urethra. The inside of the left kidney shows the renal pelvis. An inset shows the renal tubules and urine.  Also shown are the prostate and penis (left panel) and the uterus (right panel)."
                                                                src="/images/cdr/live/CDR765031-750.jpg" />
                                                            <figcaption class="caption-container">Anatomy of the male urinary system (left panel) and female urinary
                                                                system (right panel) showing the kidneys, ureters, bladder,
                                                                and urethra. Urine is made in the renal tubules and collects
                                                                in the renal pelvis of each kidney. The urine flows from
                                                                the kidneys through the ureters to the bladder. The urine
                                                                is stored in the bladder until it leaves the body through
                                                                the urethra.</figcaption>
                                                        </figure>
                                                    </section>
                                                    <section id="_359">
                                                        <h3 id="_359_toc">Histopathology</h3>
                                                        <p id="_435" tabindex="-1">Under normal conditions, the bladder, the lower part of the kidneys
                                                            (the renal pelvises), the ureters, and the proximal urethra are
                                                            lined with a specialized mucous membrane referred to as transitional
                                                            epithelium (also called urothelium). Most cancers that form in
                                                            these tissues are transitional cell carcinomas (also called urothelial
                                                            carcinomas) that derive from transitional epithelium. (Refer
                                                            to the PDQ summaries on
                                                            <a href="/types/kidney/hp/kidney-treatment-pdq">Renal Cell Cancer Treatment</a> and
                                                            <a href="/types/kidney/hp/transitional-cell-treatment-pdq">Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment</a>
                                                            for more information.)</p>
                                                        <p id="_360" tabindex="-1">Transitional cell carcinoma of the bladder can be low-grade or high-grade:
                                                            </p>
                                                        <div class="pdq-content-list">
                                                            <ul id="_363">
                                                                <li>
                                                                    <strong>Low-grade</strong> bladder cancer often recurs in the
                                                                    bladder after treatment but rarely invades the muscular
                                                                    wall of the bladder or spreads to other parts of the
                                                                    body. Patients rarely die from low-grade bladder cancer.</li>
                                                                <li>
                                                                    <strong>High-grade</strong> bladder cancer commonly recurs in
                                                                    the bladder and also has a strong tendency to invade
                                                                    the muscular wall of the bladder and spread to other
                                                                    parts of the body. High-grade bladder cancer is treated
                                                                    more aggressively than low-grade bladder cancer and is
                                                                    much more likely to result in death. Almost all deaths
                                                                    from bladder cancer result from high-grade disease.</li>
                                                            </ul>
                                                        </div>
                                                        <p id="_361" tabindex="-1">Bladder cancer is also divided into muscle-invasive and nonmuscle-invasive
                                                            disease, based on invasion of the muscularis propria (also referred
                                                            to as the detrusor muscle), which is the thick muscle deep in
                                                            the bladder wall.</p>
                                                        <div class="pdq-content-list">
                                                            <ul id="_364">
                                                                <li>
                                                                    <strong>Muscle-invasive disease</strong> is much more likely
                                                                    to spread to other parts of the body and is generally
                                                                    treated by either removing the bladder or treating the
                                                                    bladder with radiation and chemotherapy. As noted above,
                                                                    high-grade cancers are much more likely to be muscle-invasive
                                                                    than low-grade cancers. Thus, muscle-invasive cancers
                                                                    are generally treated more aggressively than nonmuscle-invasive
                                                                    cancers. </li>
                                                                <li>
                                                                    <strong>Nonmuscle-invasive disease</strong> can often be treated
                                                                    by removing the tumor(s) via a transurethral approach.
                                                                    Sometimes chemotherapy or other treatments are introduced
                                                                    into the bladder with a catheter to help fight the cancer.
                                                                    </li>
                                                            </ul>
                                                        </div>
                                                        <p id="_436" tabindex="-1">Under conditions of chronic inflammation, such as infection of the
                                                            bladder with the
                                                            <em>Schistosoma haematobium</em> parasite, squamous metaplasia may
                                                            occur in the bladder; the incidence of squamous cell carcinomas
                                                            of the bladder is higher under conditions of chronic inflammation
                                                            than is otherwise seen. In addition to transitional cell carcinomas
                                                            and squamous cell carcinomas, adenocarcinomas, small cell carcinomas,
                                                            and sarcomas can form in the bladder. In the United States, transitional
                                                            cell carcinomas represent the vast majority (&gt; 90%) of bladder
                                                            cancers. However, a significant number of transitional cell carcinomas
                                                            have areas of squamous or other differentiation.</p>
                                                    </section>
                                                    <section id="_17">
                                                        <h3 id="_17_toc">Carcinogenesis and Risk Factors</h3>
                                                        <section id="_sm_CDR0000751732_4">
                                                            <p id="_sm_CDR0000751732_13" tabindex="-1">Increasing age is the most important risk factor for most cancers.
                                                                Other risk factors for bladder cancer include:</p>
                                                            <div class="pdq-content-list">
                                                                <ul id="_sm_CDR0000751732_7">
                                                                    <li>Use of tobacco, especially cigarettes.[
                                                                        <a href="#cit/section_1.2">2</a>]</li>
                                                                    <li>Family history of bladder cancer.[
                                                                        <a href="#cit/section_1.3">3</a>]</li>
                                                                    <li>Genetic mutations.[
                                                                        <a href="#cit/section_1.4">4</a>-
                                                                        <a href="#cit/section_1.6">6</a>]
                                                                        <div class="pdq-content-list">
                                                                            <ul id="_sm_CDR0000751732_8" class="list-dash">
                                                                                <li>
                                                                                    <em>HRAS</em> mutation (Costello Syndrome,
                                                                                    Facio-Cutaneous-Skeletal Syndrome).</li>
                                                                                <li>
                                                                                    <em>Rb1</em> mutation.</li>
                                                                                <li>
                                                                                    <em>PTEN/MMAC1</em> mutation (Cowden Syndrome).</li>
                                                                                <li>
                                                                                    <em>NAT2</em> slow acetylator phenotype.</li>
                                                                                <li>
                                                                                    <em>GSTM1</em> null phenotype.</li>
                                                                            </ul>
                                                                        </div>
                                                                    </li>
                                                                    <li>Occupational exposure to chemicals in processed paint,
                                                                        dye, metal, and petroleum products that include:
                                                                        <div
                                                                            class="pdq-content-list">
                                                                            <ul id="_sm_CDR0000751732_9" class="list-dash">
                                                                                <li>Aluminum production (polycyclic aromatic
                                                                                    hydrocarbons, fluorides).[
                                                                                    <a href="#cit/section_1.2">2</a>]</li>
                                                                                <li>Aminobiphenyl and its metabolites.[
                                                                                    <a href="#cit/section_1.2">2</a>]</li>
                                                                                <li>Aromatic amines, benzidine and its derivatives.[
                                                                                    <a
                                                                                        href="#cit/section_1.2">2</a>]</li>
                                                                                <li>Certain aldehydes.[
                                                                                    <a href="#cit/section_1.7">7</a>]</li>
                                                                                <li>2-Napthylamine, beta-napthylamine.[
                                                                                    <a href="#cit/section_1.2">2</a>]</li>
                                                                                <li>
                                                                                    <em>o-Toluidine.[
                                                                                        <a href="#cit/section_1.8">8</a>]</em>
                                                                                </li>
                                                                            </ul>
                                                            </div>
                                                            </li>
                                                            <li>Treatment with cyclophosphamide, ifosfamide, or pelvic radiation
                                                                for other malignancies.[
                                                                <a href="#cit/section_1.9">9</a>-
                                                                <a href="#cit/section_1.11">11</a>]</li>
                                                            <li>Chinese herbs:
                                                                <em>aristolochic</em> (AA) extracted from species of
                                                                <em>Aristolochia fangchi</em>.[
                                                                <a href="#cit/section_1.12">12</a>]</li>
                                                            <li>Exposure to arsenic.
                                                                <div class="pdq-content-list">
                                                                    <ul id="_sm_CDR0000751732_12" class="list-dash">
                                                                        <li>Arsenic in well water.[
                                                                            <a href="#cit/section_1.13">13</a>,
                                                                            <a href="#cit/section_1.14">14</a>,
                                                                            <a href="#cit/section_1.2">2</a>]</li>
                                                                        <li>Inorganic arsenic compounds (gallium arsenide).</li>
                                                                    </ul>
                                                                </div>
                                                            </li>
                                                            <li>Chlorinated aliphatic hydrocarbons and chlorination by-products
                                                                in treated water.[
                                                                <a href="#cit/section_1.15">15</a>]</li>
                                                            <li>
                                                                <em>Schistosoma haematobium</em> bladder infections (Bilharzial
                                                                bladder cancer).[
                                                                <a href="#cit/section_1.16">16</a>]</li>
                                                            <li>Neurogenic bladder and associated indwelling catheters.[
                                                                <a href="#cit/section_1.17">17</a>]</li>
                                                            </ul>
                                                </div>
                                                </section>
                                                <p id="_18" tabindex="-1">There is strong evidence linking exposure to carcinogens to bladder cancer.
                                                    The most common risk factor for bladder cancer in the United States is
                                                    cigarette smoking. It is estimated that up to half of all bladder cancers
                                                    are caused by cigarette smoking and that smoking increases a person’s
                                                    risk of bladder cancer two to four times above baseline risk.[
                                                    <a href="#cit/section_1.18">18</a>,
                                                    <a href="#cit/section_1.19">19</a>] Smokers with less functional polymorphisms of N-acetyltransferase-2
                                                    (known as slow acetylators) have a higher risk of bladder cancer than
                                                    other smokers, presumably because of their reduced ability to detoxify
                                                    carcinogens.</p>
                                                <p id="_366" tabindex="-1">Certain occupational exposures have also been linked to bladder cancer, and
                                                    higher rates of bladder cancer have been reported in textile dye and
                                                    rubber tire industries; among painters; leather workers; shoemakers;
                                                    and aluminum-, iron-, and steelworkers. Specific chemicals linked to
                                                    bladder carcinogenesis include beta-naphthylamine, 4-aminobiphenyl, and
                                                    benzidine. Although these chemicals are now generally banned in Western
                                                    countries, many other chemicals still in use are also suspected of causing
                                                    bladder cancer.[
                                                    <a href="#cit/section_1.19">19</a>] </p>
                                                <p id="_367" tabindex="-1">Exposure to the chemotherapy drug cyclophosphamide has also been associated
                                                    with an increased risk of bladder cancer.</p>
                                                <p id="_318" tabindex="-1">Chronic urinary tract infections and infection with the parasite
                                                    <em>S. haematobium</em> have also been associated with an increased risk
                                                    of bladder cancer, often squamous cell carcinomas. Chronic inflammation
                                                    is thought to play a key role in carcinogenesis in these settings.</p>
                                                </section>
                                                <section id="_21">
                                                    <h3 id="_21_toc">Clinical Features</h3>
                                                    <p id="_22" tabindex="-1">Bladder cancer typically presents with gross or microscopic hematuria.
                                                        Less commonly, patients may complain of urinary frequency, nocturia,
                                                        and dysuria, symptoms that are more common in patients with carcinoma
                                                        <em>in situ</em>. Patients with upper urinary tract urothelial carcinomas
                                                        may present with pain resulting from obstruction by the tumor. </p>
                                                    <p id="_368" tabindex="-1">Urothelial carcinomas are often multifocal—the entire urothelium needs
                                                        to be evaluated if a tumor is found. In patients with bladder cancer,
                                                        upper urinary tract imaging is essential for staging and surveillance.
                                                        This can be accomplished with ureteroscopy, retrograde pyelograms
                                                        during cystoscopy, intravenous pyelograms, or computed tomography
                                                        (CT) urograms. Similarly, patients with an upper urinary tract transitional
                                                        cell carcinoma have a high risk of developing bladder cancer; these
                                                        patients need periodic cystoscopy and surveillance of the contralateral
                                                        upper urinary tract. </p>
                                                </section>
                                                <section id="_23">
                                                    <h3 id="_23_toc">Diagnostics</h3>
                                                    <p id="_24" tabindex="-1">When bladder cancer is suspected, the most useful diagnostic test is
                                                        cystoscopy. Radiological studies such as CT scans or ultrasound do
                                                        not have sufficient sensitivity to be useful for detecting bladder
                                                        cancers. Cystoscopy can be performed in a urology clinic. </p>
                                                    <p id="_369" tabindex="-1">If cancer is seen on cystoscopy, the patient is typically scheduled for
                                                        bimanual examination under anesthesia and a repeat cystoscopy in
                                                        an operating room so that transurethral resection of the tumor(s)
                                                        and/or biopsies can be performed. If a high-grade cancer (including
                                                        carcinoma
                                                        <em>in situ</em>) or invasive cancer is seen, the patient is staged with
                                                        a CT scan of the abdomen and pelvis (or CT urogram) and either a
                                                        chest x-ray or chest CT scan. Patients with a nonhepatic elevation
                                                        of alkaline phosphatase or symptoms suggestive of bone metastases
                                                        undergo a bone scan.</p>
                                                </section>
                                                <section id="_27">
                                                    <h3 id="_27_toc">Prognostic Factors</h3>
                                                    <p id="_265" tabindex="-1">The major prognostic factors in carcinoma of the bladder are the following:</p>
                                                    <div class="pdq-content-list">
                                                        <ul id="_447">
                                                            <li>Depth of invasion into the bladder wall.</li>
                                                            <li>Pathologic grade of the tumor.</li>
                                                            <li>Presence versus absence of carcinoma
                                                                <em>in situ</em>.</li>
                                                        </ul>
                                                    </div>
                                                    <p id="_319" tabindex="-1">Among nonmuscle-invasive cancers, the following factors are also prognostic:[
                                                        <a
                                                            href="#cit/section_1.20">20</a>] </p>
                                                    <div class="pdq-content-list">
                                                        <ul id="_320">
                                                            <li> Number of tumors. </li>
                                                            <li> Tumor size (e.g., &gt;3 cm or &lt;3 cm). </li>
                                                            <li>Invasion of the lamina propria (Ta vs. T1). </li>
                                                            <li> Whether the tumor is the primary tumor or a recurrence. </li>
                                                        </ul>
                                                    </div>
                                                    <p id="_267" tabindex="-1">Most superficial tumors are well differentiated. Patients in whom superficial
                                                        tumors are less differentiated, large, multiple, or associated with
                                                        carcinoma
                                                        <em>in situ</em> (Tis) in other areas of the bladder mucosa are at greatest
                                                        risk of recurrence and the development of invasive cancer. These
                                                        patients may be considered to have the entire urothelial surface
                                                        at risk of cancer development.</p>
                                                </section>
                                                <section id="_29">
                                                    <h3 id="_29_toc">Survival</h3>
                                                    <p id="_321" tabindex="-1">Patients who die from bladder cancer almost always have disease that
                                                        has metastasized from the bladder to other organs. Low-grade bladder
                                                        cancers rarely grow into the muscular wall of the bladder and rarely
                                                        metastasize, so patients with low-grade (grade I) bladder cancers
                                                        very rarely die from their cancer. Nonetheless, they may experience
                                                        multiple relapses that need to be resected. </p>
                                                    <p id="_322" tabindex="-1">Almost all deaths from bladder cancer are among patients with high-grade
                                                        disease, which has a much greater potential to invade deeply into
                                                        the bladder’s muscular wall and spread to other organs. </p>
                                                    <p id="_268" tabindex="-1">Approximately 70% to 80% of patients with newly diagnosed bladder cancer
                                                        will present with superficial bladder tumors (i.e., stage Ta, Tis,
                                                        or T1). The prognosis of these patients depends largely on the grade
                                                        of the tumor. Patients with high-grade tumors have a significant
                                                        risk of dying of their cancer even if it is not muscle-invasive.[
                                                        <a
                                                            href="#cit/section_1.21">21</a>] Among patients with high-grade tumors, those who present
                                                            with superficial, nonmuscle-invasive bladder cancer can usually
                                                            be cured, and those with muscle-invasive disease can sometimes
                                                            be cured.[
                                                            <a href="#cit/section_1.22">22</a>-
                                                            <a href="#cit/section_1.24">24</a>] Studies have demonstrated that some patients with distant
                                                            metastases have achieved long-term complete response after being
                                                            treated with combination chemotherapy regimens, although most
                                                            such patients have metastases limited to their lymph nodes and
                                                            have a near-normal performance status.[
                                                            <a href="#cit/section_1.25">25</a>,
                                                            <a href="#cit/section_1.26">26</a>]</p>
                                                    <p id="_270" tabindex="-1">There are clinical trials suitable for patients with all stages of bladder
                                                        cancer; whenever possible, clinical trials designed to improve upon
                                                        standard therapy should be considered.</p>
                                                    <p id="_459" tabindex="-1">General information about clinical trials is also available from the
                                                        <a href="https://www.cancer.gov/types/bladder/hp" title="https://www.cancer.gov/types/bladder/hp">NCI website</a>.</p>
                                                </section>
                                                <section id="_31">
                                                    <h3 id="_31_toc">Follow-up</h3>
                                                    <p id="_32" tabindex="-1">Bladder cancer tends to recur, even when it is noninvasive at the time
                                                        of diagnosis; therefore standard practice is to perform surveillance
                                                        of the urinary tract after a diagnosis of bladder cancer. However,
                                                        no trials have been conducted to assess whether surveillance affects
                                                        rates of progression, survival, or quality of life; nor have clinical
                                                        trials defined an optimal surveillance schedule. Urothelial carcinomas
                                                        are thought to reflect a so-called field defect whereby the cancer
                                                        emerges because of genetic mutations that are widely present in the
                                                        patient's bladder or entire urothelium. Thus, people who have had
                                                        a bladder tumor resected often subsequently have recurrent tumors
                                                        in the bladder, often in different locations from the site of the
                                                        initial tumor. Similarly, but less commonly, they may have tumors
                                                        appear in the upper urinary tract (i.e., in the renal pelvises or
                                                        ureters). </p>
                                                    <p id="_370" tabindex="-1">An alternative explanation for these patterns of recurrence is that cancer
                                                        cells that are disrupted when a tumor is resected may reimplant elsewhere
                                                        in the urothelium. Support for this second theory is that tumors
                                                        are more likely to recur downstream than upstream from the initial
                                                        cancer. Upper urinary tract cancers are more likely to recur in the
                                                        bladder than bladder cancers are to recur in the upper urinary tract.[
                                                        <a
                                                            href="#cit/section_1.27">27</a>-
                                                            <a href="#cit/section_1.30">30</a>]</p>
                                                </section>
                                                <section id="_208">
                                                    <h3 id="_208_toc">Related Summaries</h3>
                                                    <p id="_209" tabindex="-1">Other PDQ summaries containing information related to bladder cancer
                                                        include the following:</p>
                                                    <div class="pdq-content-list">
                                                        <ul id="_210">
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-screening-pdq">Bladder and Other Urothelial Cancers Screening</a>.</li>
                                                            <li>
                                                                <a href="/types/kidney/hp/kidney-treatment-pdq">Renal Cell Cancer Treatment</a>.</li>
                                                            <li>
                                                                <a href="/types/kidney/hp/transitional-cell-treatment-pdq">Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment</a>.</li>
                                                            <li>
                                                                <a href="/types/childhood-cancers/hp/unusual-cancers-childhood-pdq">Unusual Cancers of Childhood Treatment</a>.</li>
                                                        </ul>
                                                    </div>
                                                </section>
                                                <h6 do-not-show="toc">References</h6>
                                                <ol>
                                                    <li id="section_1.1">American Cancer Society: Cancer Facts and Figures 2018. Atlanta, Ga:
                                                        American Cancer Society, 2018.
                                                        <a href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf"
                                                            title="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf">Available online</a>. Last accessed January 5, 2018.</li>
                                                    <li id="section_1.2">Burger M, Catto JW, Dalbagni G, et al.: Epidemiology and risk factors
                                                        of urothelial bladder cancer. Eur Urol 63 (2): 234-41, 2013.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22877502&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22877502&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.3">Fraumeni JF Jr, Thomas LB: Malignant bladder tumors in a man and his
                                                        three sons. JAMA 201 (7): 97-9, 1967.</li>
                                                    <li id="section_1.4">Marees T, Moll AC, Imhof SM, et al.: Risk of second malignancies in survivors
                                                        of retinoblastoma: more than 40 years of follow-up. J Natl Cancer
                                                        Inst 100 (24): 1771-9, 2008.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19066271&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19066271&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.5">Gallagher DJ, Feifer A, Coleman JA: Genitourinary cancer predisposition
                                                        syndromes. Hematol Oncol Clin North Am 24 (5): 861-83, 2010.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20816578&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20816578&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.6">Lindor NM, McMaster ML, Lindor CJ, et al.: Concise handbook of familial
                                                        cancer susceptibility syndromes - second edition. J Natl Cancer Inst
                                                        Monogr (38): 1-93, 2008.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18559331&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18559331&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.7">Stadler WM: Molecular events in the initiation and progression of bladder
                                                        cancer (review). Int J Oncol 3: 549-557, 1993.</li>
                                                    <li id="section_1.8">Brown T, Slack R, Rushton L, et al.: Occupational cancer in Britain.
                                                        Urinary tract cancers: bladder and kidney. Br J Cancer 107 (Suppl
                                                        1): S76-84, 2012.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22710682&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22710682&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.9">Nieder AM, Porter MP, Soloway MS: Radiation therapy for prostate cancer
                                                        increases subsequent risk of bladder and rectal cancer: a population
                                                        based cohort study. J Urol 180 (5): 2005-9; discussion 2009-10, 2008.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18801517&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18801517&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.10">Abern MR, Dude AM, Tsivian M, et al.: The characteristics of bladder
                                                        cancer after radiotherapy for prostate cancer. Urol Oncol 31 (8):
                                                        1628-34, 2013.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22575239&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22575239&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.11">Monach PA, Arnold LM, Merkel PA: Incidence and prevention of bladder
                                                        toxicity from cyclophosphamide in the treatment of rheumatic diseases:
                                                        a data-driven review. Arthritis Rheum 62 (1): 9-21, 2010.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20039416&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20039416&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.12">Cosyns JP: Aristolochic acid and 'Chinese herbs nephropathy': a review
                                                        of the evidence to date. Drug Saf 26 (1): 33-48, 2003.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12495362&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12495362&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.13">Letašiová S, Medve'ová A, Šovčíková A, et al.: Bladder cancer, a review
                                                        of the environmental risk factors. Environ Health 11 (Suppl 1): S11,
                                                        2012.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22759493&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22759493&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.14">Fernández MI, López JF, Vivaldi B, et al.: Long-term impact of arsenic
                                                        in drinking water on bladder cancer health care and mortality rates
                                                        20 years after end of exposure. J Urol 187 (3): 856-61, 2012.
                                                        <a
                                                            href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22248521&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22248521&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.15">Villanueva CM, Cantor KP, Grimalt JO, et al.: Bladder cancer and exposure
                                                        to water disinfection by-products through ingestion, bathing, showering,
                                                        and swimming in pools. Am J Epidemiol 165 (2): 148-56, 2007.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17079692&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17079692&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.16">Kantor AF, Hartge P, Hoover RN, et al.: Urinary tract infection and risk
                                                        of bladder cancer. Am J Epidemiol 119 (4): 510-5, 1984.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6711540&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6711540&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.17">Locke JR, Hill DE, Walzer Y: Incidence of squamous cell carcinoma in
                                                        patients with long-term catheter drainage. J Urol 133 (6): 1034-5,
                                                        1985.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3999203&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3999203&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.18">Brennan P, Bogillot O, Greiser E, et al.: The contribution of cigarette
                                                        smoking to bladder cancer in women (pooled European data). Cancer
                                                        Causes Control 12 (5): 411-7, 2001.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11545456&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11545456&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.19">Kirkali Z, Chan T, Manoharan M, et al.: Bladder cancer: epidemiology,
                                                        staging and grading, and diagnosis. Urology 66 (6 Suppl 1): 4-34,
                                                        2005.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16399414&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16399414&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.20">Sylvester RJ, van der Meijden AP, Oosterlinck W, et al.: Predicting recurrence
                                                        and progression in individual patients with stage Ta T1 bladder cancer
                                                        using EORTC risk tables: a combined analysis of 2596 patients from
                                                        seven EORTC trials. Eur Urol 49 (3): 466-5; discussion 475-7, 2006.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16442208&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16442208&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.21">Herr HW: Tumor progression and survival of patients with high grade,
                                                        noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol
                                                        163 (1): 60-1; discussion 61-2, 2000.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10604314&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10604314&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.22">Stein JP, Lieskovsky G, Cote R, et al.: Radical cystectomy in the treatment
                                                        of invasive bladder cancer: long-term results in 1,054 patients.
                                                        J Clin Oncol 19 (3): 666-75, 2001.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11157016&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11157016&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.23">Madersbacher S, Hochreiter W, Burkhard F, et al.: Radical cystectomy
                                                        for bladder cancer today--a homogeneous series without neoadjuvant
                                                        therapy. J Clin Oncol 21 (4): 690-6, 2003.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12586807&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12586807&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.24">Manoharan M, Ayyathurai R, Soloway MS: Radical cystectomy for urothelial
                                                        carcinoma of the bladder: an analysis of perioperative and survival
                                                        outcome. BJU Int 104 (9): 1227-32, 2009.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19519764&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19519764&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.25">Loehrer PJ Sr, Einhorn LH, Elson PJ, et al.: A randomized comparison
                                                        of cisplatin alone or in combination with methotrexate, vinblastine,
                                                        and doxorubicin in patients with metastatic urothelial carcinoma:
                                                        a cooperative group study. J Clin Oncol 10 (7): 1066-73, 1992.
                                                        <a
                                                            href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1607913&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1607913&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.26">von der Maase H, Sengelov L, Roberts JT, et al.: Long-term survival results
                                                        of a randomized trial comparing gemcitabine plus cisplatin, with
                                                        methotrexate, vinblastine, doxorubicin, plus cisplatin in patients
                                                        with bladder cancer. J Clin Oncol 23 (21): 4602-8, 2005.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16034041&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16034041&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.27">Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, et al.: Primary
                                                        superficial bladder cancer risk groups according to progression,
                                                        mortality and recurrence. J Urol 164 (3 Pt 1): 680-4, 2000.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10954628&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10954628&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.28">Nieder AM, Brausi M, Lamm D, et al.: Management of stage T1 tumors of
                                                        the bladder: International Consensus Panel. Urology 66 (6 Suppl 1):
                                                        108-25, 2005.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16399419&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16399419&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.29">Babjuk M, Oosterlinck W, Sylvester R, et al.: EAU guidelines on non-muscle-invasive
                                                        urothelial carcinoma of the bladder. Eur Urol 54 (2): 303-14, 2008.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18468779&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18468779&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_1.30">Babjuk M, Oosterlinck W, Sylvester R, et al.: EAU guidelines on non-muscle-invasive
                                                        urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59
                                                        (6): 997-1008, 2011.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21458150&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21458150&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                </ol>
                                        </div>
                                        </section>


                                        <section id="_33">
                                            <h2>Cellular Classification of Bladder Cancer</h2>
                                            <div id="_section_33" class="pdq-sections">
                                                <p id="_34" tabindex="-1">More than 90% of bladder cancers are transitional cell carcinomas derived
                                                    from the uroepithelium. About 2% to 7% are squamous cell carcinomas,
                                                    and 2% are adenocarcinomas.[
                                                    <a href="#cit/section_2.1">1</a>] Adenocarcinomas may be of urachal origin or nonurachal origin;
                                                    the latter type is generally thought to arise from metaplasia of chronically
                                                    irritated transitional epithelium. Small cell carcinomas also may develop
                                                    in the bladder.[
                                                    <a href="#cit/section_2.2">2</a>,
                                                    <a href="#cit/section_2.3">3</a>] Sarcomas of the bladder are very rare. </p>
                                                <p id="_271" tabindex="-1">Pathologic grade of transitional cell carcinomas, which is based on cellular
                                                    atypia, nuclear abnormalities, and the number of mitotic figures, is
                                                    of great prognostic importance.</p>
                                                <h6 do-not-show="toc">References</h6>
                                                <ol>
                                                    <li id="section_2.1">Al-Ahmadie H, Lin O, Reuter VE: Pathology and cytology of tumors of the
                                                        urinary tract. In: Scardino PT, Linehan WM, Zelefsky MJ, et al.,
                                                        eds.: Comprehensive Textbook of Genitourinary Oncology. 4th ed. Philadelphia,
                                                        Pa: Lippincott Williams &amp; Wilkins, 2011, pp 295-316.</li>
                                                    <li id="section_2.2">Koay EJ, Teh BS, Paulino AC, et al.: A Surveillance, Epidemiology, and
                                                        End Results analysis of small cell carcinoma of the bladder: epidemiology,
                                                        prognostic variables, and treatment trends. Cancer 117 (23): 5325-33,
                                                        2011.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21567387&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21567387&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_2.3">Fahed E, Hansel DE, Raghavan D, et al.: Small cell bladder cancer: biology
                                                        and management. Semin Oncol 39 (5): 615-8, 2012.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23040258&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23040258&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                </ol>
                                            </div>
                                        </section>


                                        <section id="_35">
                                            <h2>Stage Information for Bladder Cancer</h2>
                                            <div id="_section_35" class="pdq-sections">
                                                <p id="_95" tabindex="-1">The clinical staging of carcinoma of the bladder is determined by the depth
                                                    of invasion of the bladder wall by the tumor. This determination requires
                                                    a cystoscopic examination that includes a biopsy and examination under
                                                    anesthesia to assess the following:</p>
                                                <div class="pdq-content-list">
                                                    <ul id="_204">
                                                        <li> Size and mobility of palpable masses.</li>
                                                        <li>Degree of induration of the bladder wall.</li>
                                                        <li>Presence of extravesical extension or invasion of adjacent organs.</li>
                                                    </ul>
                                                </div>
                                                <p id="_205" tabindex="-1">Clinical staging, even when computed tomographic (CT) and/or magnetic resonance
                                                    imaging (MRI) scans and other imaging modalities are used, often underestimates
                                                    the extent of tumor, particularly in cancers that are less differentiated
                                                    and more deeply invasive. CT imaging is the standard staging modality.
                                                    A clinical benefit from obtaining MRI or positron emission tomography
                                                    scans instead of CT imaging has not been demonstrated.[
                                                    <a href="#cit/section_3.1">1</a>,
                                                    <a href="#cit/section_3.2">2</a>] </p>
                                                <section id="_37">
                                                    <h3 id="_37_toc">AJCC Stage Groupings and TNM Definitions</h3>
                                                    <p id="_96" tabindex="-1">The American Joint Committee on Cancer (AJCC) has designated staging
                                                        by TNM classification to define bladder cancer.[
                                                        <a href="#cit/section_3.3">3</a>]</p>
                                                    <table id="_466" class="table-default expandable-container">
                                                        <caption>Table 1. Definitions of TNM Stages 0 and 0is</caption>
                                                        <colgroup>
                                                            <col width="25.00%" />
                                                            <col width="25.00%" />
                                                            <col width="25.00%" />
                                                            <col width="25.00%" />
                                                        </colgroup>
                                                        <THead>
                                                            <tr>
                                                                <th scope="col">Stage </th>
                                                                <th scope="col">TNM</th>
                                                                <th scope="col">Description</th>
                                                                <th scope="col">Illustration</th>
                                                            </tr>
                                                        </THead>
                                                        <TFoot class="pdq-footer">
                                                            <tr>
                                                                <td colspan="4">M = distant metastasis; N = regional lymph nodes; T = primary
                                                                    tumor.</td>
                                                            </tr>
                                                            <tr>
                                                                <td colspan="4">Reprinted with permission from AJCC: Urinary bladder. In:
                                                                    Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer
                                                                    Staging Manual. 7th ed. New York, NY: Springer, 2010,
                                                                    pp 497–505.</td>
                                                            </tr>
                                                        </TFoot>
                                                        <tbody>
                                                            <tr>
                                                                <td rowspan="3">0a</td>
                                                                <td rowspan="3">Ta, N0, M0</td>
                                                                <td>Ta = Noninvasive papillary carcinoma.</td>
                                                                <td rowspan="6">
                                                                    <figure id="figure_467" class="image-center">
                                                                        <a href="/images/cdr/live/CDR747928.jpg" target="_blank" class="article-image-enlarge">Enlarge</a>
                                                                        <img id="_467" alt="Stage 0 bladder cancer; drawing shows the bladder, ureter, prostate, and urethra. First inset shows papillary carcinoma on the inner lining of the bladder. Second inset shows carcinoma in situ on the inner lining of the bladder. Also shown are the layers of connective tissue and muscle tissue of the bladder and the layer of fat around the bladder."
                                                                            title="Stage 0 bladder cancer; drawing shows the bladder, ureter, prostate, and urethra. First inset shows papillary carcinoma on the inner lining of the bladder. Second inset shows carcinoma in situ on the inner lining of the bladder. Also shown are the layers of connective tissue and muscle tissue of the bladder and the layer of fat around the bladder."
                                                                            src="/images/cdr/live/CDR747928-750.jpg" />
                                                                    </figure>
                                                                </td>
                                                            </tr>
                                                            <tr>
                                                                <td>N0 = No lymph node metastasis.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>M0 = No distant metastasis.</td>
                                                            </tr>
                                                            <tr>
                                                                <td rowspan="3">0is</td>
                                                                <td rowspan="3">Tis, N0, M0</td>
                                                                <td>Tis = Carcinoma
                                                                    <em>in situ</em>: "flat tumor."</td>
                                                            </tr>
                                                            <tr>
                                                                <td>N0 = No lymph node metastasis.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>M0 = No distant metastasis.</td>
                                                            </tr>
                                                        </tbody>
                                                    </table>
                                                    <table id="_463" class="table-default expandable-container">
                                                        <caption>Table 2. Definition of TNM Stage I</caption>
                                                        <colgroup>
                                                            <col width="25.00%" />
                                                            <col width="25.00%" />
                                                            <col width="25.00%" />
                                                            <col width="25.00%" />
                                                        </colgroup>
                                                        <THead>
                                                            <tr>
                                                                <th scope="col">Stage </th>
                                                                <th scope="col">TNM</th>
                                                                <th scope="col">Description</th>
                                                                <th scope="col">Illustration</th>
                                                            </tr>
                                                        </THead>
                                                        <TFoot class="pdq-footer">
                                                            <tr>
                                                                <td colspan="4">M = distant metastasis; N = regional lymph nodes; T = primary
                                                                    tumor.</td>
                                                            </tr>
                                                            <tr>
                                                                <td colspan="4">Reprinted with permission from AJCC: Urinary bladder. In:
                                                                    Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer
                                                                    Staging Manual. 7th ed. New York, NY: Springer, 2010,
                                                                    pp 497–505.</td>
                                                            </tr>
                                                        </TFoot>
                                                        <tbody>
                                                            <tr>
                                                                <td rowspan="3">I</td>
                                                                <td rowspan="3">T1, N0, M0</td>
                                                                <td>T1 = Tumor invades subepithelial connective tissue.</td>
                                                                <td rowspan="3">
                                                                    <figure id="figure_469" class="image-center">
                                                                        <a href="/images/cdr/live/CDR749301.jpg" target="_blank" class="article-image-enlarge">Enlarge</a>
                                                                        <img id="_469" alt="Stage I bladder cancer; drawing shows the bladder, ureter, prostate, and urethra. Inset shows cancer in the inner lining of the bladder and in the layer of connective tissue next to it.  Also shown are the muscle layers of the bladder and the layer of fat around the bladder."
                                                                            title="Stage I bladder cancer; drawing shows the bladder, ureter, prostate, and urethra. Inset shows cancer in the inner lining of the bladder and in the layer of connective tissue next to it.  Also shown are the muscle layers of the bladder and the layer of fat around the bladder."
                                                                            src="/images/cdr/live/CDR749301-750.jpg" />
                                                                    </figure>
                                                                </td>
                                                            </tr>
                                                            <tr>
                                                                <td>N0 = No lymph node metastasis.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>M0 = No distant metastasis.</td>
                                                            </tr>
                                                        </tbody>
                                                    </table>
                                                    <table id="_474" class="table-default expandable-container">
                                                        <caption>Table 3. Definition of TNM Stage II</caption>
                                                        <colgroup>
                                                            <col width="25.00%" />
                                                            <col width="25.00%" />
                                                            <col width="25.00%" />
                                                            <col width="25.00%" />
                                                        </colgroup>
                                                        <THead>
                                                            <tr>
                                                                <th scope="col">Stage </th>
                                                                <th scope="col">TNM</th>
                                                                <th scope="col">Description</th>
                                                                <th scope="col">Illustration</th>
                                                            </tr>
                                                        </THead>
                                                        <TFoot class="pdq-footer">
                                                            <tr>
                                                                <td colspan="4">M = distant metastasis; N = regional lymph nodes; T = primary
                                                                    tumor.</td>
                                                            </tr>
                                                            <tr>
                                                                <td colspan="4">Reprinted with permission from AJCC: Urinary bladder. In:
                                                                    Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer
                                                                    Staging Manual. 7th ed. New York, NY: Springer, 2010,
                                                                    pp 497–505.</td>
                                                            </tr>
                                                        </TFoot>
                                                        <tbody>
                                                            <tr>
                                                                <td rowspan="6">II</td>
                                                                <td rowspan="3">T2a, N0, M0</td>
                                                                <td>T2a = Tumor invades superficial muscularis propria (inner
                                                                    half).</td>
                                                                <td rowspan="6">
                                                                    <figure id="figure_475" class="image-center">
                                                                        <a href="/images/cdr/live/CDR749308.jpg" target="_blank" class="article-image-enlarge">Enlarge</a>
                                                                        <img id="_475" alt="Stage II bladder cancer; drawing shows the bladder, ureter, prostate, and urethra. Inset shows cancer in the inner lining of the bladder, the layer of connective tissue, and the muscle layers. Also shown is the layer of fat around the bladder."
                                                                            title="Stage II bladder cancer; drawing shows the bladder, ureter, prostate, and urethra. Inset shows cancer in the inner lining of the bladder, the layer of connective tissue, and the muscle layers. Also shown is the layer of fat around the bladder."
                                                                            src="/images/cdr/live/CDR749308-750.jpg" />
                                                                    </figure>
                                                                </td>
                                                            </tr>
                                                            <tr>
                                                                <td>N0 = No lymph node metastasis. </td>
                                                            </tr>
                                                            <tr>
                                                                <td>M0 = No distant metastasis.</td>
                                                            </tr>
                                                            <tr>
                                                                <td rowspan="3">T2b, N0, M0</td>
                                                                <td>T2b = Tumor invades deep muscularis propria (outer half).</td>
                                                            </tr>
                                                            <tr>
                                                                <td>N0 = No lymph node metastasis.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>M0 = No distant metastasis.</td>
                                                            </tr>
                                                        </tbody>
                                                    </table>
                                                    <table id="_476" class="table-default expandable-container">
                                                        <caption>Table 4. Definition of TNM Stage III</caption>
                                                        <colgroup>
                                                            <col width="25.00%" />
                                                            <col width="24.75%" />
                                                            <col width="25.24%" />
                                                            <col width="25.00%" />
                                                        </colgroup>
                                                        <THead>
                                                            <tr>
                                                                <th scope="col">Stage </th>
                                                                <th scope="col">TNM</th>
                                                                <th scope="col">Description</th>
                                                                <th scope="col">Illustration</th>
                                                            </tr>
                                                        </THead>
                                                        <TFoot class="pdq-footer">
                                                            <tr>
                                                                <td colspan="4">M = distant metastasis; N = regional lymph nodes; T = primary
                                                                    tumor.</td>
                                                            </tr>
                                                            <tr>
                                                                <td colspan="4">Reprinted with permission from AJCC: Urinary bladder. In:
                                                                    Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer
                                                                    Staging Manual. 7th ed. New York, NY: Springer, 2010,
                                                                    pp 497–505.</td>
                                                            </tr>
                                                        </TFoot>
                                                        <tbody>
                                                            <tr>
                                                                <td rowspan="9">III</td>
                                                                <td rowspan="3">T3a, N0, M0</td>
                                                                <td>T3a = Tumor invades perivesical tissue microscopically.</td>
                                                                <td rowspan="9">
                                                                    <figure id="figure_477" class="image-center">
                                                                        <a href="/images/cdr/live/CDR749310.jpg" target="_blank" class="article-image-enlarge">Enlarge</a>
                                                                        <img id="_477" alt="Stage III bladder cancer; drawing shows the bladder, ureter, prostate, and urethra. Inset shows cancer in the inner lining of the bladder, the layer of connective tissue, the muscle layers, and the layer of fat around the bladder."
                                                                            title="Stage III bladder cancer; drawing shows the bladder, ureter, prostate, and urethra. Inset shows cancer in the inner lining of the bladder, the layer of connective tissue, the muscle layers, and the layer of fat around the bladder."
                                                                            src="/images/cdr/live/CDR749310-750.jpg" />
                                                                    </figure>
                                                                </td>
                                                            </tr>
                                                            <tr>
                                                                <td>N0 = No lymph node metastasis.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>M0 = No distant metastasis. </td>
                                                            </tr>
                                                            <tr>
                                                                <td rowspan="3">T3b, N0, M0</td>
                                                                <td>T3b = Tumor invades perivesical tissue macroscopically (extravesical
                                                                    mass).</td>
                                                            </tr>
                                                            <tr>
                                                                <td> N0 = No lymph node metastasis. </td>
                                                            </tr>
                                                            <tr>
                                                                <td>M0 = No distant metastasis.</td>
                                                            </tr>
                                                            <tr>
                                                                <td rowspan="3">T4a, N0, M0</td>
                                                                <td>T4a = Tumor invades prostatic stroma, uterus, vagina.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>N0 = No lymph node metastasis.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>M0 = No distant metastasis.</td>
                                                            </tr>
                                                        </tbody>
                                                    </table>
                                                    <table id="_472" class="table-default expandable-container">
                                                        <caption>Table 5. Definition of TNM Stage IV</caption>
                                                        <colgroup>
                                                            <col width="25.00%" />
                                                            <col width="25.00%" />
                                                            <col width="25.00%" />
                                                            <col width="25.00%" />
                                                        </colgroup>
                                                        <THead>
                                                            <tr>
                                                                <th scope="col">Stage </th>
                                                                <th scope="col">TNM</th>
                                                                <th scope="col">Description</th>
                                                                <th scope="col">Illustration</th>
                                                            </tr>
                                                        </THead>
                                                        <TFoot class="pdq-footer">
                                                            <tr>
                                                                <td colspan="4">M = distant metastasis; N = regional lymph nodes; T = primary
                                                                    tumor.</td>
                                                            </tr>
                                                            <tr>
                                                                <td colspan="4">Reprinted with permission from AJCC: Urinary bladder. In:
                                                                    Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer
                                                                    Staging Manual. 7th ed. New York, NY: Springer, 2010,
                                                                    pp 497–505.</td>
                                                            </tr>
                                                        </TFoot>
                                                        <tbody>
                                                            <tr>
                                                                <td rowspan="41">IV</td>
                                                                <td rowspan="3">T4b, N0, M0</td>
                                                                <td>T4b = Tumor invades pelvic wall, abdominal wall. </td>
                                                                <td rowspan="41">
                                                                    <figure id="figure_473" class="image-center">
                                                                        <a href="/images/cdr/live/CDR749892.jpg" target="_blank" class="article-image-enlarge">Enlarge</a>
                                                                        <img id="_473" alt="Stage IV bladder cancer; drawing shows cancer in the bladder, the pelvic wall, and lymph nodes. Inset shows some other parts of the body where cancer can spread from the bladder: the lung, liver, and bone."
                                                                            title="Stage IV bladder cancer; drawing shows cancer in the bladder, the pelvic wall, and lymph nodes. Inset shows some other parts of the body where cancer can spread from the bladder: the lung, liver, and bone."
                                                                            src="/images/cdr/live/CDR749892-750.jpg" />
                                                                    </figure>
                                                                </td>
                                                            </tr>
                                                            <tr>
                                                                <td>N0 = No lymph node metastasis.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>M0 = No distant metastasis.</td>
                                                            </tr>
                                                            <tr>
                                                                <td rowspan="18">Any T, N1–N3, M0</td>
                                                                <td>TX = Primary tumor cannot be assessed.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>T0 = No evidence of primary tumor.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>Ta = Noninvasive papillary carcinoma.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>Tis = Carcinoma
                                                                    <em>in situ</em>: “flat tumor.”</td>
                                                            </tr>
                                                            <tr>
                                                                <td>T1 = Tumor invades subepithelial connective tissue.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>T2 = Tumor invades muscularis propria.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>pT2a = Tumor invades superficial muscularis propria (inner
                                                                    half).</td>
                                                            </tr>
                                                            <tr>
                                                                <td>pT2b = Tumor invades deep muscularis propria (outer half).</td>
                                                            </tr>
                                                            <tr>
                                                                <td>T3 = Tumor invades perivesical tissue.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>pT3a = Tumor invades perivesical tissue microscopically.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>pT3b = Tumor invades perivesical tissue macroscopically (extravesical
                                                                    mass).</td>
                                                            </tr>
                                                            <tr>
                                                                <td>T4 = Tumor invades any of the following: prostatic stroma,
                                                                    seminal vesicles, uterus, vagina, pelvic wall, abdominal
                                                                    wall.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>T4a = Tumor invades prostatic stroma, uterus, vagina.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>T4b = Tumor invades pelvic wall, abdominal wall.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>N1 = Single regional lymph node metastasis in the true pelvis
                                                                    (hypogastric, obturator, external iliac, or presacral
                                                                    lymph node).</td>
                                                            </tr>
                                                            <tr>
                                                                <td> N2 = Multiple regional lymph node metastases in the true
                                                                    pelvis (hypogastric, obturator, external iliac, or presacral
                                                                    lymph node).</td>
                                                            </tr>
                                                            <tr>
                                                                <td> N3 = Lymph node metastases to the common iliac lymph nodes.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>M0 = No distant metastasis.</td>
                                                            </tr>
                                                            <tr>
                                                                <td rowspan="20">Any T, any N, M1</td>
                                                                <td>TX = Primary tumor cannot be assessed.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>T0 = No evidence of primary tumor.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>Ta = Noninvasive papillary carcinoma.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>Tis = Carcinoma
                                                                    <em>in situ</em>: "flat tumor."</td>
                                                            </tr>
                                                            <tr>
                                                                <td>T1 = Tumor invades subepithelial connective tissue.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>T2 = Tumor invades muscularis propria.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>pT2a = Tumor invades superficial muscularis propria (inner
                                                                    half).</td>
                                                            </tr>
                                                            <tr>
                                                                <td>pT2b = Tumor invades deep muscularis propria (outer half).</td>
                                                            </tr>
                                                            <tr>
                                                                <td>T3 = Tumor invades perivesical tissue.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>pT3a = Tumor invades perivesical tissue microscopically.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>pT3b = Tumor invades perivesical tissue macroscopically (extravesical
                                                                    mass).</td>
                                                            </tr>
                                                            <tr>
                                                                <td>T4 = Tumor invades any of the following: prostatic stroma,
                                                                    seminal vesicles, uterus, vagina, pelvic wall, abdominal
                                                                    wall.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>T4a = Tumor invades prostatic stroma, uterus, vagina.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>T4b = Tumor invades pelvic wall, abdominal wall.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>NX = Lymph nodes cannot be assessed.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>N0 = No lymph node metastasis.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>N1 = Single regional lymph node metastasis in the true pelvis
                                                                    (hypogastric, obturator, external iliac, or presacral
                                                                    lymph node).</td>
                                                            </tr>
                                                            <tr>
                                                                <td>N2 = Multiple regional lymph node metastases in the true
                                                                    pelvis (hypogastric, obturator, external iliac, or presacral
                                                                    lymph node).</td>
                                                            </tr>
                                                            <tr>
                                                                <td>N3 = Lymph node metastases to the common iliac lymph nodes.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>M1 = Distant metastasis.</td>
                                                            </tr>
                                                        </tbody>
                                                    </table>
                                                    <table id="_460" class="table-default expandable-container">
                                                        <caption>Table 6. WHO/ISUP Recommended Grading System</caption>
                                                        <colgroup>
                                                            <col width="12.46%" />
                                                            <col width="87.53%" />
                                                        </colgroup>
                                                        <TFoot class="pdq-footer">
                                                            <tr>
                                                                <td colspan="2">ISUP = International Society of Urologic Pathology; WHO =
                                                                    World Health Organization.</td>
                                                            </tr>
                                                            <tr>
                                                                <td colspan="2">Reprinted with permission from AJCC: Urinary bladder. In:
                                                                    Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer
                                                                    Staging Manual. 7th ed. New York, NY: Springer, 2010,
                                                                    p 497.</td>
                                                            </tr>
                                                        </TFoot>
                                                        <tbody>
                                                            <tr>
                                                                <td>GX
                                                                </td>
                                                                <td>Grade cannot be assessed.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>G1
                                                                </td>
                                                                <td>Well differentiated.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>G2
                                                                </td>
                                                                <td>Moderately differentiated.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>G3

                                                                </td>
                                                                <td>Poorly differentiated.</td>
                                                            </tr>
                                                            <tr>
                                                                <td>G4</td>
                                                                <td>Undifferentiated.</td>
                                                            </tr>
                                                        </tbody>
                                                    </table>
                                                </section>
                                                <h6 do-not-show="toc">References</h6>
                                                <ol>
                                                    <li id="section_3.1">Cowan NC, Crew JP: Imaging bladder cancer. Curr Opin Urol 20 (5): 409-13,
                                                        2010.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20625298&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20625298&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_3.2">Green DA, Durand M, Gumpeni N, et al.: Role of magnetic resonance imaging
                                                        in bladder cancer: current status and emerging techniques. BJU Int
                                                        110 (10): 1463-70, 2012.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22500557&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22500557&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_3.3">Urinary bladder. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC
                                                        Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 497-505.</li>
                                                </ol>
                                            </div>
                                        </section>


                                        <section id="_39">
                                            <h2>Treatment Option Overview for Bladder Cancer</h2>
                                            <div id="_section_39" class="pdq-sections">
                                                <section id="_323">
                                                    <h3 id="_323_toc">Nonmuscle-Invasive Bladder Cancer</h3>
                                                    <p id="_324" tabindex="-1">Treatment of nonmuscle-invasive bladder cancers (Ta, Tis, T1) is based
                                                        on risk stratification. Essentially all patients are initially treated
                                                        with a transurethral resection (TUR) of the bladder tumor followed
                                                        by a single immediate instillation of intravesical chemotherapy (mitomycin
                                                        C is typically used in the United States).[
                                                        <a href="#cit/section_4.1">1</a>-
                                                        <a href="#cit/section_4.7">7</a>]</p>
                                                    <p id="_325" tabindex="-1">Subsequent therapy after the treatment above is based on risk and typically
                                                        consists of one of the following:[
                                                        <a href="#cit/section_4.6">6</a>-
                                                        <a href="#cit/section_4.9">9</a>]</p>
                                                    <div class="pdq-content-list">
                                                        <ul id="_326">
                                                            <li> Surveillance for relapse or recurrence (typically used for tumors
                                                                with low risk of recurrence or progression). </li>
                                                            <li> A minimum of 1 year of intravesical treatments with bacillus
                                                                Calmette-Guérin (BCG) plus surveillance for relapse (typically
                                                                used for tumors at intermediate or high risk of progression
                                                                to muscle-invasive disease).</li>
                                                            <li> Additional intravesical chemotherapy (typically used for tumors
                                                                with a high risk of recurrence but low risk of progression
                                                                to muscle-invasive disease). </li>
                                                        </ul>
                                                    </div>
                                                </section>
                                                <section id="_327">
                                                    <h3 id="_327_toc">Muscle-invasive Bladder Cancer</h3>
                                                    <p id="_328" tabindex="-1"> Standard treatment for patients with muscle-invasive bladder cancers
                                                        whose goal is cure is either neoadjuvant multiagent cisplatin–based
                                                        chemotherapy followed by radical cystectomy and urinary diversion
                                                        or radiation therapy with concomitant chemotherapy.[
                                                        <a href="#cit/section_4.10">10</a>-
                                                        <a href="#cit/section_4.13">13</a>] Other treatment approaches include the following:</p>
                                                    <div class="pdq-content-list">
                                                        <ul id="_329">
                                                            <li> Radical cystectomy followed by multiagent cisplatin–based chemotherapy.</li>
                                                            <li> Radical cystectomy without perioperative chemotherapy.[
                                                                <a href="#cit/section_4.14">14</a>-
                                                                <a href="#cit/section_4.16">16</a>]</li>
                                                            <li> Radiation therapy without concomitant chemotherapy.[
                                                                <a href="#cit/section_4.17">17</a>]</li>
                                                            <li> Partial cystectomy with or without perioperative chemotherapy.[
                                                                <a
                                                                    href="#cit/section_4.18">18</a>]</li>
                                                        </ul>
                                                    </div>
                                                </section>
                                                <p id="_97" tabindex="-1">Many patients newly diagnosed with bladder cancer are candidates for participation
                                                    in clinical trials. </p>
                                                <p id="_98" tabindex="-1">Reconstructive techniques that fashion low-pressure storage reservoirs from
                                                    the reconfigured small and large bowel eliminate the need for external
                                                    drainage devices and, in many patients, allow voiding per urethra. These
                                                    techniques are designed to improve the quality of life for patients who
                                                    require cystectomy.[
                                                    <a href="#cit/section_4.19">19</a>]</p>
                                                <table id="_461" class="table-default expandable-container">
                                                    <caption>Table 7. Standard Treatment Options for Bladder Cancer</caption>
                                                    <colgroup>
                                                        <col width="27.57%" />
                                                        <col width="22.42%" />
                                                        <col width="50.00%" />
                                                    </colgroup>
                                                    <THead>
                                                        <tr>
                                                            <th colspan="2" scope="col">Stage (
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_37">TNM Staging Criteria</a>) </th>
                                                            <th scope="col">Standard Treatment Options </th>
                                                        </tr>
                                                    </THead>
                                                    <TFoot class="pdq-footer">
                                                        <tr>
                                                            <td colspan="3">BCG = bacillus Calmette-Guérin; EBRT = external-beam radiation
                                                                therapy; TNM = T, size of tumor and any spread of cancer
                                                                into nearby tissue; N, spread of cancer to nearby lymph nodes;
                                                                M, metastasis or spread of cancer to other parts of body;
                                                                TUR = transurethral resection.</td>
                                                        </tr>
                                                    </TFoot>
                                                    <tbody>
                                                        <tr>
                                                            <td rowspan="6" colspan="2">Stage 0 Bladder Cancer </td>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_46">TUR with fulguration followed by an immediate postoperative
                                                                    instillation of intravesical chemotherapy</a>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td>TUR with fulguration</td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_52">TUR with fulguration followed by an immediate postoperative
                                                                    instillation of intravesical chemotherapy followed by
                                                                    periodic intravesical instillations of BCG</a>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td>TUR with fulguration followed by an immediate postoperative instillation
                                                                of intravesical chemotherapy followed by intravesical chemotherapy</td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_55">Segmental cystectomy</a> (rarely indicated)</td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_58">Radical cystectomy</a> (in rare, highly selected patients
                                                                with extensive or refractory superficial high-grade tumors)</td>
                                                        </tr>
                                                        <tr>
                                                            <td rowspan="6" colspan="2">Stage I Bladder Cancer </td>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_69">TUR with fulguration followed by an immediate postoperative
                                                                    instillation of intravesical chemotherapy</a>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_333">TUR with fulguration</a>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_72">TUR with fulguration followed by an immediate postoperative
                                                                    instillation of intravesical chemotherapy followed by
                                                                    periodic intravesical instillations of BCG</a>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_75">TUR with fulguration followed by an immediate postoperative
                                                                    instillation of intravesical chemotherapy followed by
                                                                    intravesical chemotherapy</a>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_78">Segmental cystectomy</a> (rarely indicated)</td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_81">Radical cystectomy</a> in selected patients with extensive
                                                                or refractory superficial tumors</td>
                                                        </tr>
                                                        <tr>
                                                            <td rowspan="5" colspan="2">Stages II and III Bladder Cancer</td>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_108">Radical cystectomy</a>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_112">Neoadjuvant combination chemotherapy</a> followed by radical
                                                                cystectomy</td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_117">EBRT with or without concomitant chemotherapy</a>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_437">Segmental cystectomy</a> (in selected patients)</td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_455">TUR with fulguration</a> (in selected patients) </td>
                                                        </tr>
                                                        <tr>
                                                            <td rowspan="10">Stage IV Bladder Cancer </td>
                                                            <td rowspan="6">T4b, N0, M0 and any T, N1–N3, M0 </td>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_350">Chemotherapy alone</a>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_165">Radical cystectomy</a>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td>Radical cystectomy followed by chemotherapy</td>
                                                        </tr>
                                                        <tr>
                                                            <td>Radical cystectomy alone</td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_167">EBRT with or without concomitant chemotherapy</a>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_169">Urinary diversion or cystectomy</a> for palliation</td>
                                                        </tr>
                                                        <tr>
                                                            <td rowspan="4">Any T, any N, M1 </td>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_174">Chemotherapy</a> alone or as an adjunct to local treatment</td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_507">Immunotherapy</a>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_176">EBRT</a> for palliation</td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_178">Urinary diversion or cystectomy</a> for palliation</td>
                                                        </tr>
                                                        <tr>
                                                            <td rowspan="5" colspan="2">Recurrent Bladder Cancer</td>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_185">Combination chemotherapy</a>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_521">Immunotherapy</a>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_484">Surgery</a> for new superficial or localized tumors</td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_486">Palliative therapy</a>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_488">Clinical trials</a>
                                                            </td>
                                                        </tr>
                                                    </tbody>
                                                </table>
                                                <h6 do-not-show="toc">References</h6>
                                                <ol>
                                                    <li id="section_4.1">Sylvester RJ, Oosterlinck W, van der Meijden AP: A single immediate postoperative
                                                        instillation of chemotherapy decreases the risk of recurrence in
                                                        patients with stage Ta T1 bladder cancer: a meta-analysis of published
                                                        results of randomized clinical trials. J Urol 171 (6 Pt 1): 2186-90,
                                                        quiz 2435, 2004.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15126782&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15126782&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_4.2">Mariappan P, Smith G: A surveillance schedule for G1Ta bladder cancer
                                                        allowing efficient use of check cystoscopy and safe discharge at
                                                        5 years based on a 25-year prospective database. J Urol 173 (4):
                                                        1108-11, 2005.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15758711&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15758711&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_4.3">Nieder AM, Brausi M, Lamm D, et al.: Management of stage T1 tumors of
                                                        the bladder: International Consensus Panel. Urology 66 (6 Suppl 1):
                                                        108-25, 2005.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16399419&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16399419&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_4.4">Oosterlinck W, Solsona E, Akaza H, et al.: Low-grade Ta (noninvasive)
                                                        urothelial carcinoma of the bladder. Urology 66 (6 Suppl 1): 75-89,
                                                        2005.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16399417&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16399417&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_4.5">Sylvester RJ, van der Meijden A, Witjes JA, et al.: High-grade Ta urothelial
                                                        carcinoma and carcinoma in situ of the bladder. Urology 66 (6 Suppl
                                                        1): 90-107, 2005.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16399418&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16399418&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_4.6">Babjuk M, Oosterlinck W, Sylvester R, et al.: EAU guidelines on non-muscle-invasive
                                                        urothelial carcinoma of the bladder. Eur Urol 54 (2): 303-14, 2008.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18468779&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18468779&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_4.7">Babjuk M, Oosterlinck W, Sylvester R, et al.: EAU guidelines on non-muscle-invasive
                                                        urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59
                                                        (6): 997-1008, 2011.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21458150&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21458150&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_4.8">Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, et al.: Upper
                                                        urinary tract tumors after primary superficial bladder tumors: prognostic
                                                        factors and risk groups. J Urol 164 (4): 1183-7, 2000.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10992362&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10992362&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_4.9">Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, et al.: Multivariate
                                                        analysis of the prognostic factors of primary superficial bladder
                                                        cancer. J Urol 163 (1): 73-8, 2000.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10604317&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10604317&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_4.10">Sauer R, Birkenhake S, Kühn R, et al.: Efficacy of radiochemotherapy
                                                        with platin derivatives compared to radiotherapy alone in organ-sparing
                                                        treatment of bladder cancer. Int J Radiat Oncol Biol Phys 40 (1):
                                                        121-7, 1998.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9422567&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9422567&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_4.11">Advanced Bladder Cancer Meta-analysis Collaboration: Neoadjuvant chemotherapy
                                                        in invasive bladder cancer: a systematic review and meta-analysis.
                                                        Lancet 361 (9373): 1927-34, 2003.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12801735&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12801735&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_4.12">Winquist E, Kirchner TS, Segal R, et al.: Neoadjuvant chemotherapy for
                                                        transitional cell carcinoma of the bladder: a systematic review and
                                                        meta-analysis. J Urol 171 (2 Pt 1): 561-9, 2004.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14713760&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14713760&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_4.13">James ND, Hussain SA, Hall E, et al.: Radiotherapy with or without chemotherapy
                                                        in muscle-invasive bladder cancer. N Engl J Med 366 (16): 1477-88,
                                                        2012.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22512481&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22512481&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_4.14">Madersbacher S, Hochreiter W, Burkhard F, et al.: Radical cystectomy
                                                        for bladder cancer today--a homogeneous series without neoadjuvant
                                                        therapy. J Clin Oncol 21 (4): 690-6, 2003.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12586807&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12586807&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_4.15">Stein JP, Dunn MD, Quek ML, et al.: The orthotopic T pouch ileal neobladder:
                                                        experience with 209 patients. J Urol 172 (2): 584-7, 2004.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15247737&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15247737&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_4.16">Manoharan M, Ayyathurai R, Soloway MS: Radical cystectomy for urothelial
                                                        carcinoma of the bladder: an analysis of perioperative and survival
                                                        outcome. BJU Int 104 (9): 1227-32, 2009.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19519764&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19519764&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_4.17">Widmark A, Flodgren P, Damber JE, et al.: A systematic overview of radiation
                                                        therapy effects in urinary bladder cancer. Acta Oncol 42 (5-6): 567-81,
                                                        2003.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14596515&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14596515&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_4.18">Holzbeierlein JM, Lopez-Corona E, Bochner BH, et al.: Partial cystectomy:
                                                        a contemporary review of the Memorial Sloan-Kettering Cancer Center
                                                        experience and recommendations for patient selection. J Urol 172
                                                        (3): 878-81, 2004.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15310988&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15310988&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_4.19">Hautmann RE, Miller K, Steiner U, et al.: The ileal neobladder: 6 years
                                                        of experience with more than 200 patients. J Urol 150 (1): 40-5,
                                                        1993.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8510272&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8510272&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                </ol>
                                            </div>
                                        </section>


                                        <section id="_42">
                                            <h2>Stage 0 Bladder Cancer Treatment</h2>
                                            <div id="_section_42" class="pdq-sections">
                                                <section id="_43">
                                                    <h3 id="_43_toc">Standard Treatment Options for Stage 0 Bladder Cancer</h3>
                                                    <p id="_99" tabindex="-1">Patients with
                                                        <a href="/types/bladder/hp/bladder-treatment-pdq#link/_466">stage 0 bladder tumors</a> can be cured by a variety of treatments,
                                                        even though the tendency for new tumor formation is high. In a series
                                                        of patients with Ta or T1 tumors who were followed for a minimum
                                                        of 20 years or until death, the risk of bladder cancer recurrence
                                                        after initial resection was 80%.[
                                                        <a href="#cit/section_5.1">1</a>] Of greater concern than recurrence is the risk of progression
                                                        to muscle-invasive, locally-advanced, or metastatic bladder cancer.
                                                        While progression is rare for patients with low-grade tumors, it
                                                        is common among patients with high-grade cancers. </p>
                                                    <p id="_372" tabindex="-1">One series of 125 patients with TaG3 cancers followed for 15 to 20 years
                                                        reported that 39% progressed to more advanced-stage disease while
                                                        26% died of urothelial cancer. In comparison, among 23 patients with
                                                        TaG1 tumors, none died and only 5% progressed.[
                                                        <a href="#cit/section_5.2">2</a>] Risk factors for recurrence and progression are the following:[
                                                        <a
                                                            href="#cit/section_5.2">2</a>-
                                                            <a href="#cit/section_5.6">6</a>]</p>
                                                    <div class="pdq-content-list">
                                                        <ul id="_448">
                                                            <li>High-grade disease.</li>
                                                            <li>Presence of carcinoma
                                                                <em>in situ</em>.</li>
                                                            <li> Tumor larger than 3 cm.</li>
                                                            <li>Multiple tumors.</li>
                                                            <li>History of prior bladder cancer.</li>
                                                        </ul>
                                                    </div>
                                                    <p id="_44" tabindex="-1">Standard treatment options for stage 0 bladder cancer include the following:</p>
                                                    <div class="pdq-content-list">
                                                        <ol id="_45">
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_46">Transurethral resection (TUR) with fulguration followed by
                                                                    an immediate postoperative instillation of intravesical
                                                                    chemotherapy</a>.</li>
                                                            <li>TUR with fulguration.</li>
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_52">TUR with fulguration followed by an immediate postoperative
                                                                    instillation of intravesical chemotherapy followed by
                                                                    periodic intravesical instillations of bacillus Calmette-Guérin
                                                                    (BCG)</a>.</li>
                                                            <li>TUR with fulguration followed by an immediate postoperative instillation
                                                                of intravesical chemotherapy followed by intravesical chemotherapy.</li>
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_55">Segmental cystectomy</a> (rarely indicated).</li>
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_58">Radical cystectomy</a> (in rare, highly selected patients
                                                                with extensive or refractory superficial high-grade tumors).</li>
                                                        </ol>
                                                    </div>
                                                    <section id="_46">
                                                        <h4 id="_46_toc">Transurethral resection (TUR) with fulguration followed by an immediate
                                                            postoperative instillation of intravesical chemotherapy</h4>
                                                        <p id="_47" tabindex="-1">TUR and fulguration are the most common and conservative forms of
                                                            management. Careful surveillance of subsequent bladder tumor
                                                            progression is important. Because most bladder cancers recur
                                                            after TUR, one immediate intravesical instillation of chemotherapy
                                                            after TUR is often administered. Numerous randomized controlled
                                                            trials have evaluated this practice, and a meta-analysis of seven
                                                            trials reported that a single intravesical treatment with chemotherapy
                                                            reduced the odds of recurrence by 39% (odds ratio, [OR] 0.61;
                                                            <em>P</em> &lt; .0001).[
                                                            <a href="#cit/section_5.7">7</a>,
                                                            <a href="#cit/section_5.8">8</a>] However, although a single instillation of chemotherapy
                                                            lowers the relapse rate in patients with multiple tumors, the
                                                            majority still relapse. Such treatment is thus not sufficient
                                                            by itself for these patients.</p>
                                                        <p id="_274" tabindex="-1">One retrospective series addressed the value of performing a second
                                                            TUR within 2 to 6 weeks of the first TUR.[
                                                            <a href="#cit/section_5.9">9</a>][
                                                            <a href="/Common/PopUps/popDefinition.aspx?id=587990&amp;version=HealthProfessional&amp;language=English"
                                                                onclick="javascript:popWindow('defbyid','CDR0000587990&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiDiv</a>] A second TUR performed on 38 patients
                                                            with Tis or Ta disease revealed that nine patients (24%) had
                                                            lamina propria invasion (T1) and three patients (8%) had muscle
                                                            invasion (T2).[
                                                            <a href="#cit/section_5.9">9</a>]</p>
                                                        <p id="_275" tabindex="-1">Such information may change the definitive management options in
                                                            these individuals. Patients with extensive multifocal recurrent
                                                            disease and/or other unfavorable prognostic features require
                                                            more aggressive forms of treatment.</p>
                                                        <p id="_214" tabindex="-1">Evidence (TUR with fulguration followed by immediate postoperative
                                                            instillation of intravesical chemotherapy):</p>
                                                        <div class="pdq-content-list">
                                                            <ol id="_276">
                                                                <li>A 2004 meta-analysis of seven randomized controlled trials
                                                                    (1,476 subjects with stage Ta or stage T1 bladder cancer)
                                                                    compared TUR alone with TUR followed by a single immediate
                                                                    intravesical instillation of chemotherapy.[
                                                                    <a href="#cit/section_5.7">7</a>]
                                                                    <div class="pdq-content-list">
                                                                        <ul id="_410">
                                                                            <li>The relapse rate for TUR alone was 48% and 37%
                                                                                for TUR plus intravesical chemotherapy (OR,
                                                                                0.61;
                                                                                <em>P</em> &lt; .0001). The risk of recurrence
                                                                                declined for patients with single (OR, 0.61)
                                                                                or multiple (OR, 0.44) tumors, but 65% of
                                                                                those with multiple tumors relapsed despite
                                                                                intravesical chemotherapy. </li>
                                                                            <li>Agents studied included epirubicin, mitomycin
                                                                                C (MMC), thiotepa, and pirarubicin.</li>
                                                                        </ul>
                                                                    </div>
                                                                </li>
                                                                <li>A subsequent multicenter randomized controlled trial confirmed
                                                                    the reduction in risk of recurrence. A 404-patient study
                                                                    reported a relapse rate of 51% for epirubicin immediately
                                                                    after TUR and a relapse rate of 63% for placebo immediately
                                                                    after TUR (
                                                                    <em>P</em> = .04). However, only small recurrences were prevented
                                                                    in this study, drawing into question the magnitude of
                                                                    benefit.[
                                                                    <a href="#cit/section_5.10">10</a>] </li>
                                                                <li>Similarly, another multicenter randomized controlled trial
                                                                    confirmed the reduction in risk of recurrence. A 305-patient
                                                                    study randomly assigned subjects to an instillation of
                                                                    epirubicin versus no further treatment after TUR and
                                                                    reported relapse rates of 62% with epirubicin and 77%
                                                                    in the control arm (
                                                                    <em>P</em> = .016).[
                                                                    <a href="#cit/section_5.8">8</a>]
                                                                    <div class="pdq-content-list">
                                                                        <ul id="_411">
                                                                            <li>The hazard ratio for recurrence was 0.56 (
                                                                                <em>P</em> = .002) with epirubicin. However,
                                                                                the main benefit was seen in patients at
                                                                                lower risk of relapse. Among patients at
                                                                                intermediate or high risk of relapse, the
                                                                                relapse rates were 81% with epirubicin versus
                                                                                85% with no further treatment (
                                                                                <em>P</em> = .35).</li>
                                                                        </ul>
                                                                    </div>
                                                                </li>
                                                            </ol>
                                                        </div>
                                                    </section>
                                                    <section id="_52">
                                                        <h4 id="_52_toc">TUR with fulguration followed by an immediate postoperative instillation
                                                            of intravesical chemotherapy followed by periodic intravesical
                                                            instillations of BCG</h4>
                                                        <p id="_457" tabindex="-1">Intravesical BCG is the treatment of choice for reducing the risk
                                                            of cancer progression and is mainly used for cancers with an
                                                            intermediate or high risk of progressing.[
                                                            <a href="#cit/section_5.6">6</a>,
                                                            <a href="#cit/section_5.11">11</a>-
                                                            <a href="#cit/section_5.13">13</a>] An individual patient meta-analysis of randomized trials
                                                            comparing intravesical BCG with intravesical MMC reported that
                                                            there was a 32% reduction in risk of recurrence with BCG but
                                                            only when the BCG treatment included a maintenance phase whereby
                                                            BCG was given periodically for at least 1 year (typically an
                                                            induction phase of six weekly treatments followed by three weekly
                                                            treatments every 3 months).[
                                                            <a href="#cit/section_5.12">12</a>] Intravesical chemotherapy is tolerated better than intravesical
                                                            BCG.[
                                                            <a href="#cit/section_5.14">14</a>-
                                                            <a href="#cit/section_5.18">18</a>] Although BCG may not prolong overall survival for Tis
                                                            disease, it appears to afford complete response rates of about
                                                            70%, thereby decreasing the need for salvage cystectomy.[
                                                            <a href="#cit/section_5.17">17</a>] Studies show that intravesical BCG delays tumor recurrence
                                                            and tumor progression.[
                                                            <a href="#cit/section_5.19">19</a>,
                                                            <a href="#cit/section_5.18">18</a>]</p>
                                                        <p id="_53" tabindex="-1">Intravesical therapy with thiotepa, MMC, doxorubicin, or BCG is most
                                                            often used in patients with multiple tumors or recurrent tumors
                                                            or as a prophylactic measure in high-risk patients after TUR.[
                                                            <a
                                                                href="#cit/section_5.20">20</a>-
                                                                <a href="#cit/section_5.22">22</a>] </p>
                                                        <p id="_216" tabindex="-1">Evidence (TUR with fulguration followed by an immediate postoperative
                                                            instillation of intravesical chemotherapy followed by periodic
                                                            intravesical instillations of BCG):</p>
                                                        <p id="_458" tabindex="-1">Intravesical chemotherapy </p>
                                                        <div class="pdq-content-list">
                                                            <ol id="_248">
                                                                <li>Three meta-analyses of randomized controlled trials that
                                                                    compared TUR alone with TUR followed by intravesical
                                                                    chemotherapy reported that adjuvant therapy was associated
                                                                    with a statistically significant increase in time to
                                                                    recurrence.[
                                                                    <a href="#cit/section_5.23">23</a>-
                                                                    <a href="#cit/section_5.25">25</a>] No advantage has been shown with respect to survival
                                                                    or prevention of progression to invasive disease or metastases.</li>
                                                            </ol>
                                                        </div>
                                                        <p id="_375" tabindex="-1">Intravesical BCG with maintenance BCG treatments</p>
                                                        <div class="pdq-content-list">
                                                            <ol id="_376">
                                                                <li>An individual patient meta-analysis of nine randomized trials
                                                                    (2,820 subjects with Ta or T1 bladder cancer) that compared
                                                                    intravesical BCG with intravesical MMC was published.[
                                                                    <a
                                                                        href="#cit/section_5.12">12</a>]
                                                                        <div class="pdq-content-list">
                                                                            <ul id="_412">
                                                                                <li>Among trials in which the BCG treatment included
                                                                                    a maintenance component, there was a
                                                                                    32% reduction in risk of recurrence (
                                                                                    <em>P</em> &lt; .0001) compared with MMC;
                                                                                    BCG was associated with a 28% increase
                                                                                    in the risk of recurrence when there
                                                                                    was no maintenance BCG administered compared
                                                                                    with MMC. </li>
                                                                                <li>There were no differences in progression
                                                                                    or death.[
                                                                                    <a href="#cit/section_5.12">12</a>]</li>
                                                                            </ul>
                                                                        </div>
                                                                </li>
                                                                <li>A meta-analysis of nine randomized controlled trials (2,410
                                                                    subjects) that compared intravesical BCG with MMC was
                                                                    published.[
                                                                    <a href="#cit/section_5.26">26</a>]
                                                                    <div class="pdq-content-list">
                                                                        <ul id="_413">
                                                                            <li>Progression was observed in 7.67% of the BCG
                                                                                subjects and 9.44% of MMC subjects at a median
                                                                                follow-up of 26 months (
                                                                                <em>P</em> = .08).</li>
                                                                            <li> When the analysis was limited to trials in which
                                                                                the BCG arm included a maintenance component,
                                                                                the progression rate was significantly lower
                                                                                in the BCG subjects (OR, 0.66; 95% confidence
                                                                                interval, 0.47-0.94;
                                                                                <em>P</em> = .02).</li>
                                                                        </ul>
                                                                    </div>
                                                                </li>
                                                                <li>A meta-analysis of the published results of nine randomized
                                                                    controlled trials that compared intravesical BCG with
                                                                    intravesical chemotherapy in 700 patients with carcinoma
                                                                    <em>in situ</em> of the bladder was published.[
                                                                    <a href="#cit/section_5.11">11</a>]
                                                                    <div class="pdq-content-list">
                                                                        <ul id="_414">
                                                                            <li>With a median follow-up of 3.6 years, 47% of
                                                                                the BCG group had no evidence of disease
                                                                                and 26% of the chemotherapy group had no
                                                                                evidence of disease. </li>
                                                                            <li>BCG was superior to MMC at preventing recurrence
                                                                                only when maintenance BCG was part of the
                                                                                treatment.</li>
                                                                        </ul>
                                                                    </div>
                                                                </li>
                                                                <li>A controlled trial evaluated 384 patients randomly assigned
                                                                    to induction intravesical BCG or induction intravesical
                                                                    BCG followed by maintenance intravesical BCG.[
                                                                    <a href="#cit/section_5.27">27</a>]
                                                                    <div class="pdq-content-list">
                                                                        <ul id="_415">
                                                                            <li>Median recurrence-free survival was 36 months
                                                                                without maintenance BCG and 77 months in
                                                                                the maintenance arm (
                                                                                <em>P</em> &lt; .0001). The risk of disease worsening
                                                                                (progression to T2 or greater disease, use
                                                                                of cystectomy, systemic chemotherapy, or
                                                                                radiation therapy) was greater in the induction
                                                                                arm than in the maintenance arm
                                                                                <em>(P</em> = .04). </li>
                                                                            <li>5-year overall survival was 78% in the induction-only
                                                                                arm versus 83% in the maintenance arm, but
                                                                                this difference was not statistically significant.</li>
                                                                        </ul>
                                                                    </div>
                                                                </li>
                                                            </ol>
                                                        </div>
                                                        <p id="_387" tabindex="-1">BCG is associated with a risk of significant toxicity, including
                                                            rare deaths from BCG sepsis. Compared with MMC, BCG produces
                                                            more local toxicity (44% with BCG vs. 30% with MMC) and systemic
                                                            side effects (19% with BCG vs. 12% with MMC). Because of concerns
                                                            about side effects and toxicity, BCG is not generally used for
                                                            patients with a low risk of progression to advanced-stage disease.[
                                                            <a
                                                                href="#cit/section_5.6">6</a>,
                                                                <a href="#cit/section_5.26">26</a>]</p>
                                                    </section>
                                                    <section id="_55">
                                                        <h4 id="_55_toc">Segmental cystectomy (rarely indicated)</h4>
                                                        <p id="_56" tabindex="-1">Segmental cystectomy is rarely indicated.[
                                                            <a href="#cit/section_5.22">22</a>] It is applicable to only a small minority of patients
                                                            because of the tendency of bladder cancer to involve multiple
                                                            regions of the bladder mucosa and to occur in areas that cannot
                                                            be segmentally resected. Moreover, cystectomy (whether segmental
                                                            or radical) is generally not indicated for T0 bladder cancer
                                                            (see
                                                            <a href="/types/bladder/hp/bladder-treatment-pdq#link/_58">radical cystectomy</a> below).[
                                                            <a href="#cit/section_5.28">28</a>,
                                                            <a href="#cit/section_5.29">29</a>]</p>
                                                    </section>
                                                    <section id="_58">
                                                        <h4 id="_58_toc">Radical cystectomy (in rare, highly selected patients with extensive
                                                            or refractory superficial high-grade tumors)</h4>
                                                        <p id="_59" tabindex="-1">Radical cystectomy is used in selected patients with extensive or
                                                            refractory superficial tumor,[
                                                            <a href="#cit/section_5.30">30</a>,
                                                            <a href="#cit/section_5.2">2</a>,
                                                            <a href="#cit/section_5.31">31</a>] based on reports that up to 20% of patients with Tis
                                                            will die of bladder cancer. However, cystectomy (whether segmental
                                                            or radical) is generally not indicated for patients with Ta or
                                                            Tis bladder cancer. Patients at high risk of progression, typically
                                                            those with recurrent high-grade tumors with carcinoma
                                                            <em>in situ</em> after intravesical therapy with BCG, should be considered
                                                            for radical cystectomy.[
                                                            <a href="#cit/section_5.32">32</a>-
                                                            <a href="#cit/section_5.35">35</a>]</p>
                                                    </section>
                                                </section>
                                                <section id="_TrialSearch_42_sid_5">
                                                    <h3 id="_TrialSearch_42_sid_5_toc">Current Clinical Trials</h3>
                                                    <p id="_TrialSearch_42_22" tabindex="-1">Use our
                                                        <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search"
                                                            title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">advanced clinical trial search</a> to find NCI-supported cancer clinical
                                                        trials that are now enrolling patients. The search can be narrowed
                                                        by location of the trial, type of treatment, name of the drug, and
                                                        other criteria.
                                                        <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/"
                                                            title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/">General information</a> about clinical trials is also available.</p>
                                                </section>
                                                <h6 do-not-show="toc">References</h6>
                                                <ol>
                                                    <li id="section_5.1">Holmäng S, Hedelin H, Anderström C, et al.: The relationship among multiple
                                                        recurrences, progression and prognosis of patients with stages Ta
                                                        and T1 transitional cell cancer of the bladder followed for at least
                                                        20 years. J Urol 153 (6): 1823-6; discussion 1826-7, 1995.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7752327&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7752327&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.2">Herr HW: Tumor progression and survival of patients with high grade,
                                                        noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol
                                                        163 (1): 60-1; discussion 61-2, 2000.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10604314&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10604314&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.3">Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, et al.: Upper
                                                        urinary tract tumors after primary superficial bladder tumors: prognostic
                                                        factors and risk groups. J Urol 164 (4): 1183-7, 2000.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10992362&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10992362&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.4">Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, et al.: Multivariate
                                                        analysis of the prognostic factors of primary superficial bladder
                                                        cancer. J Urol 163 (1): 73-8, 2000.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10604317&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10604317&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.5">Babjuk M, Oosterlinck W, Sylvester R, et al.: EAU guidelines on non-muscle-invasive
                                                        urothelial carcinoma of the bladder. Eur Urol 54 (2): 303-14, 2008.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18468779&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18468779&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.6">Babjuk M, Oosterlinck W, Sylvester R, et al.: EAU guidelines on non-muscle-invasive
                                                        urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59
                                                        (6): 997-1008, 2011.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21458150&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21458150&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.7">Sylvester RJ, Oosterlinck W, van der Meijden AP: A single immediate postoperative
                                                        instillation of chemotherapy decreases the risk of recurrence in
                                                        patients with stage Ta T1 bladder cancer: a meta-analysis of published
                                                        results of randomized clinical trials. J Urol 171 (6 Pt 1): 2186-90,
                                                        quiz 2435, 2004.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15126782&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15126782&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.8">Gudjónsson S, Adell L, Merdasa F, et al.: Should all patients with non-muscle-invasive
                                                        bladder cancer receive early intravesical chemotherapy after transurethral
                                                        resection? The results of a prospective randomised multicentre study.
                                                        Eur Urol 55 (4): 773-80, 2009.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19153001&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19153001&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.9">Herr HW: The value of a second transurethral resection in evaluating
                                                        patients with bladder tumors. J Urol 162 (1): 74-6, 1999.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10379743&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10379743&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.10">Berrum-Svennung I, Granfors T, Jahnson S, et al.: A single instillation
                                                        of epirubicin after transurethral resection of bladder tumors prevents
                                                        only small recurrences. J Urol 179 (1): 101-5; discussion 105-6,
                                                        2008.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17997459&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17997459&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.11">Sylvester RJ, van der Meijden AP, Witjes JA, et al.: Bacillus calmette-guerin
                                                        versus chemotherapy for the intravesical treatment of patients with
                                                        carcinoma in situ of the bladder: a meta-analysis of the published
                                                        results of randomized clinical trials. J Urol 174 (1): 86-91; discussion
                                                        91-2, 2005.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15947584&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15947584&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.12">Malmström PU, Sylvester RJ, Crawford DE, et al.: An individual patient
                                                        data meta-analysis of the long-term outcome of randomised studies
                                                        comparing intravesical mitomycin C versus bacillus Calmette-Guérin
                                                        for non-muscle-invasive bladder cancer. Eur Urol 56 (2): 247-56,
                                                        2009.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19409692&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19409692&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.13">Stenzl A, Cowan NC, De Santis M, et al.: Treatment of muscle-invasive
                                                        and metastatic bladder cancer: update of the EAU guidelines. Eur
                                                        Urol 59 (6): 1009-18, 2011.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21454009&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21454009&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.14">Herr HW, Schwalb DM, Zhang ZF, et al.: Intravesical bacillus Calmette-Guérin
                                                        therapy prevents tumor progression and death from superficial bladder
                                                        cancer: ten-year follow-up of a prospective randomized trial. J Clin
                                                        Oncol 13 (6): 1404-8, 1995.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7751885&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7751885&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.15">Sarosdy MF, Lamm DL: Long-term results of intravesical bacillus Calmette-Guerin
                                                        therapy for superficial bladder cancer. J Urol 142 (3): 719-22, 1989.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2769847&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2769847&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.16">Catalona WJ, Hudson MA, Gillen DP, et al.: Risks and benefits of repeated
                                                        courses of intravesical bacillus Calmette-Guerin therapy for superficial
                                                        bladder cancer. J Urol 137 (2): 220-4, 1987.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3806806&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3806806&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.17">De Jager R, Guinan P, Lamm D, et al.: Long-term complete remission in
                                                        bladder carcinoma in situ with intravesical TICE bacillus Calmette
                                                        Guerin. Overview analysis of six phase II clinical trials. Urology
                                                        38 (6): 507-13, 1991.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1836081&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1836081&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.18">Herr HW, Wartinger DD, Fair WR, et al.: Bacillus Calmette-Guerin therapy
                                                        for superficial bladder cancer: a 10-year followup. J Urol 147 (4):
                                                        1020-3, 1992.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1552578&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1552578&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.19">Lamm DL, Griffith JG: Intravesical therapy: does it affect the natural
                                                        history of superficial bladder cancer? Semin Urol 10 (1): 39-44,
                                                        1992.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1565903&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1565903&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.20">Igawa M, Urakami S, Shirakawa H, et al.: Intravesical instillation of
                                                        epirubicin: effect on tumour recurrence in patients with dysplastic
                                                        epithelium after transurethral resection of superficial bladder tumour.
                                                        Br J Urol 77 (3): 358-62, 1996.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8814838&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8814838&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.21">Lamm DL, Blumenstein BA, Crawford ED, et al.: A randomized trial of intravesical
                                                        doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell
                                                        carcinoma of the bladder. N Engl J Med 325 (17): 1205-9, 1991.
                                                        <a
                                                            href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1922207&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1922207&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.22">Soloway MS: The management of superficial bladder cancer. In: Javadpour
                                                        N, ed.: Principles and Management of Urologic Cancer. 2nd ed. Baltimore,
                                                        Md: Williams and Wilkins, 1983, pp 446-467.</li>
                                                    <li id="section_5.23">Pawinski A, Sylvester R, Kurth KH, et al.: A combined analysis of European
                                                        Organization for Research and Treatment of Cancer, and Medical Research
                                                        Council randomized clinical trials for the prophylactic treatment
                                                        of stage TaT1 bladder cancer. European Organization for Research
                                                        and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group
                                                        and the Medical Research Council Working Party on Superficial Bladder
                                                        Cancer. J Urol 156 (6): 1934-40, discussion 1940-1, 1996.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8911360&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8911360&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.24">Huncharek M, Geschwind JF, Witherspoon B, et al.: Intravesical chemotherapy
                                                        prophylaxis in primary superficial bladder cancer: a meta-analysis
                                                        of 3703 patients from 11 randomized trials. J Clin Epidemiol 53 (7):
                                                        676-80, 2000.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10941943&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10941943&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.25">Huncharek M, McGarry R, Kupelnick B: Impact of intravesical chemotherapy
                                                        on recurrence rate of recurrent superficial transitional cell carcinoma
                                                        of the bladder: results of a meta-analysis. Anticancer Res 21 (1B):
                                                        765-9, 2001 Jan-Feb.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11299841&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11299841&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.26">Böhle A, Bock PR: Intravesical bacille Calmette-Guérin versus mitomycin
                                                        C in superficial bladder cancer: formal meta-analysis of comparative
                                                        studies on tumor progression. Urology 63 (4): 682-6; discussion 686-7,
                                                        2004.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15072879&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15072879&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.27">Lamm DL, Blumenstein BA, Crissman JD, et al.: Maintenance bacillus Calmette-Guerin
                                                        immunotherapy for recurrent TA, T1 and carcinoma in situ transitional
                                                        cell carcinoma of the bladder: a randomized Southwest Oncology Group
                                                        Study. J Urol 163 (4): 1124-9, 2000.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10737480&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10737480&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.28">Holzbeierlein JM, Lopez-Corona E, Bochner BH, et al.: Partial cystectomy:
                                                        a contemporary review of the Memorial Sloan-Kettering Cancer Center
                                                        experience and recommendations for patient selection. J Urol 172
                                                        (3): 878-81, 2004.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15310988&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15310988&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.29">Fahmy N, Aprikian A, Tanguay S, et al.: Practice patterns and recurrence
                                                        after partial cystectomy for bladder cancer. World J Urol 28 (4):
                                                        419-23, 2010.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19826825&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19826825&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.30">Amling CL, Thrasher JB, Frazier HA, et al.: Radical cystectomy for stages
                                                        Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol
                                                        151 (1): 31-5; discussion 35-6, 1994.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8254828&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8254828&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.31">Sylvester RJ, van der Meijden A, Witjes JA, et al.: High-grade Ta urothelial
                                                        carcinoma and carcinoma in situ of the bladder. Urology 66 (6 Suppl
                                                        1): 90-107, 2005.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16399418&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16399418&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.32">Madersbacher S, Hochreiter W, Burkhard F, et al.: Radical cystectomy
                                                        for bladder cancer today--a homogeneous series without neoadjuvant
                                                        therapy. J Clin Oncol 21 (4): 690-6, 2003.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12586807&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12586807&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.33">Stein JP, Dunn MD, Quek ML, et al.: The orthotopic T pouch ileal neobladder:
                                                        experience with 209 patients. J Urol 172 (2): 584-7, 2004.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15247737&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15247737&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.34">Lerner SP, Tangen CM, Sucharew H, et al.: Failure to achieve a complete
                                                        response to induction BCG therapy is associated with increased risk
                                                        of disease worsening and death in patients with high risk non-muscle
                                                        invasive bladder cancer. Urol Oncol 27 (2): 155-9, 2009 Mar-Apr.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18367117&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18367117&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_5.35">Manoharan M, Ayyathurai R, Soloway MS: Radical cystectomy for urothelial
                                                        carcinoma of the bladder: an analysis of perioperative and survival
                                                        outcome. BJU Int 104 (9): 1227-32, 2009.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19519764&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19519764&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                </ol>
                                            </div>
                                        </section>


                                        <section id="_65">
                                            <h2>Stage I Bladder Cancer Treatment</h2>
                                            <div id="_section_65" class="pdq-sections">
                                                <section id="_66">
                                                    <h3 id="_66_toc">Standard Treatment Options for Stage I Bladder Cancer</h3>
                                                    <p id="_104" tabindex="-1">Patients with
                                                        <a href="/types/bladder/hp/bladder-treatment-pdq#link/_463">stage I bladder tumors</a> are unlikely to die from bladder cancer,
                                                        but the tendency for new tumor formation is high. In a series of
                                                        patients with Ta or T1 tumors who were followed for a minimum of
                                                        20 years or until death, the risk of bladder recurrence after initial
                                                        resection was 80%.[
                                                        <a href="#cit/section_6.1">1</a>] Of greater concern than recurrence is the risk of progression
                                                        to muscle-invasive, locally-advanced, or metastatic bladder cancer.
                                                        While progression is rare for low-grade tumors, it is common among
                                                        high-grade cancers. </p>
                                                    <p id="_382" tabindex="-1">One series of 125 patients with TaG3 cancers followed for 15 to 20 years
                                                        reported that 39% progressed to more advanced stage disease, while
                                                        26% died of urothelial cancer. In comparison, among 23 patients with
                                                        TaG1 tumors, none died and 5% progressed.[
                                                        <a href="#cit/section_6.2">2</a>] Risk factors for recurrence and progression include the following:[
                                                        <a
                                                            href="#cit/section_6.2">2</a>-
                                                            <a href="#cit/section_6.6">6</a>]</p>
                                                    <div class="pdq-content-list">
                                                        <ul id="_332">
                                                            <li>High-grade disease.</li>
                                                            <li>Presence of carcinoma
                                                                <em>in situ</em>.</li>
                                                            <li>Tumor larger than 3 cm.</li>
                                                            <li>Multiple tumors.</li>
                                                            <li>History of prior bladder cancer.</li>
                                                        </ul>
                                                    </div>
                                                    <p id="_67" tabindex="-1">Standard treatment options for stage I bladder cancer include the following:</p>
                                                    <div class="pdq-content-list">
                                                        <ol id="_68">
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_69">Transurethral resection (TUR) with fulguration followed by
                                                                    an immediate postoperative instillation of intravesical
                                                                    chemotherapy</a>.</li>
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_333">TUR with fulguration</a>.</li>
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_72">TUR with fulguration followed by an immediate postoperative
                                                                    instillation of intravesical chemotherapy followed by
                                                                    periodic intravesical instillations of bacillus Calmette-Guérin
                                                                    (BCG)</a>.</li>
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_75">TUR with fulguration followed by an immediate postoperative
                                                                    instillation of intravesical chemotherapy followed by
                                                                    intravesical chemotherapy</a>. </li>
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_78">Segmental cystectomy</a> (rarely indicated).</li>
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_81">Radical cystectomy</a> (in selected patients with extensive
                                                                or refractory superficial tumors).</li>
                                                        </ol>
                                                    </div>
                                                    <section id="_69">
                                                        <h4 id="_69_toc">TUR with fulguration followed by an immediate postoperative instillation
                                                            of intravesical chemotherapy</h4>
                                                        <p id="_70" tabindex="-1">TUR and fulguration are the most common and conservative forms of
                                                            management. Careful surveillance of subsequent bladder tumor
                                                            progression is important. Because most bladder cancers recur
                                                            after TUR, one immediate intravesical instillation of chemotherapy
                                                            after TUR is widely used. Numerous randomized, controlled trials
                                                            have evaluated this practice, and a meta-analysis of seven trials
                                                            reported that a single intravesical treatment with chemotherapy
                                                            reduced the odds of recurrence by 39% (odds ratio [OR], 0.61;
                                                            <em>P </em>&lt; .0001).[
                                                            <a href="#cit/section_6.7">7</a>,
                                                            <a href="#cit/section_6.8">8</a>]</p>
                                                    </section>
                                                    <section id="_333">
                                                        <h4 id="_333_toc">TUR with fulguration</h4>
                                                        <p id="_334" tabindex="-1">Staging a bladder cancer via TUR is based on the extent of invasion.
                                                            To assess whether cancer has invaded the muscle, muscularis propria
                                                            must be present in the resected tissue. While a repeat TUR is
                                                            generally considered mandatory for T1 and high-grade noninvasive
                                                            bladder cancers if no muscularis propria is present in the resected
                                                            tissue from the first TUR, many experts recommend that a second
                                                            TUR be routinely performed within 2 to 6 weeks of the first TUR
                                                            to confirm staging and achieve a more complete resection. The
                                                            rationale for this derives from numerous findings, including
                                                            the following: </p>
                                                        <div class="pdq-content-list">
                                                            <ul id="_383">
                                                                <li>The risk of local recurrence after TUR is high.</li>
                                                                <li>Residual cancer is often found when a repeat TUR is performed.</li>
                                                                <li>More-advanced–stage cancer is sometimes found with repeat
                                                                    TUR.</li>
                                                                <li>Patients undergoing radical cystectomy for nonmuscle-invasive
                                                                    bladder cancer are often found to have T2 or greater
                                                                    disease when the cystectomy specimen is examined.</li>
                                                                <li>A substantial number of patients with high-grade nonmuscle-invasive
                                                                    bladder cancer subsequently die from their disease.</li>
                                                            </ul>
                                                        </div>
                                                        <p id="_425" tabindex="-1">Evidence (routine repeat TUR):</p>
                                                        <div class="pdq-content-list">
                                                            <ol id="_426">
                                                                <li>A review of more than 2,400 patients from over 60 different
                                                                    institutions reported a 3-month recurrence rate of roughly
                                                                    14% to 20% after TUR, while a literature review reported
                                                                    that up to 10% of patients who underwent a second TUR
                                                                    for Ta to T1 cancer were upstaged to T2.[
                                                                    <a href="#cit/section_6.9">9</a>] The likelihood of being upstaged to T2 is much
                                                                    higher when no muscularis propria is present in the initial
                                                                    TUR tissue.[
                                                                    <a href="#cit/section_6.10">10</a>]</li>
                                                                <li>One retrospective series of 38 patients with Tis or Ta disease
                                                                    who underwent a second TUR found that nine patients (24%)
                                                                    had lamina propria invasion (T1) and three patients (8%)
                                                                    had muscle invasion (T2).[
                                                                    <a href="#cit/section_6.11">11</a>] </li>
                                                                <li>A subsequent study from a different institution reported
                                                                    that among 214 patients with Ta to T1 cancers who underwent
                                                                    a second TUR, 27% of Ta and 37% of T1 patients had residual
                                                                    cancer detected.[
                                                                    <a href="#cit/section_6.12">12</a>] </li>
                                                                <li>A review of other published papers reported that residual
                                                                    tumor was present in 27% to 62% of cases, and muscle-invasive
                                                                    disease was discovered in 1% to 10% of case series with
                                                                    at least 50 subjects.[
                                                                    <a href="#cit/section_6.10">10</a>]</li>
                                                            </ol>
                                                        </div>
                                                        <p id="_336" tabindex="-1">Repeat TUR has not been shown to reduce relapse rates or prolong
                                                            survival, but there is a clear rationale for seeking accurate
                                                            staging information on which to base treatment decisions. Such
                                                            information may change the definitive management options for
                                                            patients and identify patients who are more likely to benefit
                                                            from more aggressive treatment.</p>
                                                    </section>
                                                    <section id="_72">
                                                        <h4 id="_72_toc">TUR with fulguration followed by an immediate postoperative instillation
                                                            of intravesical chemotherapy followed by periodic intravesical
                                                            instillations of BCG</h4>
                                                        <p id="_337" tabindex="-1">Intravesical BCG is the treatment of choice for reducing the risk
                                                            of cancer progression and is mainly used for cancers with an
                                                            intermediate or high risk of progressing.[
                                                            <a href="#cit/section_6.6">6</a>,
                                                            <a href="#cit/section_6.13">13</a>-
                                                            <a href="#cit/section_6.15">15</a>] An individual patient meta-analysis of randomized trials
                                                            that compared intravesical BCG with intravesical mitomycin C
                                                            (MMC) reported that there was a 32% reduction in risk of recurrence
                                                            with BCG but only when the BCG treatment included a maintenance
                                                            phase whereby BCG was given periodically for at least 1 year
                                                            (typically an induction phase of six weekly treatments followed
                                                            by three weekly treatments every 3 months).[
                                                            <a href="#cit/section_6.14">14</a>] Intravesical chemotherapy is tolerated better than intravesical
                                                            BCG.[
                                                            <a href="#cit/section_6.16">16</a>-
                                                            <a href="#cit/section_6.20">20</a>] Although BCG may not prolong overall survival for Tis
                                                            disease, it appears to afford complete response rates of about
                                                            70%, thereby decreasing the need for salvage cystectomy.[
                                                            <a href="#cit/section_6.19">19</a>] Studies show that intravesical BCG delays tumor recurrence
                                                            and tumor progression.[
                                                            <a href="#cit/section_6.21">21</a>,
                                                            <a href="#cit/section_6.20">20</a>]</p>
                                                        <p id="_221" tabindex="-1">Evidence (immediate intravesical chemotherapy after transurethral
                                                            resection):</p>
                                                        <div class="pdq-content-list">
                                                            <ol id="_282">
                                                                <li>A 2004 meta-analysis of seven randomized controlled trials
                                                                    (1,476 patients with Ta or T1 bladder cancer) compared
                                                                    TUR alone with TUR followed by a single immediate intravesical
                                                                    instillation of chemotherapy.[
                                                                    <a href="#cit/section_6.7">7</a>]
                                                                    <div class="pdq-content-list">
                                                                        <ul id="_416">
                                                                            <li> The relapse rates were 48% with TUR alone and
                                                                                37% for TUR plus intravesical chemotherapy
                                                                                (OR, 0.61;
                                                                                <em>P</em> &lt; .0001). The risk of recurrence
                                                                                declined for patients with single (OR, 0.61)
                                                                                or multiple (OR, 0.44) tumors, but 65% of
                                                                                those with multiple tumors relapsed despite
                                                                                intravesical chemotherapy.</li>
                                                                            <li>Agents studied included epirubicin, MMC, thiotepa,
                                                                                and pirarubicin.[
                                                                                <a href="#cit/section_6.7">7</a>]</li>
                                                                        </ul>
                                                                    </div>
                                                                </li>
                                                                <li>A subsequent multicenter, randomized, controlled trial confirmed
                                                                    the reduction in risk of recurrence. A 404-patient study
                                                                    reported a relapse rate of 51% for epirubicin immediately
                                                                    after TUR and a relapse rate of 63% for placebo immediately
                                                                    after TUR (
                                                                    <em>P</em> = .04). However, only small recurrences were prevented
                                                                    in this study, drawing into question the magnitude of
                                                                    benefit.[
                                                                    <a href="#cit/section_6.22">22</a>] </li>
                                                                <li>Similarly, another multicenter, randomized, controlled trial
                                                                    confirmed the reduction in risk of recurrence. A 305-patient
                                                                    study randomly assigned subjects to an instillation of
                                                                    epirubicin or no further treatment after TUR and reported
                                                                    relapse rates of 62% with epirubicin versus 77% in the
                                                                    control arm (
                                                                    <em>P</em> = .016).[
                                                                    <a href="#cit/section_6.8">8</a>]
                                                                    <div class="pdq-content-list">
                                                                        <ul id="_417">
                                                                            <li>The hazard ratio for recurrence was 0.56 (
                                                                                <em>P</em> = .002) with epirubicin. However,
                                                                                the main benefit was seen in patients at
                                                                                lower risk of relapse. Among patients at
                                                                                intermediate or high risk of relapse, the
                                                                                relapse rates were 81% with epirubicin versus
                                                                                85% with no further treatment (
                                                                                <em>P</em> = .35).</li>
                                                                        </ul>
                                                                    </div>
                                                                </li>
                                                            </ol>
                                                        </div>
                                                        <p id="_388" tabindex="-1">Evidence (intravesical BCG with maintenance BCG treatments):</p>
                                                        <div class="pdq-content-list">
                                                            <ol id="_389">
                                                                <li>An individual patient meta-analysis of nine randomized trials
                                                                    (2,820 subjects with Ta or T1 bladder cancer) that compared
                                                                    intravesical BCG with intravesical MMC was published.[
                                                                    <a
                                                                        href="#cit/section_6.14">14</a>]
                                                                        <div class="pdq-content-list">
                                                                            <ul id="_418">
                                                                                <li>Among trials in which the BCG treatment included
                                                                                    a maintenance component, there was a
                                                                                    32% reduction in risk of recurrence (
                                                                                    <em>P</em> &lt; .0001) compared with MMC;
                                                                                    BCG was associated with a 28% increase
                                                                                    in the risk of recurrence when no maintenance
                                                                                    BCG was given compared with MMC. </li>
                                                                                <li>There were no differences in progression
                                                                                    or death.</li>
                                                                            </ul>
                                                                        </div>
                                                                </li>
                                                                <li>A meta-analysis of nine randomized, controlled trials (2,410
                                                                    subjects) that compared intravesical BCG with MMC was
                                                                    published.[
                                                                    <a href="#cit/section_6.23">23</a>]
                                                                    <div class="pdq-content-list">
                                                                        <ul id="_419">
                                                                            <li>Progression was seen in 7.67% of the BCG subjects
                                                                                and 9.44% of MMC subjects at a median follow-up
                                                                                of 26 months (
                                                                                <em>P</em> = .08).</li>
                                                                            <li> When the analysis was limited to trials in which
                                                                                the BCG arm included a maintenance component,
                                                                                the progression rate was significantly lower
                                                                                in the BCG subjects (OR, 0.66; 95% confidence
                                                                                interval, 0.47–0.94;
                                                                                <em>P</em> = .02).</li>
                                                                        </ul>
                                                                    </div>
                                                                </li>
                                                                <li>A meta-analysis of the published results of nine randomized,
                                                                    controlled trials that compared intravesical BCG with
                                                                    intravesical chemotherapy in 700 patients with carcinoma
                                                                    <em>in situ</em> of the bladder was published.[
                                                                    <a href="#cit/section_6.13">13</a>]
                                                                    <div class="pdq-content-list">
                                                                        <ul id="_420">
                                                                            <li>With a median follow-up of 3.6 years, 47% of
                                                                                the BCG group had no evidence of disease
                                                                                and 26% of the chemotherapy group had no
                                                                                evidence of disease. </li>
                                                                            <li>In this meta-analysis, BCG was superior to MMC
                                                                                at preventing recurrence only when maintenance
                                                                                BCG was part of the treatment.</li>
                                                                        </ul>
                                                                    </div>
                                                                </li>
                                                                <li>A controlled trial evaluated 384 patients randomly assigned
                                                                    to induction intravesical BCG or induction intravesical
                                                                    BCG followed by maintenance intravesical BCG.[
                                                                    <a href="#cit/section_6.24">24</a>]
                                                                    <div class="pdq-content-list">
                                                                        <ul id="_421">
                                                                            <li>Median recurrence-free survival was 36 months
                                                                                without maintenance BCG and 77 months in
                                                                                the maintenance arm (
                                                                                <em>P</em> &lt; .0001). The risk of disease worsening
                                                                                (progression to T2 or greater disease, use
                                                                                of cystectomy, systemic chemotherapy, or
                                                                                radiation therapy) was greater in the induction
                                                                                arm than in the maintenance arm (
                                                                                <em>P</em> = .04). </li>
                                                                            <li>5-year overall survival was 78% in the induction-only
                                                                                arm versus 83% in the maintenance arm, but
                                                                                this difference was not statistically significant.</li>
                                                                        </ul>
                                                                    </div>
                                                                </li>
                                                            </ol>
                                                        </div>
                                                        <p id="_394" tabindex="-1">BCG is associated with a risk of significant toxicity, including
                                                            rare deaths from BCG sepsis. Compared with MMC, BCG produces
                                                            more local toxicity (44% with BCG vs. 30% with MMC) and systemic
                                                            side effects (19% with BCG vs. 12% with MMC). Because of concerns
                                                            about side effects and toxicity, BCG is not generally used for
                                                            patients with a low risk of progression to more-advanced–stage
                                                            disease.[
                                                            <a href="#cit/section_6.6">6</a>,
                                                            <a href="#cit/section_6.23">23</a>]</p>
                                                        <p id="_395" tabindex="-1">Evidence (two treatment courses of intravesical BCG):</p>
                                                        <div class="pdq-content-list">
                                                            <ol id="_396">
                                                                <li>Two nonconsecutive 6-week courses with BCG may be necessary
                                                                    to obtain optimal response.[
                                                                    <a href="#cit/section_6.25">25</a>] Patients with a T1 tumor at the 3-month evaluation
                                                                    after a 6-week course of BCG and patients with Tis that
                                                                    persists after a second 6-week BCG course have a high
                                                                    likelihood of developing muscle-invasive disease and
                                                                    should be considered for cystectomy.[
                                                                    <a href="#cit/section_6.18">18</a>,
                                                                    <a href="#cit/section_6.25">25</a>,
                                                                    <a href="#cit/section_6.26">26</a>]</li>
                                                            </ol>
                                                        </div>
                                                    </section>
                                                    <section id="_75">
                                                        <h4 id="_75_toc">TUR with fulguration followed by an immediate postoperative instillation
                                                            of intravesical chemotherapy followed by intravesical chemotherapy</h4>
                                                        <p id="_76" tabindex="-1">Intravesical therapy with thiotepa, mitomycin, doxorubicin, or BCG
                                                            is most often used in patients with multiple tumors or recurrent
                                                            tumors or as a prophylactic measure in high-risk patients after
                                                            TUR.[
                                                            <a href="#cit/section_6.27">27</a>,
                                                            <a href="#cit/section_6.28">28</a>]</p>
                                                        <p id="_340" tabindex="-1">Evidence (intravesical chemotherapy):</p>
                                                        <div class="pdq-content-list">
                                                            <ol id="_341">
                                                                <li>Three meta-analyses of randomized controlled trials that
                                                                    compared TUR alone with TUR followed by intravesical
                                                                    chemotherapy reported that adjuvant therapy was associated
                                                                    with a statistically significant increase in time to
                                                                    recurrence. No advantage has been shown with respect
                                                                    to survival or prevention of progression to invasive
                                                                    disease or metastases.[
                                                                    <a href="#cit/section_6.29">29</a>-
                                                                    <a href="#cit/section_6.31">31</a>]
                                                                    <div class="pdq-content-list">
                                                                        <ul id="_422">
                                                                            <li>One analysis of eight studies with a combined
                                                                                total of 1,609 patients reported that intravesical
                                                                                chemotherapy reduced the risk of relapse
                                                                                at 1 year by 38% and by as much as 70% at
                                                                                3 years, depending on which drugs were used.[
                                                                                <a
                                                                                    href="#cit/section_6.30">30</a>] </li>
                                                                            <li>Another analysis of 11 studies that enrolled
                                                                                a total of 3,703 patients reported a 44%
                                                                                reduction in 1-year recurrence rates.[
                                                                                <a
                                                                                    href="#cit/section_6.30">30</a>] </li>
                                                                            <li>An earlier study of 2,535 patients enrolled in
                                                                                six different randomized controlled trials
                                                                                reported a decreased risk of recurrence but
                                                                                not significant benefit with regard to risk
                                                                                of progression to more-advanced–stage disease
                                                                                or survival.[
                                                                                <a href="#cit/section_6.29">29</a>]</li>
                                                                        </ul>
                                                                    </div>
                                                                </li>
                                                            </ol>
                                                        </div>
                                                    </section>
                                                    <section id="_78">
                                                        <h4 id="_78_toc">Segmental cystectomy (rarely indicated)</h4>
                                                        <p id="_79" tabindex="-1">Segmental cystectomy is rarely indicated.[
                                                            <a href="#cit/section_6.32">32</a>] It is applicable to only a small minority of patients
                                                            because of the tendency of bladder carcinoma to involve multiple
                                                            regions of the bladder mucosa and to occur in areas that cannot
                                                            be segmentally resected. Moreover, cystectomy (whether segmental
                                                            or radical) is generally not indicated for patients with T0 bladder
                                                            cancer.[
                                                            <a href="#cit/section_6.33">33</a>,
                                                            <a href="#cit/section_6.34">34</a>]</p>
                                                    </section>
                                                    <section id="_81">
                                                        <h4 id="_81_toc">Radical cystectomy in selected patients with extensive or refractory
                                                            superficial tumors</h4>
                                                        <p id="_82" tabindex="-1">Radical cystectomy is used in selected patients with extensive or
                                                            refractory superficial tumor.[
                                                            <a href="#cit/section_6.35">35</a>-
                                                            <a href="#cit/section_6.43">43</a>] Patients at high risk of progression, typically those
                                                            with recurrent high-grade tumors with carcinoma
                                                            <em>in situ</em> after intravesical therapy with BCG, should be considered
                                                            for radical cystectomy. Other risk factors include multiple tumors
                                                            and tumors larger than 3 cm. </p>
                                                        <p id="_398" tabindex="-1">Certain patients with nonmuscle-invasive bladder cancer face a substantial
                                                            risk of progression and death from their cancers. </p>
                                                        <p id="_428" tabindex="-1">Evidence (radical cystectomy): </p>
                                                        <div class="pdq-content-list">
                                                            <ol id="_399">
                                                                <li>One analysis of 307 patients enrolled in studies of intravesical
                                                                    BCG in the 1980s reported that among 85 patients with
                                                                    T1 recurrence, 60 progressed to at least stage II disease.
                                                                    Five years after T1 recurrence, 71% had progressed and
                                                                    48% had died of their cancer.[
                                                                    <a href="#cit/section_6.44">44</a>]</li>
                                                                <li>By comparison, in another cohort of 589 patients treated
                                                                    with BCG between 1992 and 2004, 65 of the 120 patients
                                                                    with T1 recurrence underwent immediate cystectomy. Among
                                                                    all patients with T1 recurrence, 28% progressed to more-advanced–stage
                                                                    disease and 31% died of their cancer. While these data
                                                                    confirm that patients with recurring cancer after intravesical
                                                                    BCG face a substantial risk of dying of their disease,
                                                                    they do not provide strong evidence that immediate cystectomy
                                                                    results in a lower risk of death or progression.[
                                                                    <a href="#cit/section_6.44">44</a>]</li>
                                                            </ol>
                                                        </div>
                                                    </section>
                                                </section>
                                                <section id="_TrialSearch_65_sid_6">
                                                    <h3 id="_TrialSearch_65_sid_6_toc">Current Clinical Trials</h3>
                                                    <p id="_TrialSearch_65_22" tabindex="-1">Use our
                                                        <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search"
                                                            title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">advanced clinical trial search</a> to find NCI-supported cancer clinical
                                                        trials that are now enrolling patients. The search can be narrowed
                                                        by location of the trial, type of treatment, name of the drug, and
                                                        other criteria.
                                                        <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/"
                                                            title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/">General information</a> about clinical trials is also available.</p>
                                                </section>
                                                <h6 do-not-show="toc">References</h6>
                                                <ol>
                                                    <li id="section_6.1">Holmäng S, Hedelin H, Anderström C, et al.: The relationship among multiple
                                                        recurrences, progression and prognosis of patients with stages Ta
                                                        and T1 transitional cell cancer of the bladder followed for at least
                                                        20 years. J Urol 153 (6): 1823-6; discussion 1826-7, 1995.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7752327&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7752327&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.2">Herr HW: Tumor progression and survival of patients with high grade,
                                                        noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol
                                                        163 (1): 60-1; discussion 61-2, 2000.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10604314&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10604314&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.3">Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, et al.: Upper
                                                        urinary tract tumors after primary superficial bladder tumors: prognostic
                                                        factors and risk groups. J Urol 164 (4): 1183-7, 2000.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10992362&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10992362&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.4">Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, et al.: Multivariate
                                                        analysis of the prognostic factors of primary superficial bladder
                                                        cancer. J Urol 163 (1): 73-8, 2000.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10604317&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10604317&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.5">Babjuk M, Oosterlinck W, Sylvester R, et al.: EAU guidelines on non-muscle-invasive
                                                        urothelial carcinoma of the bladder. Eur Urol 54 (2): 303-14, 2008.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18468779&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18468779&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.6">Babjuk M, Oosterlinck W, Sylvester R, et al.: EAU guidelines on non-muscle-invasive
                                                        urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59
                                                        (6): 997-1008, 2011.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21458150&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21458150&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.7">Sylvester RJ, Oosterlinck W, van der Meijden AP: A single immediate postoperative
                                                        instillation of chemotherapy decreases the risk of recurrence in
                                                        patients with stage Ta T1 bladder cancer: a meta-analysis of published
                                                        results of randomized clinical trials. J Urol 171 (6 Pt 1): 2186-90,
                                                        quiz 2435, 2004.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15126782&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15126782&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.8">Gudjónsson S, Adell L, Merdasa F, et al.: Should all patients with non-muscle-invasive
                                                        bladder cancer receive early intravesical chemotherapy after transurethral
                                                        resection? The results of a prospective randomised multicentre study.
                                                        Eur Urol 55 (4): 773-80, 2009.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19153001&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19153001&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.9">Brausi M, Collette L, Kurth K, et al.: Variability in the recurrence
                                                        rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional
                                                        cell carcinoma of the bladder: a combined analysis of seven EORTC
                                                        studies. Eur Urol 41 (5): 523-31, 2002.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12074794&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12074794&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.10">Jakse G, Algaba F, Malmström PU, et al.: A second-look TUR in T1 transitional
                                                        cell carcinoma: why? Eur Urol 45 (5): 539-46; discussion 546, 2004.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15082193&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15082193&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.11">Herr HW: The value of a second transurethral resection in evaluating
                                                        patients with bladder tumors. J Urol 162 (1): 74-6, 1999.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10379743&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10379743&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.12">Zurkirchen MA, Sulser T, Gaspert A, et al.: Second transurethral resection
                                                        of superficial transitional cell carcinoma of the bladder: a must
                                                        even for experienced urologists. Urol Int 72 (2): 99-102, 2004.
                                                        <a
                                                            href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14963348&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14963348&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.13">Sylvester RJ, van der Meijden AP, Witjes JA, et al.: Bacillus calmette-guerin
                                                        versus chemotherapy for the intravesical treatment of patients with
                                                        carcinoma in situ of the bladder: a meta-analysis of the published
                                                        results of randomized clinical trials. J Urol 174 (1): 86-91; discussion
                                                        91-2, 2005.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15947584&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15947584&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.14">Malmström PU, Sylvester RJ, Crawford DE, et al.: An individual patient
                                                        data meta-analysis of the long-term outcome of randomised studies
                                                        comparing intravesical mitomycin C versus bacillus Calmette-Guérin
                                                        for non-muscle-invasive bladder cancer. Eur Urol 56 (2): 247-56,
                                                        2009.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19409692&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19409692&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.15">Stenzl A, Cowan NC, De Santis M, et al.: Treatment of muscle-invasive
                                                        and metastatic bladder cancer: update of the EAU guidelines. Eur
                                                        Urol 59 (6): 1009-18, 2011.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21454009&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21454009&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.16">Herr HW, Schwalb DM, Zhang ZF, et al.: Intravesical bacillus Calmette-Guérin
                                                        therapy prevents tumor progression and death from superficial bladder
                                                        cancer: ten-year follow-up of a prospective randomized trial. J Clin
                                                        Oncol 13 (6): 1404-8, 1995.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7751885&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7751885&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.17">Sarosdy MF, Lamm DL: Long-term results of intravesical bacillus Calmette-Guerin
                                                        therapy for superficial bladder cancer. J Urol 142 (3): 719-22, 1989.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2769847&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2769847&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.18">Catalona WJ, Hudson MA, Gillen DP, et al.: Risks and benefits of repeated
                                                        courses of intravesical bacillus Calmette-Guerin therapy for superficial
                                                        bladder cancer. J Urol 137 (2): 220-4, 1987.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3806806&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3806806&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.19">De Jager R, Guinan P, Lamm D, et al.: Long-term complete remission in
                                                        bladder carcinoma in situ with intravesical TICE bacillus Calmette
                                                        Guerin. Overview analysis of six phase II clinical trials. Urology
                                                        38 (6): 507-13, 1991.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1836081&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1836081&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.20">Herr HW, Wartinger DD, Fair WR, et al.: Bacillus Calmette-Guerin therapy
                                                        for superficial bladder cancer: a 10-year followup. J Urol 147 (4):
                                                        1020-3, 1992.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1552578&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1552578&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.21">Lamm DL, Griffith JG: Intravesical therapy: does it affect the natural
                                                        history of superficial bladder cancer? Semin Urol 10 (1): 39-44,
                                                        1992.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1565903&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1565903&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.22">Berrum-Svennung I, Granfors T, Jahnson S, et al.: A single instillation
                                                        of epirubicin after transurethral resection of bladder tumors prevents
                                                        only small recurrences. J Urol 179 (1): 101-5; discussion 105-6,
                                                        2008.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17997459&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17997459&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.23">Böhle A, Bock PR: Intravesical bacille Calmette-Guérin versus mitomycin
                                                        C in superficial bladder cancer: formal meta-analysis of comparative
                                                        studies on tumor progression. Urology 63 (4): 682-6; discussion 686-7,
                                                        2004.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15072879&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15072879&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.24">Lamm DL, Blumenstein BA, Crissman JD, et al.: Maintenance bacillus Calmette-Guerin
                                                        immunotherapy for recurrent TA, T1 and carcinoma in situ transitional
                                                        cell carcinoma of the bladder: a randomized Southwest Oncology Group
                                                        Study. J Urol 163 (4): 1124-9, 2000.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10737480&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10737480&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.25">Coplen DE, Marcus MD, Myers JA, et al.: Long-term followup of patients
                                                        treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin:
                                                        analysis of possible predictors of response free of tumor. J Urol
                                                        144 (3): 652-7, 1990.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2388321&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2388321&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.26">Herr HW: Progression of stage T1 bladder tumors after intravesical bacillus
                                                        Calmette-Guerin. J Urol 145 (1): 40-3; discussion 43-4, 1991.
                                                        <a
                                                            href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1984096&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1984096&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.27">Igawa M, Urakami S, Shirakawa H, et al.: Intravesical instillation of
                                                        epirubicin: effect on tumour recurrence in patients with dysplastic
                                                        epithelium after transurethral resection of superficial bladder tumour.
                                                        Br J Urol 77 (3): 358-62, 1996.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8814838&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8814838&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.28">Rintala E, Jauhiainen K, Kaasinen E, et al.: Alternating mitomycin C
                                                        and bacillus Calmette-Guerin instillation prophylaxis for recurrent
                                                        papillary (stages Ta to T1) superficial bladder cancer. Finnbladder
                                                        Group. J Urol 156 (1): 56-9; discussion 59-60, 1996.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8648837&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8648837&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.29">Pawinski A, Sylvester R, Kurth KH, et al.: A combined analysis of European
                                                        Organization for Research and Treatment of Cancer, and Medical Research
                                                        Council randomized clinical trials for the prophylactic treatment
                                                        of stage TaT1 bladder cancer. European Organization for Research
                                                        and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group
                                                        and the Medical Research Council Working Party on Superficial Bladder
                                                        Cancer. J Urol 156 (6): 1934-40, discussion 1940-1, 1996.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8911360&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8911360&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.30">Huncharek M, Geschwind JF, Witherspoon B, et al.: Intravesical chemotherapy
                                                        prophylaxis in primary superficial bladder cancer: a meta-analysis
                                                        of 3703 patients from 11 randomized trials. J Clin Epidemiol 53 (7):
                                                        676-80, 2000.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10941943&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10941943&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.31">Huncharek M, McGarry R, Kupelnick B: Impact of intravesical chemotherapy
                                                        on recurrence rate of recurrent superficial transitional cell carcinoma
                                                        of the bladder: results of a meta-analysis. Anticancer Res 21 (1B):
                                                        765-9, 2001 Jan-Feb.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11299841&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11299841&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.32">Soloway MS: The management of superficial bladder cancer. In: Javadpour
                                                        N, ed.: Principles and Management of Urologic Cancer. 2nd ed. Baltimore,
                                                        Md: Williams and Wilkins, 1983, pp 446-467.</li>
                                                    <li id="section_6.33">Holzbeierlein JM, Lopez-Corona E, Bochner BH, et al.: Partial cystectomy:
                                                        a contemporary review of the Memorial Sloan-Kettering Cancer Center
                                                        experience and recommendations for patient selection. J Urol 172
                                                        (3): 878-81, 2004.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15310988&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15310988&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.34">Fahmy N, Aprikian A, Tanguay S, et al.: Practice patterns and recurrence
                                                        after partial cystectomy for bladder cancer. World J Urol 28 (4):
                                                        419-23, 2010.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19826825&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19826825&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.35">Lambert EH, Pierorazio PM, Olsson CA, et al.: The increasing use of intravesical
                                                        therapies for stage T1 bladder cancer coincides with decreasing survival
                                                        after cystectomy. BJU Int 100 (1): 33-6, 2007.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17552951&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17552951&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.36">Skinner EC: The best treatment for high-grade T1 bladder cancer is cystectomy.
                                                        Urol Oncol 25 (6): 523-5, 2007 Nov-Dec.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18047965&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18047965&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.37">Stein JP, Penson DF: Invasive T1 bladder cancer: indications and rationale
                                                        for radical cystectomy. BJU Int 102 (3): 270-5, 2008.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18494831&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18494831&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.38">Boström PJ, Alkhateeb S, van Rhijn BW, et al.: Optimal timing of radical
                                                        cystectomy in T1 high-grade bladder cancer. Expert Rev Anticancer
                                                        Ther 10 (12): 1891-902, 2010.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21110756&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21110756&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.39">Fritsche HM, Burger M, Svatek RS, et al.: Characteristics and outcomes
                                                        of patients with clinical T1 grade 3 urothelial carcinoma treated
                                                        with radical cystectomy: results from an international cohort. Eur
                                                        Urol 57 (2): 300-9, 2010.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19766384&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19766384&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.40">Ali-El-Dein B, Al-Marhoon MS, Abdel-Latif M, et al.: Survival after primary
                                                        and deferred cystectomy for stage T1 transitional cell carcinoma
                                                        of the bladder. Urol Ann 3 (3): 127-32, 2011.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21976924&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21976924&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.41">Canter D, Egleston B, Wong YN, et al.: Use of radical cystectomy as initial
                                                        therapy for the treatment of high-grade T1 urothelial carcinoma of
                                                        the bladder: a SEER database analysis. Urol Oncol 31 (6): 866-70,
                                                        2013.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21906968&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21906968&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.42">Chalasani V, Kassouf W, Chin JL, et al.: Radical cystectomy for the treatment
                                                        of T1 bladder cancer: the Canadian Bladder Cancer Network experience.
                                                        Can Urol Assoc J 5 (2): 83-7, 2011.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21470529&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21470529&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.43">Segal R, Yafi FA, Brimo F, et al.: Prognostic factors and outcome in
                                                        patients with T1 high-grade bladder cancer: can we identify patients
                                                        for early cystectomy? BJU Int 109 (7): 1026-30, 2012.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21883838&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21883838&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_6.44">Raj GV, Herr H, Serio AM, et al.: Treatment paradigm shift may improve
                                                        survival of patients with high risk superficial bladder cancer. J
                                                        Urol 177 (4): 1283-6; discussion 1286, 2007.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17382713&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17382713&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                </ol>
                                            </div>
                                        </section>


                                        <section id="_90">
                                            <h2>Stages II and III Bladder Cancer Treatment</h2>
                                            <div id="_section_90" class="pdq-sections">
                                                <section id="_91">
                                                    <h3 id="_91_toc">Standard Treatment Options for Stages II and III Bladder Cancer</h3>
                                                    <p id="_92" tabindex="-1">Standard treatment options for
                                                        <a href="/types/bladder/hp/bladder-treatment-pdq#link/_474">stage II bladder cancer</a> and
                                                        <a href="/types/bladder/hp/bladder-treatment-pdq#link/_476">stage III bladder cancer</a> include the following:</p>
                                                    <div class="pdq-content-list">
                                                        <ol id="_107">
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_108">Radical cystectomy</a>.</li>
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_112">Neoadjuvant combination chemotherapy</a> followed by radical
                                                                cystectomy.</li>
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_117">External-beam radiation therapy (EBRT) with or without concomitant
                                                                    chemotherapy</a>.</li>
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_437">Segmental cystectomy</a> (in selected patients).</li>
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_455">Transurethral resection (TUR) with fulguration</a> (in selected
                                                                patients).</li>
                                                        </ol>
                                                    </div>
                                                    <p id="_343" tabindex="-1">The most common treatments for muscle-invasive bladder cancer are radical
                                                        cystectomy and radiation therapy. There is no strong evidence from
                                                        randomized controlled trials to determine whether surgery or radiation
                                                        therapy is more effective. There is strong evidence that both therapies
                                                        become more effective when combined with chemotherapy. At the present
                                                        time, the treatments with the highest level of evidence supporting
                                                        their effectiveness are radical cystectomy preceded by multiagent
                                                        cisplatin-based chemotherapy and radiation therapy with concomitant
                                                        chemotherapy. </p>
                                                    <section id="_108">
                                                        <h4 id="_108_toc">Radical cystectomy</h4>
                                                        <p id="_109" tabindex="-1">Radical cystectomy is a standard treatment option for stage II and
                                                            stage III bladder cancer, and its effectiveness at prolonging
                                                            survival increases if it is preceded by cisplatin-based multiagent
                                                            chemotherapy.[
                                                            <a href="#cit/section_7.1">1</a>-
                                                            <a href="#cit/section_7.4">4</a>] Radical cystectomy is accompanied by pelvic lymph node
                                                            dissection and includes removal of the bladder, perivesical tissues,
                                                            prostate, and seminal vesicles in men and removal of the uterus,
                                                            tubes, ovaries, anterior vaginal wall, and urethra in women.[
                                                            <a
                                                                href="#cit/section_7.5">5</a>-
                                                                <a href="#cit/section_7.8">8</a>] Studies of outcomes after radical cystectomy report
                                                                increased survival in patients who had more, rather than
                                                                fewer, lymph nodes resected; whether this represents a therapeutic
                                                                benefit of resecting additional nodes or stage migration
                                                                is unknown.[
                                                                <a href="#cit/section_7.9">9</a>] There are no randomized controlled trials evaluating
                                                                the therapeutic benefit of lymph node dissection in this
                                                                setting.</p>
                                                        <p id="_401" tabindex="-1">Radical cystectomy is a major operation with a perioperative mortality
                                                            rate of 2% to 3% when performed at centers of excellence.[
                                                            <a
                                                                href="#cit/section_7.6">6</a>-
                                                                <a href="#cit/section_7.8">8</a>] Postoperative complications include ileus. Most men
                                                                have erectile dysfunction after radical cystectomy; sexual
                                                                dysfunction after this operation is also common in women.[
                                                                <a
                                                                    href="#cit/section_7.10">10</a>-
                                                                    <a href="#cit/section_7.12">12</a>]</p>
                                                        <p id="_344" tabindex="-1"> One study of 27 women who underwent radical cystectomy reported diminished
                                                            ability to have orgasm in 45%, decreased lubrication in 41%,
                                                            decreased sexual desire in 37%, and pain with vaginal intercourse
                                                            in 22%. Fewer than one-half were able to have successful vaginal
                                                            intercourse and most reported decreased satisfaction with their
                                                            sexual lives after surgery.[
                                                            <a href="#cit/section_7.12">12</a>] Studies suggest that radical cystectomy with preservation
                                                            of sexual function can be performed in some men. In addition,
                                                            new forms of urinary diversion can obviate the need for an external
                                                            urinary appliance.[
                                                            <a href="#cit/section_7.13">13</a>-
                                                            <a href="#cit/section_7.16">16</a>]</p>
                                                        <p id="_402" tabindex="-1">In a retrospective analysis from a single institution, elderly patients
                                                            (≥70 years) in good general health were found to have clinical
                                                            and functional results after radical cystectomy similar to younger
                                                            patients.[
                                                            <a href="#cit/section_7.17">17</a>]</p>
                                                        <p id="_288" tabindex="-1">After radical cystectomy, however, an approximate 30% to 40% risk
                                                            of recurrence still exists for patients with muscle-invasive
                                                            disease, even at centers of excellence.[
                                                            <a href="#cit/section_7.6">6</a>-
                                                            <a href="#cit/section_7.8">8</a>] Five-year overall survival (OS) has generally been reported
                                                            to be in the range of 50% to 60% but varies by stage.[
                                                            <a href="#cit/section_7.4">4</a>] The addition of preoperative radiation therapy to radical
                                                            cystectomy did not result in any survival advantage when compared
                                                            with radical cystectomy alone in a prospective randomized trial.[
                                                            <a
                                                                href="#cit/section_7.18">18</a>]</p>
                                                    </section>
                                                    <section id="_112">
                                                        <h4 id="_112_toc">Neoadjuvant combination chemotherapy followed by radical cystectomy</h4>
                                                        <p id="_113" tabindex="-1">Because bladder cancer commonly recurs with distant metastases, systemic
                                                            chemotherapy administered before or after cystectomy has been
                                                            evaluated as a means of improving outcome. Administration of
                                                            chemotherapy before cystectomy (i.e., neoadjuvant chemotherapy)
                                                            may be preferable to postoperative treatment because tumor downstaging
                                                            from chemotherapy may enhance resectability; occult metastatic
                                                            disease may be treated as early as possible; and chemotherapy
                                                            may be better tolerated. Currently, the body of evidence supporting
                                                            preoperative chemotherapy is much stronger than the evidence
                                                            supporting postoperative chemotherapy.</p>
                                                        <p id="_225" tabindex="-1">Evidence (neoadjuvant combination chemotherapy followed by radical
                                                            cystectomy):</p>
                                                        <div class="pdq-content-list">
                                                            <ol id="_252">
                                                                <li>A controlled trial of preoperative chemotherapy conducted
                                                                    by the Medical Research Council and the European Organization
                                                                    for Research and Treatment of Cancer randomly assigned
                                                                    976 patients with locally advanced (T3 or T4a) or high-grade
                                                                    muscle-invasive (T2) bladder cancer to undergo either
                                                                    definitive treatment immediately or definitive treatment
                                                                    preceded by three cycles of neoadjuvant cisplatin, vinblastine,
                                                                    and methotrexate.[
                                                                    <a href="#cit/section_7.19">19</a>,
                                                                    <a href="#cit/section_7.20">20</a>] In this study, definitive treatment consisted
                                                                    of radical cystectomy (n = 428), radiation therapy (n
                                                                    = 403), or preoperative radiation therapy followed by
                                                                    radical cystectomy (n = 66).
                                                                    <div class="pdq-content-list">
                                                                        <ul id="_403">
                                                                            <li>At a median follow-up of 8.0 years for patients
                                                                                still alive, OS was significantly greater
                                                                                in the arm randomly assigned to receive neoadjuvant
                                                                                chemotherapy (hazard ratio [HR], 0.84; 95%
                                                                                confidence interval [CI], 0.72–0.99;
                                                                                <em>P</em> = .037). The survival benefit from
                                                                                neoadjuvant chemotherapy compared with definitive
                                                                                treatment alone conferred a 6% absolute increase
                                                                                in the likelihood of being alive at 3 years
                                                                                (56% vs. 50%), 5 years (49% vs. 43%), and
                                                                                10 years (36% vs. 30%).[
                                                                                <a href="#cit/section_7.20">20</a>][
                                                                                <a href="/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English"
                                                                                    onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>]</li>
                                                                        </ul>
                                                                    </div>
                                                                </li>
                                                                <li>A randomized study conducted by the Southwest Oncology Group
                                                                    compared three cycles of neoadjuvant cisplatin, methotrexate,
                                                                    vinblastine, and doxorubicin administered before cystectomy
                                                                    with cystectomy alone in 317 patients with stage T2 to
                                                                    stage T4a bladder cancer.[
                                                                    <a href="#cit/section_7.21">21</a>]
                                                                    <div class="pdq-content-list">
                                                                        <ul id="_289">
                                                                            <li>The study showed that 5-year survival was 57%
                                                                                in the group that received neoadjuvant chemotherapy
                                                                                and 43% in the group treated with cystectomy
                                                                                alone, which is a difference of borderline
                                                                                statistical significance (two-sided
                                                                                <em>P</em> value = .06 by stratified log-rank
                                                                                test).</li>
                                                                            <li>No deaths were associated with neoadjuvant chemotherapy,
                                                                                and there was no difference in the rate or
                                                                                severity of postoperative complications in
                                                                                patients who received immediate surgery and
                                                                                in those who received preoperative chemotherapy.
                                                                                Cystectomy was performed as planned for 82%
                                                                                of patients assigned to preoperative chemotherapy
                                                                                and 81% of those assigned to cystectomy alone.
                                                                                This study provided evidence that preoperative
                                                                                chemotherapy does not prevent patients from
                                                                                undergoing cystectomy and does not increase
                                                                                the risk of perioperative complications.</li>
                                                                            <li>Thirty-eight percent of patients who received
                                                                                neoadjuvant chemotherapy had a pathologic
                                                                                complete response at the time of surgery,
                                                                                and 85% of those achieving a pathologic complete
                                                                                response were alive at 5 years.</li>
                                                                        </ul>
                                                                    </div>
                                                                </li>
                                                                <li>A meta-analysis of ten randomized trials of neoadjuvant chemotherapy,
                                                                    including updated data for 2,688 individual patients,
                                                                    showed that cisplatin-based combination chemotherapy
                                                                    was associated with a significant 13% relative reduction
                                                                    in the risk of death and resulted in an improvement in
                                                                    5-year survival from 45% to 50% (
                                                                    <em>P</em> = .016). Neoadjuvant single-agent cisplatin was
                                                                    not associated with any survival benefit in the meta-analysis.[
                                                                    <a
                                                                        href="#cit/section_7.2">2</a>] </li>
                                                                <li>A subsequent meta-analysis evaluated a nearly identical body
                                                                    of data (11 randomized controlled trials enrolling a
                                                                    total of 2,605 patients) and reached similar conclusions.
                                                                    When the analysis was limited to the eight trials that
                                                                    used multiagent, cisplatin-based chemotherapy, neoadjuvant
                                                                    chemotherapy compared with cystectomy alone was associated
                                                                    with a 6.5% absolute benefit in 5-year OS (56.5% vs.
                                                                    50%;
                                                                    <em>P</em> = .006).[
                                                                    <a href="#cit/section_7.4">4</a>] </li>
                                                            </ol>
                                                        </div>
                                                        <p id="_404" tabindex="-1">Of note, the vast majority of patients included in these studies
                                                            received cisplatin, methotrexate, and vinblastine with or without
                                                            doxorubicin. It is not known whether the doublet regimen of cisplatin
                                                            plus gemcitabine offers any benefit when administered in the
                                                            preoperative setting, nor is there any evidence of benefit for
                                                            carboplatin-based chemotherapy regimens.</p>
                                                        <p id="_405" tabindex="-1">On the basis of these findings, preoperative cisplatin-based combination
                                                            chemotherapy followed by radical cystectomy represents a standard
                                                            therapeutic option for patients with muscle-invasive bladder
                                                            cancer who are fit for chemotherapy and for whom the priority
                                                            is to maximize survival.</p>
                                                    </section>
                                                    <section id="_117">
                                                        <h4 id="_117_toc">EBRT with or without concomitant chemotherapy</h4>
                                                        <p id="_118" tabindex="-1">
                                                            Definitive radiation therapy is a standard option that yields a 5-year survival of approximately 30% to 40%.[
                                                            <a
                                                                href="#cit/section_7.22">22</a>] When radiation therapy and chemotherapy are administered
                                                                concomitantly, the results are better. However, while the
                                                                addition of chemotherapy to radiation therapy has been shown
                                                                to reduce local relapse rates, it has not been shown to result
                                                                in increased survival, decreased mortality, or improved quality
                                                                of life. </p>
                                                        <p id="_347" tabindex="-1">Most protocols for bladder preservation that use combined chemotherapy
                                                            and radiation therapy have followed a relatively complex algorithm.
                                                            After the initial stage TUR of the bladder tumor, patients undergo
                                                            a repeat TUR to maximally resect the tumor. The patient is then
                                                            treated with synchronous chemoradiation therapy to a dose of
                                                            roughly 40 Gy followed by a repeat cystoscopy with biopsies to
                                                            assess for residual cancer. If residual cancer is detected histopathologically,
                                                            then the chemoradiation therapy is judged to have failed and
                                                            the patient is advised to undergo a radical cystectomy. If the
                                                            biopsies at 40 Gy are benign, then chemoradiation therapy is
                                                            completed to a dose of about 65 Gy.</p>
                                                        <p id="_348" tabindex="-1">With definitive radiation therapy, best results are seen in patients
                                                            with solitary lesions and without carcinoma
                                                            <em>in situ</em> or hydronephrosis</p>
                                                        <p id="_349" tabindex="-1">After radiation therapy, approximately 50% of patients have dysuria
                                                            and urinary frequency during treatment, which resolves several
                                                            weeks after treatment, and 15% report acute toxic effects of
                                                            the bowel.</p>
                                                        <p id="_291" tabindex="-1">Randomized trials that directly compare the bladder-preserving chemoradiation
                                                            therapy approach with radical cystectomy have not been performed;
                                                            the relative effectiveness of these two treatments is thus unknown.</p>
                                                        <p id="_429" tabindex="-1">Evidence (EBRT with or without concomitant chemotherapy):</p>
                                                        <p id="_449" tabindex="-1">TUR followed by chemoradiation therapy</p>
                                                        <div class="pdq-content-list">
                                                            <ol id="_430">
                                                                <li>A multicenter phase III trial randomly assigned 360 patients
                                                                    with muscle-invasive bladder cancer to radiation therapy
                                                                    with or without synchronous chemotherapy using fluorouracil
                                                                    and mitomycin C.[
                                                                    <a href="#cit/section_7.22">22</a>]
                                                                    <div class="pdq-content-list">
                                                                        <ul id="_431">
                                                                            <li>Two-year locoregional disease-free survival was
                                                                                higher in the chemoradiation therapy group
                                                                                (67% vs. 54%; HR, 0.68; 95% CI, 0.48–0.96;
                                                                                <em>P</em> = .03). Five-year OS was 48% in the
                                                                                chemoradiation therapy group and 35% in the
                                                                                radiation therapy group, but the difference
                                                                                was not statistically significant (
                                                                                <em>P</em> = .16).</li>
                                                                        </ul>
                                                                    </div>
                                                                </li>
                                                                <li>Similarly, synchronous chemoradiation therapy using other
                                                                    chemotherapy regimens, such as cisplatin alone or combined
                                                                    with fluorouracil, have reported 5-year OS rates of 50%
                                                                    to 60% and survival with an intact bladder in 40% to
                                                                    45% of patients, figures that are higher than has generally
                                                                    been reported in studies of radiation therapy alone.[
                                                                    <a
                                                                        href="#cit/section_7.23">23</a>]</li>
                                                            </ol>
                                                        </div>
                                                        <p id="_450" tabindex="-1">TUR followed by chemoradiation therapy</p>
                                                        <div class="pdq-content-list">
                                                            <ol id="_451">
                                                                <li>In some nonrandomized studies, 50% or more of the patients
                                                                    who underwent bladder-preserving therapy (i.e., initial
                                                                    TUR of as much tumor as possible followed by concurrent
                                                                    chemoradiation therapy) were alive at 5 years, and 75%
                                                                    of those survivors had an intact bladder.[
                                                                    <a href="#cit/section_7.24">24</a>-
                                                                    <a href="#cit/section_7.26">26</a>]</li>
                                                            </ol>
                                                        </div>
                                                        <p id="_452" tabindex="-1">Radiation therapy and chemotherapy</p>
                                                        <div class="pdq-content-list">
                                                            <ol id="_453">
                                                                <li>A randomized controlled trial randomly assigned 99 patients
                                                                    with T2 to T4b urothelial carcinoma of the bladder to
                                                                    radiation therapy with or without three 14-day cycles
                                                                    of cisplatin (100 mg/m
                                                                    <span class="sup">2</span> on day 1). Patients and their physicians chose
                                                                    whether the radiation therapy was definitive or administered
                                                                    as precystectomy treatment. The pelvic relapse rate was
                                                                    reduced (multivariable regression model HR, 0.50; 90%
                                                                    CI, 0.29–0.86;
                                                                    <em>P</em> = .036), but there was no difference in the occurrence
                                                                    of distant metastases or OS. The reduction in pelvic
                                                                    relapse was similar in patients who received definitive
                                                                    radiation therapy and precystectomy radiation therapy.[
                                                                    <a
                                                                        href="#cit/section_7.27">27</a>]</li>
                                                            </ol>
                                                        </div>
                                                        <p id="_454" tabindex="-1">Neoadjuvant chemotherapy followed by chemoradiation therapy</p>
                                                        <div class="pdq-content-list">
                                                            <ol id="_434">
                                                                <li>In a phase III study (
                                                                    <a href="https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=8903"
                                                                        title="https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=8903">RTOG-8903</a>), the Radiation Therapy Oncology Group
                                                                    evaluated the potential benefit of adding two cycles
                                                                    of neoadjuvant methotrexate, cisplatin, and vinblastine
                                                                    before concurrent cisplatin and radiation therapy. Neoadjuvant
                                                                    chemotherapy was associated with increased hematologic
                                                                    toxic effects and yielded no improvement in response
                                                                    rate, freedom from distant metastases, or OS compared
                                                                    with chemoradiation therapy alone.[
                                                                    <a href="#cit/section_7.28">28</a>]</li>
                                                            </ol>
                                                        </div>
                                                    </section>
                                                    <section id="_437">
                                                        <h4 id="_437_toc">Segmental cystectomy (in selected patients)</h4>
                                                        <p id="_438" tabindex="-1">Segmental cystectomy is appropriate only in very selected patients.[
                                                            <a
                                                                href="#cit/section_7.1">1</a>] There are no randomized controlled trials comparing segmental
                                                                cystectomy with radical cystectomy. Only patients with adenocarcinomas
                                                                of the urachus are routinely treated with segmental cystectomy.
                                                                These tumors typically are mucinous adenocarcinomas occurring
                                                                at the dome of the bladder and are treated with an en bloc
                                                                resection of the bladder dome and urachal remnant, including
                                                                the umbilicus.[
                                                                <a href="#cit/section_7.29">29</a>-
                                                                <a href="#cit/section_7.32">32</a>]</p>
                                                    </section>
                                                    <section id="_455">
                                                        <h4 id="_455_toc">TUR with fulguration (in selected patients)</h4>
                                                        <p id="_456" tabindex="-1">Stage II bladder cancer may be controlled in some patients by TUR,
                                                            but more aggressive forms of treatment are often dictated by
                                                            recurrent tumor or by the large size, multiple foci, or undifferentiated
                                                            grade of the neoplasm.</p>
                                                    </section>
                                                </section>
                                                <section id="_TrialSearch_90_sid_7">
                                                    <h3 id="_TrialSearch_90_sid_7_toc">Current Clinical Trials</h3>
                                                    <p id="_TrialSearch_90_22" tabindex="-1">Use our
                                                        <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search"
                                                            title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">advanced clinical trial search</a> to find NCI-supported cancer clinical
                                                        trials that are now enrolling patients. The search can be narrowed
                                                        by location of the trial, type of treatment, name of the drug, and
                                                        other criteria.
                                                        <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/"
                                                            title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/">General information</a> about clinical trials is also available.</p>
                                                </section>
                                                <h6 do-not-show="toc">References</h6>
                                                <ol>
                                                    <li id="section_7.1">Richie JP: Surgery for invasive bladder cancer. Hematol Oncol Clin North
                                                        Am 6 (1): 129-45, 1992.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1556046&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1556046&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.2">Advanced Bladder Cancer Meta-analysis Collaboration: Neoadjuvant chemotherapy
                                                        in invasive bladder cancer: a systematic review and meta-analysis.
                                                        Lancet 361 (9373): 1927-34, 2003.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12801735&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12801735&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.3">Sherif A, Holmberg L, Rintala E, et al.: Neoadjuvant cisplatinum based
                                                        combination chemotherapy in patients with invasive bladder cancer:
                                                        a combined analysis of two Nordic studies. Eur Urol 45 (3): 297-303,
                                                        2004.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15036674&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15036674&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.4">Winquist E, Kirchner TS, Segal R, et al.: Neoadjuvant chemotherapy for
                                                        transitional cell carcinoma of the bladder: a systematic review and
                                                        meta-analysis. J Urol 171 (2 Pt 1): 561-9, 2004.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14713760&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14713760&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.5">Olsson CA: Management of invasive carcinoma of the bladder. In: deKernion
                                                        JB, Paulson DF, eds.: Genitourinary Cancer Management. Philadelphia,
                                                        Pa: Lea and Febiger, 1987, pp 59-94.</li>
                                                    <li id="section_7.6">Stein JP, Lieskovsky G, Cote R, et al.: Radical cystectomy in the treatment
                                                        of invasive bladder cancer: long-term results in 1,054 patients.
                                                        J Clin Oncol 19 (3): 666-75, 2001.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11157016&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11157016&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.7">Madersbacher S, Hochreiter W, Burkhard F, et al.: Radical cystectomy
                                                        for bladder cancer today--a homogeneous series without neoadjuvant
                                                        therapy. J Clin Oncol 21 (4): 690-6, 2003.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12586807&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12586807&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.8">Manoharan M, Ayyathurai R, Soloway MS: Radical cystectomy for urothelial
                                                        carcinoma of the bladder: an analysis of perioperative and survival
                                                        outcome. BJU Int 104 (9): 1227-32, 2009.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19519764&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19519764&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.9">Ather MH, Fatima S, Sinanoglu O: Extent of lymphadenectomy in radical
                                                        cystectomy for bladder cancer. World J Surg Oncol 3: 43, 2005.
                                                        <a
                                                            href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16022725&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16022725&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.10">Hart S, Skinner EC, Meyerowitz BE, et al.: Quality of life after radical
                                                        cystectomy for bladder cancer in patients with an ileal conduit,
                                                        cutaneous or urethral kock pouch. J Urol 162 (1): 77-81, 1999.
                                                        <a
                                                            href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10379744&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10379744&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.11">Miyao N, Adachi H, Sato Y, et al.: Recovery of sexual function after
                                                        nerve-sparing radical prostatectomy or cystectomy. Int J Urol 8 (4):
                                                        158-64, 2001.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11260347&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11260347&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.12">Zippe CD, Raina R, Shah AD, et al.: Female sexual dysfunction after radical
                                                        cystectomy: a new outcome measure. Urology 63 (6): 1153-7, 2004.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15183970&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15183970&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.13">Brendler CB, Steinberg GD, Marshall FF, et al.: Local recurrence and
                                                        survival following nerve-sparing radical cystoprostatectomy. J Urol
                                                        144 (5): 1137-40; discussion 1140-1, 1990.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2231885&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2231885&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.14">Skinner DG, Boyd SD, Lieskovsky G: Clinical experience with the Kock
                                                        continent ileal reservoir for urinary diversion. J Urol 132 (6):
                                                        1101-7, 1984.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6502796&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6502796&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.15">Fowler JE: Continent urinary reservoirs and bladder substitutes in the
                                                        adult: part I. Monographs in Urology 8 (2): 1987.</li>
                                                    <li id="section_7.16">Fowler JE: Continent urinary reservoirs and bladder substitutes in the
                                                        adult: part II. Monographs in Urology 8 (3): 1987.</li>
                                                    <li id="section_7.17">Figueroa AJ, Stein JP, Dickinson M, et al.: Radical cystectomy for elderly
                                                        patients with bladder carcinoma: an updated experience with 404 patients.
                                                        Cancer 83 (1): 141-7, 1998.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9655304&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9655304&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.18">Smith JA Jr, Crawford ED, Paradelo JC, et al.: Treatment of advanced
                                                        bladder cancer with combined preoperative irradiation and radical
                                                        cystectomy versus radical cystectomy alone: a phase III intergroup
                                                        study. J Urol 157 (3): 805-7; discussion 807-8, 1997.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9072571&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9072571&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.19">Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for
                                                        muscle-invasive bladder cancer: a randomised controlled trial. International
                                                        collaboration of trialists. Lancet 354 (9178): 533-40, 1999.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10470696&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10470696&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.20">Griffiths G, Hall R, Sylvester R, et al.: International phase III trial
                                                        assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy
                                                        for muscle-invasive bladder cancer: long-term results of the BA06
                                                        30894 trial. J Clin Oncol 29 (16): 2171-7, 2011.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21502557&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21502557&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.21">Grossman HB, Natale RB, Tangen CM, et al.: Neoadjuvant chemotherapy plus
                                                        cystectomy compared with cystectomy alone for locally advanced bladder
                                                        cancer. N Engl J Med 349 (9): 859-66, 2003.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12944571&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12944571&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.22">James ND, Hussain SA, Hall E, et al.: Radiotherapy with or without chemotherapy
                                                        in muscle-invasive bladder cancer. N Engl J Med 366 (16): 1477-88,
                                                        2012.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22512481&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22512481&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.23">Efstathiou JA, Zietman AL, Kaufman DS, et al.: Bladder-sparing approaches
                                                        to invasive disease. World J Urol 24 (5): 517-29, 2006.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17082940&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17082940&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.24">Kachnic LA, Kaufman DS, Heney NM, et al.: Bladder preservation by combined
                                                        modality therapy for invasive bladder cancer. J Clin Oncol 15 (3):
                                                        1022-9, 1997.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9060542&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9060542&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.25">Housset M, Maulard C, Chretien Y, et al.: Combined radiation and chemotherapy
                                                        for invasive transitional-cell carcinoma of the bladder: a prospective
                                                        study. J Clin Oncol 11 (11): 2150-7, 1993.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8229129&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8229129&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.26">Rödel C, Grabenbauer GG, Kühn R, et al.: Combined-modality treatment
                                                        and selective organ preservation in invasive bladder cancer: long-term
                                                        results. J Clin Oncol 20 (14): 3061-71, 2002.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12118019&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12118019&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.27">Coppin CM, Gospodarowicz MK, James K, et al.: Improved local control
                                                        of invasive bladder cancer by concurrent cisplatin and preoperative
                                                        or definitive radiation. The National Cancer Institute of Canada
                                                        Clinical Trials Group. J Clin Oncol 14 (11): 2901-7, 1996.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8918486&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8918486&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.28">Shipley WU, Winter KA, Kaufman DS, et al.: Phase III trial of neoadjuvant
                                                        chemotherapy in patients with invasive bladder cancer treated with
                                                        selective bladder preservation by combined radiation therapy and
                                                        chemotherapy: initial results of Radiation Therapy Oncology Group
                                                        89-03. J Clin Oncol 16 (11): 3576-83, 1998.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817278&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817278&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.29">Ashley RA, Inman BA, Sebo TJ, et al.: Urachal carcinoma: clinicopathologic
                                                        features and long-term outcomes of an aggressive malignancy. Cancer
                                                        107 (4): 712-20, 2006.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16826585&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16826585&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.30">Siefker-Radtke A: Urachal carcinoma: surgical and chemotherapeutic options.
                                                        Expert Rev Anticancer Ther 6 (12): 1715-21, 2006.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17181485&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17181485&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.31">Herr HW, Bochner BH, Sharp D, et al.: Urachal carcinoma: contemporary
                                                        surgical outcomes. J Urol 178 (1): 74-8; discussion 78, 2007.
                                                        <a
                                                            href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17499279&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17499279&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_7.32">Bruins HM, Visser O, Ploeg M, et al.: The clinical epidemiology of urachal
                                                        carcinoma: results of a large, population based study. J Urol 188
                                                        (4): 1102-7, 2012.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22901574&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22901574&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                </ol>
                                            </div>
                                        </section>


                                        <section id="_156">
                                            <h2>Stage IV Bladder Cancer Treatment</h2>
                                            <div id="_section_156" class="pdq-sections">
                                                <p id="_189" tabindex="-1">Only a small fraction of patients with
                                                    <a href="/types/bladder/hp/bladder-treatment-pdq#link/_472">stage IV bladder cancer</a> can be cured and for many patients, the emphasis
                                                    is on palliation of symptoms. The potential for cure is restricted to
                                                    patients with stage IV disease with involvement of pelvic organs by direct
                                                    extension or metastases to regional lymph nodes.[
                                                    <a href="#cit/section_8.1">1</a>]</p>
                                                <section id="_157">
                                                    <h3 id="_157_toc">Standard Treatment Options for Stage IV Bladder Cancer</h3>
                                                    <section id="_158">
                                                        <h4 id="_158_toc">Standard treatment options for patients with T4b, N0, M0 or any T,
                                                            N1–N3, M0 disease</h4>
                                                        <p id="_159" tabindex="-1">Treatment options for patients with T4b, N0, M0 or any T, N1–N3,
                                                            M0 disease include the following:</p>
                                                        <div class="pdq-content-list">
                                                            <ol id="_164">
                                                                <li>
                                                                    <a href="/types/bladder/hp/bladder-treatment-pdq#link/_350">Chemotherapy alone</a>.</li>
                                                                <li>
                                                                    <a href="/types/bladder/hp/bladder-treatment-pdq#link/_165">Radical cystectomy</a>.</li>
                                                                <li>Radical cystectomy followed by chemotherapy.</li>
                                                                <li>Radical cystectomy alone.</li>
                                                                <li>
                                                                    <a href="/types/bladder/hp/bladder-treatment-pdq#link/_167">External-beam radiation therapy</a> (EBRT) with or without
                                                                    concomitant chemotherapy.</li>
                                                                <li>
                                                                    <a href="/types/bladder/hp/bladder-treatment-pdq#link/_169">Urinary diversion or cystectomy</a> for palliation.</li>
                                                            </ol>
                                                        </div>
                                                        <section id="_350">
                                                            <h5 id="_350_toc">Chemotherapy alone</h5>
                                                            <p id="_351" tabindex="-1">Cisplatin-based combination chemotherapy regimens are the standard
                                                                of care for stage IV bladder cancer.[
                                                                <a href="#cit/section_8.2">2</a>-
                                                                <a href="#cit/section_8.6">6</a>] The only chemotherapy regimens that have been shown
                                                                to result in longer survival in randomized controlled trials
                                                                are methotrexate, vinblastine, doxorubicin, and cisplatin
                                                                (MVAC); high-dose MVAC; and cisplatin, methotrexate, and
                                                                vinblastine (CMV). Gemcitabine plus cisplatin (GC) was compared
                                                                with MVAC in a randomized controlled trial and no difference
                                                                in response rate or survival was reported. Of note, patients
                                                                with good performance status and lymph node-only disease
                                                                have a low but significant rate of achieving a durable complete
                                                                remission with MVAC or GC. In the large randomized controlled
                                                                trial that compared MVAC with GC, for example, 5-year overall
                                                                survival (OS) in patients with lymph node-only disease was
                                                                20.9%.[
                                                                <a href="#cit/section_8.7">7</a>]</p>
                                                            <p id="_445" tabindex="-1">Single-agent cisplatin and multiagent regimens that do not include
                                                                cisplatin have never been shown to improve survival in a
                                                                randomized controlled trial. Thus, there is no regimen that
                                                                has been shown to prolong survivalinpatients who are not
                                                                candidates for cisplatin-based multiagent chemotherapy regimens.
                                                                Many regimens have been shown to be active, however, with
                                                                regard to producing radiologically measurable responses:</p>
                                                            <p id="_446" tabindex="-1">These include carboplatin plus paclitaxel,[
                                                                <a href="#cit/section_8.8">8</a>] carboplatin plus gemcitabine,[
                                                                <a href="#cit/section_8.9">9</a>-
                                                                <a href="#cit/section_8.11">11</a>] paclitaxel plus gemcitabine,[
                                                                <a href="#cit/section_8.12">12</a>-
                                                                <a href="#cit/section_8.14">14</a>] single-agent gemcitabine,[
                                                                <a href="#cit/section_8.15">15</a>,
                                                                <a href="#cit/section_8.16">16</a>] and single-agent paclitaxel.[
                                                                <a href="#cit/section_8.17">17</a>-
                                                                <a href="#cit/section_8.19">19</a>] Regimens of carboplatin, methotrexate, and vinblastine;
                                                                carboplatin, epirubicin, methotrexate, and vinblastine; and
                                                                paclitaxel, gemcitabine, and carboplatin have been studied
                                                                but are not widely used.[
                                                                <a href="#cit/section_8.20">20</a>-
                                                                <a href="#cit/section_8.23">23</a>]</p>
                                                            <p id="_352" tabindex="-1">Evidence (chemotherapy alone):</p>
                                                            <div class="pdq-content-list">
                                                                <ol id="_353">
                                                                    <li>Results from a randomized controlled trial that compared
                                                                        MVAC with docetaxel plus cisplatin in 220 patients
                                                                        reported that MVAC was associated with longer OS
                                                                        (median survival, 14.2 months vs. 9.3 months;
                                                                        <em>
                                                                        P</em> = .026).[
                                                                        <a href="#cit/section_8.24">24</a>]</li>
                                                                    <li>A randomized trial that compared MVAC with cisplatin,
                                                                        cyclophosphamide, and doxorubicin demonstrated improved
                                                                        response and median survival rates (48 weeks vs.
                                                                        36 weeks;
                                                                        <em>P</em> = .003) with the MVAC regimen.[
                                                                        <a href="#cit/section_8.25">25</a>] </li>
                                                                    <li>Results from a randomized trial that compared MVAC with
                                                                        single-agent cisplatin in advanced bladder cancer
                                                                        also showed a significant advantage with MVAC in
                                                                        both response rate and median survival (12.5 months
                                                                        vs. 8.2 months;
                                                                        <em>P</em> = .002).[
                                                                        <a href="#cit/section_8.26">26</a>]</li>
                                                                    <li>A multicenter randomized controlled trial compared CMV
                                                                        with methotrexate plus vinblastine without cisplatin
                                                                        in 214 patients. The relative risk of dying was 0.68
                                                                        (95% confidence interval [CI], 0.51–0.90;
                                                                        <em>P</em> = .0065) in favor of CMV. The median survival
                                                                        was 7 months with CMV and 4.5 months with methotrexate
                                                                        plus vinblastine.[
                                                                        <a href="#cit/section_8.27">27</a>]</li>
                                                                    <li>The European Organisation for Research and Treatment
                                                                        of Cancer (EORTC) conducted another randomized trial
                                                                        that studied 263 patients with advanced bladder cancer
                                                                        and evaluated the efficacy of a high-dose intensity
                                                                        MVAC regimen administered every 2 weeks with granulocyte
                                                                        colony-stimulating factor (G-CSF) versus a classic
                                                                        MVAC regimen administered every 4 weeks.[
                                                                        <a href="#cit/section_8.28">28</a>]
                                                                        <div class="pdq-content-list">
                                                                            <ul id="_439">
                                                                                <li>Although there was no significant difference
                                                                                    in OS at a median follow-up of 3.2 years
                                                                                    (hazard ratio [HR], 0.80; 95% CI, 0.60–1.06;
                                                                                    <em>P</em> = .122), an update at a median
                                                                                    follow-up of 7.3 years reported that
                                                                                    the high-dose intensity MVAC regimen
                                                                                    was associated with improved OS (HR,
                                                                                    0.76; 95% CI, 0.58–0.99;
                                                                                    <em>P</em> = .042), with a 5-year survival
                                                                                    rate of 22% compared with 14% in patients
                                                                                    treated with the classic MVAC regimen.</li>
                                                                                <li>The high-dose intensity MVAC regimen was
                                                                                    also associated with higher response
                                                                                    rates (72% vs. 58%;
                                                                                    <em>P</em> = .016), improved median progression-free
                                                                                    survival (9.5 months vs. 8.1 months;
                                                                                    <em>P</em> = .017), and decreased neutropenic
                                                                                    fever (10% vs. 26%;
                                                                                    <em>P</em> &lt; .001), although only 19%
                                                                                    of patients treated with a classic MVAC
                                                                                    regimen ever received G-CSF.[
                                                                                    <a href="#cit/section_8.28">28</a>][
                                                                                    <a href="/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English"
                                                                                        onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>] An imbalance
                                                                                    in baseline prognostic factors (i.e.,
                                                                                    visceral metastases were found in 37
                                                                                    patients randomly assigned to the high-dose
                                                                                    MVAC regimen and 47 patients assigned
                                                                                    to the classic MVAC regimen) may account,
                                                                                    in part, for these results.</li>
                                                                            </ul>
                                                                        </div>
                                                                    </li>
                                                                    <li>Gemcitabine plus cisplatin.
                                                                        <div class="pdq-content-list">
                                                                            <ul id="_440">
                                                                                <li>In a multicenter randomized phase III trial
                                                                                    that compared GC with the MVAC regimen
                                                                                    in 405 patients with advanced or metastatic
                                                                                    bladder cancer, GC yielded response rates,
                                                                                    time-to-progression, and OS (HR, 1.04;
                                                                                    95% CI, 0.82–1.32;
                                                                                    <em>P</em> = .75) similar to MVAC, but GC
                                                                                    had a better safety profile and was better
                                                                                    tolerated than MVAC.</li>
                                                                                <li>Although this study was not designed to show
                                                                                    the equivalence of the two regimens,
                                                                                    the similar efficacy and reduced toxic
                                                                                    effects of GC make it a reasonable alternative
                                                                                    in patients who may not tolerate the
                                                                                    MVAC regimen.[
                                                                                    <a href="#cit/section_8.29">29</a>][
                                                                                    <a href="/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English"
                                                                                        onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>]</li>
                                                                            </ul>
                                                                        </div>
                                                                    </li>
                                                                </ol>
                                                            </div>
                                                        </section>
                                                        <section id="_165">
                                                            <h5 id="_165_toc">Radical cystectomy</h5>
                                                            <p id="_166" tabindex="-1">Patients with stage IV disease with involvement of pelvic organs
                                                                by direct extension or metastases to regional lymph nodes
                                                                may undergo radical cystectomy with pelvic lymph node dissection.[
                                                                <a
                                                                    href="#cit/section_8.30">30</a>-
                                                                    <a href="#cit/section_8.32">32</a>] The extent of lymph node dissection during cystectomy
                                                                    is controversial [
                                                                    <a href="#cit/section_8.30">30</a>] because there are no data from prospective trials
                                                                    demonstrating improved outcomes with lymph node dissection.
                                                                    Because T4b tumors cannot generally be completely resected
                                                                    and because lymph node metastases usually signal distant
                                                                    micrometastases, patients with locally advanced bladder
                                                                    cancer are usually given chemotherapy before surgery
                                                                    with the goal of facilitating resection and eliminating
                                                                    micrometastatic disease. While there are data supporting
                                                                    preoperative chemotherapy for clinical stage II and stage
                                                                    III disease, patients with stage IV disease were excluded
                                                                    from most clinical trials investigating the role or preoperative
                                                                    chemotherapy.</p>
                                                        </section>
                                                        <section id="_167">
                                                            <h5 id="_167_toc">External-beam radiation therapy (EBRT) with or without concomitant
                                                                chemotherapy</h5>
                                                            <p id="_168" tabindex="-1">Definitive radiation therapy with or without concurrent chemotherapy,
                                                                evaluated mainly in patients with locally advanced (T2–T4)
                                                                disease, appears to have minimal curative potential in patients
                                                                with regional lymph node metastases.[
                                                                <a href="#cit/section_8.33">33</a>,
                                                                <a href="#cit/section_8.34">34</a>] Patients with evidence of lymph node metastases have
                                                                generally been excluded from phase III trials of radiation
                                                                therapy.[
                                                                <a href="#cit/section_8.35">35</a>,
                                                                <a href="#cit/section_8.36">36</a>]</p>
                                                        </section>
                                                        <section id="_169">
                                                            <h5 id="_169_toc">Urinary diversion or cystectomy for palliation</h5>
                                                            <p id="_170" tabindex="-1">Urinary diversion may be indicated, not only for palliation of
                                                                urinary symptoms but also for preservation of renal function
                                                                in candidates for chemotherapy.</p>
                                                        </section>
                                                    </section>
                                                    <section id="_160">
                                                        <h4 id="_160_toc">Standard treatment options for patients with any T, any N, M1 disease</h4>
                                                        <p id="_161" tabindex="-1">Standard treatment options for patients with any T, any N, M1 disease
                                                            include the following:</p>
                                                        <div class="pdq-content-list">
                                                            <ol id="_173">
                                                                <li>
                                                                    <a href="/types/bladder/hp/bladder-treatment-pdq#link/_174">Chemotherapy</a> alone or as an adjunct to local treatment.</li>
                                                                <li>
                                                                    <a href="/types/bladder/hp/bladder-treatment-pdq#link/_507">Immunotherapy</a>.</li>
                                                                <li>
                                                                    <a href="/types/bladder/hp/bladder-treatment-pdq#link/_176">EBRT </a> for palliation.</li>
                                                                <li>
                                                                    <a href="/types/bladder/hp/bladder-treatment-pdq#link/_178">Urinary diversion or cystectomy</a> for palliation.</li>
                                                            </ol>
                                                        </div>
                                                        <section id="_174">
                                                            <h5 id="_174_toc">Chemotherapy alone or as an adjunct to local treatment </h5>
                                                            <p id="_441" tabindex="-1">Cisplatin-based combination chemotherapy regimens are the standard
                                                                of care for stage IV bladder cancer.[
                                                                <a href="#cit/section_8.2">2</a>-
                                                                <a href="#cit/section_8.6">6</a>] The only chemotherapy regimens that have been shown
                                                                to result in longer survival in randomized controlled trials
                                                                are MVAC, high-dose MVAC, and CMV. GC was compared with MVAC
                                                                in a randomized controlled trial and no difference in response
                                                                rate or survival was reported. Of note, patients with good
                                                                performance status and lymph node-only disease have a low
                                                                but significant rate of achieving a durable complete remission
                                                                with MVAC or GC. In the large randomized controlled trial
                                                                comparing MVAC with GC, for example, 5-year OS in patients
                                                                with lymph node-only disease was 20.9%.[
                                                                <a href="#cit/section_8.7">7</a>]</p>
                                                            <p id="_442" tabindex="-1">Single-agent cisplatin and multiagent regimens that do not include
                                                                cisplatin have never been shown to improve survival in a
                                                                randomized controlled trial. Thus, there is no regimen that
                                                                has been shown to prolong survivalinpatients who are not
                                                                candidates for cisplatin-based multiagent chemotherapy regimens.
                                                                Many regimens have been shown to be active, however, with
                                                                regard to producing radiologically measurable responses:Thus,
                                                                for patients who are not candidates for cisplatin-based multiagent
                                                                chemotherapy regimens, there is no regimen that has been
                                                                shown to prolong their survival. Many regimens have been
                                                                shown to be active, however, with regard to producing radiologically
                                                                measurable responses.</p>
                                                            <p id="_443" tabindex="-1">These include carboplatin plus paclitaxel,[
                                                                <a href="#cit/section_8.8">8</a>] carboplatin plus gemcitabine,[
                                                                <a href="#cit/section_8.9">9</a>-
                                                                <a href="#cit/section_8.11">11</a>] paclitaxel plus gemcitabine,[
                                                                <a href="#cit/section_8.12">12</a>-
                                                                <a href="#cit/section_8.14">14</a>] single-agent gemcitabine,[
                                                                <a href="#cit/section_8.15">15</a>,
                                                                <a href="#cit/section_8.16">16</a>] and single-agent paclitaxel.[
                                                                <a href="#cit/section_8.17">17</a>-
                                                                <a href="#cit/section_8.19">19</a>] The regimens of carboplatin, methotrexate, and vinblastine;
                                                                carboplatin, epirubicin, methotrexate, and vinblastine; and
                                                                paclitaxel, gemcitabine, and carboplatin have been studied
                                                                but are not widely used.[
                                                                <a href="#cit/section_8.20">20</a>-
                                                                <a href="#cit/section_8.23">23</a>]</p>
                                                            <p id="_310" tabindex="-1">Ongoing studies are evaluating new chemotherapy combinations.</p>
                                                            <p id="_240" tabindex="-1">Evidence (chemotherapy):</p>
                                                            <div class="pdq-content-list">
                                                                <ol id="_261">
                                                                    <li>A prospective randomized trial that compared MVAC with
                                                                        cisplatin, cyclophosphamide, and doxorubicin demonstrated
                                                                        improved response rate and longer median survival
                                                                        (48 weeks vs. 36 weeks;
                                                                        <em>P</em> = .003) with the MVAC regimen.[
                                                                        <a href="#cit/section_8.25">25</a>]</li>
                                                                    <li>Results from a randomized trial that compared MVAC with
                                                                        single-agent cisplatin in advanced bladder cancer
                                                                        also showed a significant advantage with MVAC in
                                                                        both response rate and median survival (12.5 months
                                                                        vs. 8.2 months;
                                                                        <em>P</em> = .002).[
                                                                        <a href="#cit/section_8.26">26</a>]</li>
                                                                    <li>A multicenter randomized controlled trial compared CMV
                                                                        with methotrexate plus vinblastine without cisplatin
                                                                        in 214 patients. The relative risk of dying was 0.68
                                                                        (95% CI, 0.51–0.90;
                                                                        <em>P</em> = .0065) in favor of CMV. The median survival
                                                                        was 7 months with CMV compared with 4.5 months for
                                                                        methotrexate plus vinblastine.[
                                                                        <a href="#cit/section_8.27">27</a>]</li>
                                                                    <li>The EORTC conducted another randomized trial that studied
                                                                        263 patients with advanced bladder cancer and evaluated
                                                                        the efficacy of a high-dose intensity MVAC regimen
                                                                        given every 2 weeks with G-CSF compared with a classic
                                                                        MVAC regimen given every 4 weeks.[
                                                                        <a href="#cit/section_8.28">28</a>]
                                                                        <div class="pdq-content-list">
                                                                            <ul id="_311">
                                                                                <li>Although there was no significant difference
                                                                                    in OS at a median follow-up of 3.2 years
                                                                                    (HR, 0.80; 95% CI, 0.60–1.06;
                                                                                    <em>P</em> = .122), an update at a median
                                                                                    follow-up of 7.3 years reported that
                                                                                    the high-dose intensity MVAC regimen
                                                                                    was associated with improved OS (HR,
                                                                                    0.76; 95% CI, 0.58–0.99;
                                                                                    <em>P</em> = .042), with a 5-year survival
                                                                                    rate of 22%, compared with 14% in patients
                                                                                    treated with the classic MVAC regimen.</li>
                                                                                <li>The high-dose intensity MVAC regimen was
                                                                                    also associated with higher response
                                                                                    rates (72% vs. 58%;
                                                                                    <em>P</em> = .016), improved median progression-free
                                                                                    survival (9.5 months vs. 8.1 months;
                                                                                    <em>P</em> = .017), and decreased neutropenic
                                                                                    fever (10% vs. 26%,
                                                                                    <em>P</em> &lt; .001), although only 19%
                                                                                    of patients treated with a classic MVAC
                                                                                    regimen ever received G-CSF.[
                                                                                    <a href="#cit/section_8.28">28</a>][
                                                                                    <a href="/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English"
                                                                                        onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>] An imbalance
                                                                                    in baseline prognostic factors (i.e.,
                                                                                    visceral metastases were found in 37
                                                                                    patients randomly assigned to the high-dose
                                                                                    MVAC regimen and 47 patients assigned
                                                                                    to the classic MVAC regimen) may account,
                                                                                    in part, for these results.</li>
                                                                            </ul>
                                                                        </div>
                                                                    </li>
                                                                    <li>Gemcitabine plus cisplatin:
                                                                        <div class="pdq-content-list">
                                                                            <ul id="_312">
                                                                                <li>In a multicenter randomized phase III trial
                                                                                    that compared GC with the MVAC regimen
                                                                                    in 405 patients with advanced or metastatic
                                                                                    bladder cancer, GC yielded response rates,
                                                                                    time-to-progression, and OS (HR = 1.04;
                                                                                    95% CI, 0.82–1.32;
                                                                                    <em>P</em> = .75) similar to MVAC, but GC
                                                                                    had a better safety profile and was better
                                                                                    tolerated than MVAC.</li>
                                                                                <li>Although this study was not designed to show
                                                                                    the equivalence of the two regimens,
                                                                                    the similar efficacy and reduced toxic
                                                                                    effects of GC make it a reasonable alternative
                                                                                    in patients who may not tolerate the
                                                                                    MVAC regimen.[
                                                                                    <a href="#cit/section_8.29">29</a>][
                                                                                    <a href="/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English"
                                                                                        onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>]</li>
                                                                            </ul>
                                                                        </div>
                                                                    </li>
                                                                </ol>
                                                            </div>
                                                            <p id="_444" tabindex="-1">Ongoing studies are evaluating new chemotherapy combinations.</p>
                                                        </section>
                                                        <section id="_507">
                                                            <h5 id="_507_toc">Immunotherapy</h5>
                                                            <p id="_508" tabindex="-1">Immunotherapy has emerged as a treatment alternative for patients
                                                                with stage IV bladder cancer. Immune checkpoint inhibitors
                                                                that have anti−programmed death-1 (PD-1) or anti−programmed
                                                                death-ligand 1 (PD-L1) activity have been shown in clinical
                                                                trials to have activity against urothelial carcinoma in patients
                                                                who have previously been treated with platinum-based chemotherapy.[
                                                                <a
                                                                    href="#cit/section_8.37">37</a>-
                                                                    <a href="#cit/section_8.41">41</a>]</p>
                                                            <section id="_509">
                                                                <h6 id="_509_toc">Atezolizumab</h6>
                                                                <p id="_510" tabindex="-1">Atezolizumab is a humanized monoclonal antibody that binds
                                                                    to PD-L1 and prevents it from binding to its receptors
                                                                    PD-1 or B7-1. There are no published controlled trials
                                                                    and thus no data regarding whether atezolizumab results
                                                                    in longer survival or improved quality of life.</p>
                                                                <p id="_511" tabindex="-1">Evidence (atezolizumab):</p>
                                                                <div class="pdq-content-list">
                                                                    <ol id="_512">
                                                                        <li> In a multicenter, single-arm trial of atezolizumab
                                                                            (1,200 mg intravenously [IV] every 21 days) in
                                                                            315 patients with inoperable locally advanced
                                                                            or metastatic urothelial carcinoma, the overall
                                                                            response rate was 15%.[
                                                                            <a href="#cit/section_8.40">40</a>][
                                                                            <a href="/Common/PopUps/popDefinition.aspx?id=335135&amp;version=HealthProfessional&amp;language=English"
                                                                                onclick="javascript:popWindow('defbyid','CDR0000335135&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 2iD</a>]
                                                                            <div class="pdq-content-list">
                                                                                <ul id="_513">
                                                                                    <li>With a median follow-up of 11.7 months,
                                                                                        38 of 45 responders (84%) had an
                                                                                        ongoing response. </li>
                                                                                    <li>The response rate was 27% in those with
                                                                                        PD-L1 expression of at least 5%,
                                                                                        10% in those with PD-L1 expression
                                                                                        of 1% to 5%, and 8% in those with
                                                                                        PD-L1 expression of less than 1%.
                                                                                        </li>
                                                                                    <li>Grade 3/4 AEs were reported in 16% of
                                                                                        patients, and high-grade immune-related
                                                                                        adverse events were reported in 5%
                                                                                        of patients.</li>
                                                                                </ul>
                                                                            </div>
                                                                        </li>
                                                                        <li>Similarly, a study of 123 patients with cisplatin-ineligible,
                                                                            locally advanced metastatic urothelial carcinoma
                                                                            who were treated with atezolizumab reported that
                                                                            at 17.2 months' median follow-up, the objective
                                                                            response rate was 23%, and 9% had complete responses.[
                                                                            <a
                                                                                href="#cit/section_8.41">41</a>][
                                                                                <a href="/Common/PopUps/popDefinition.aspx?id=335135&amp;version=HealthProfessional&amp;language=English"
                                                                                    onclick="javascript:popWindow('defbyid','CDR0000335135&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 2iD</a>]
                                                                                <div class="pdq-content-list">
                                                                                    <ul id="_514">
                                                                                        <li>Of the 27 responses, 19 were ongoing
                                                                                            at the time of data analysis.
                                                                                            Median OS was 15.9 months. </li>
                                                                                        <li>High-grade adverse events were reported
                                                                                            in 16% of patients, 8% of patients
                                                                                            discontinued treatment because
                                                                                            of the AEs, and there was one
                                                                                            treatment-related death.</li>
                                                                                    </ul>
                                                                                </div>
                                                                        </li>
                                                                    </ol>
                                                                </div>
                                                            </section>
                                                            <section id="_515">
                                                                <h6 id="_515_toc">Nivolumab</h6>
                                                                <p id="_516" tabindex="-1">Nivolumab is a fully human immunoglobulin G4 PD-1 immune
                                                                    checkpoint inhibitor antibody that blocks interaction
                                                                    between PD-L1 and PD-L2 with PD-1. There are no published
                                                                    controlled trials and thus no data regarding whether
                                                                    nivolumab results in longer survival or improved quality
                                                                    of life.</p>
                                                                <p id="_517" tabindex="-1">Evidence (nivolumab):</p>
                                                                <div class="pdq-content-list">
                                                                    <ol id="_518">
                                                                        <li>In a multicenter trial of 86 patients with metastatic
                                                                            urothelial carcinoma whose disease progressed
                                                                            after platinum-based chemotherapy, patients were
                                                                            treated with nivolumab (3 mg/kg IV every 2 weeks).[
                                                                            <a
                                                                                href="#cit/section_8.39">39</a>][
                                                                                <a href="/Common/PopUps/popDefinition.aspx?id=335135&amp;version=HealthProfessional&amp;language=English"
                                                                                    onclick="javascript:popWindow('defbyid','CDR0000335135&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 2iD</a>]
                                                                                <div class="pdq-content-list">
                                                                                    <ul id="_519">
                                                                                        <li>With a minimum follow-up of 9 months
                                                                                            and a median follow-up of 15
                                                                                            months, 24% had an objective
                                                                                            response, and 22% had grade 3
                                                                                            or 4 AEs.</li>
                                                                                        <li>The most common AEs were elevated
                                                                                            lipase or amylase, fatigue, rash,
                                                                                            dyspnea, lymphopenia, and neutropenia.</li>
                                                                                    </ul>
                                                                                </div>
                                                                        </li>
                                                                        <li>Another multicenter study in 270 patients with locally
                                                                            advanced or metastatic urothelial carcinoma that
                                                                            had progressed after treatment with platinum-based
                                                                            chemotherapy reported an objective response rate
                                                                            of 20%.[
                                                                            <a href="#cit/section_8.38">38</a>][
                                                                            <a href="/Common/PopUps/popDefinition.aspx?id=335135&amp;version=HealthProfessional&amp;language=English"
                                                                                onclick="javascript:popWindow('defbyid','CDR0000335135&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 2iD</a>]
                                                                            <div class="pdq-content-list">
                                                                                <ul id="_520">
                                                                                    <li>When evaluated by PD-L1 expression, the
                                                                                        objective response rate was 28% in
                                                                                        those with PD-L1 expression of 5%
                                                                                        or greater; 24% in those with PD-L1
                                                                                        expression of 1% or greater; and
                                                                                        16% in those with PD-L1 expression
                                                                                        of less than 1%.</li>
                                                                                    <li>Grade 3/4 adverse events were reported
                                                                                        in 18% of patients.</li>
                                                                                    <li>There were three treatment-related deaths.
                                                                                        </li>
                                                                                </ul>
                                                                            </div>
                                                                        </li>
                                                                    </ol>
                                                                </div>
                                                            </section>
                                                        </section>
                                                        <section id="_176">
                                                            <h5 id="_176_toc">EBRT for palliation</h5>
                                                            <p id="_177" tabindex="-1">Definitive radiation therapy with or without concurrent chemotherapy,
                                                                evaluated mainly in patients with locally advanced (T2–T4)
                                                                disease, appears to have minimal curative potential in patients
                                                                with regional lymph node metastases.</p>
                                                        </section>
                                                        <section id="_178">
                                                            <h5 id="_178_toc">Urinary diversion or cystectomy for palliation</h5>
                                                            <p id="_179" tabindex="-1">Urinary diversion may be indicated, not only for palliation of
                                                                urinary symptoms, but also for preservation of renal function
                                                                in candidates for chemotherapy.</p>
                                                        </section>
                                                    </section>
                                                </section>
                                                <section id="_162">
                                                    <h3 id="_162_toc">Treatment Options Under Clinical Evaluation for Patients With Any T,
                                                        Any N, M1 Disease</h3>
                                                    <p id="_198" tabindex="-1">Prognosis is poor in patients with stage IV disease and consideration
                                                        of entry into a clinical trial is appropriate.</p>
                                                    <p id="_163" tabindex="-1">Other chemotherapy regimens appear to be active in the treatment of metastatic
                                                        disease. Chemotherapy agents that have shown activity in metastatic
                                                        bladder cancer include paclitaxel, docetaxel, ifosfamide, gallium
                                                        nitrate, and pemetrexed.[
                                                        <a href="#cit/section_8.42">42</a>,
                                                        <a href="#cit/section_8.43">43</a>][
                                                        <a href="/Common/PopUps/popDefinition.aspx?id=587991&amp;version=HealthProfessional&amp;language=English"
                                                            onclick="javascript:popWindow('defbyid','CDR0000587991&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiiDiv</a>]</p>
                                                </section>
                                                <section id="_TrialSearch_156_sid_8">
                                                    <h3 id="_TrialSearch_156_sid_8_toc">Current Clinical Trials</h3>
                                                    <p id="_TrialSearch_156_22" tabindex="-1">Use our
                                                        <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search"
                                                            title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">advanced clinical trial search</a> to find NCI-supported cancer clinical
                                                        trials that are now enrolling patients. The search can be narrowed
                                                        by location of the trial, type of treatment, name of the drug, and
                                                        other criteria.
                                                        <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/"
                                                            title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/">General information</a> about clinical trials is also available.</p>
                                                </section>
                                                <h6 do-not-show="toc">References</h6>
                                                <ol>
                                                    <li id="section_8.1">Vieweg J, Gschwend JE, Herr HW, et al.: The impact of primary stage on
                                                        survival in patients with lymph node positive bladder cancer. J Urol
                                                        161 (1): 72-6, 1999.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10037372&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10037372&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.2">Kachnic LA, Kaufman DS, Heney NM, et al.: Bladder preservation by combined
                                                        modality therapy for invasive bladder cancer. J Clin Oncol 15 (3):
                                                        1022-9, 1997.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9060542&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9060542&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.3">Tester W, Porter A, Asbell S, et al.: Combined modality program with
                                                        possible organ preservation for invasive bladder carcinoma: results
                                                        of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 25 (5): 783-90,
                                                        1993.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8478228&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8478228&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.4">Logothetis CJ, Johnson DE, Chong C, et al.: Adjuvant chemotherapy of
                                                        bladder cancer: a preliminary report. J Urol 139 (6): 1207-11, 1988.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3373589&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3373589&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.5">Skinner DG, Daniels JR, Russell CA, et al.: The role of adjuvant chemotherapy
                                                        following cystectomy for invasive bladder cancer: a prospective comparative
                                                        trial. J Urol 145 (3): 459-64; discussion 464-7, 1991.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1997689&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1997689&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.6">Scher HI: Chemotherapy for invasive bladder cancer: neoadjuvant versus
                                                        adjuvant. Semin Oncol 17 (5): 555-65, 1990.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2218568&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2218568&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.7">von der Maase H, Sengelov L, Roberts JT, et al.: Long-term survival results
                                                        of a randomized trial comparing gemcitabine plus cisplatin, with
                                                        methotrexate, vinblastine, doxorubicin, plus cisplatin in patients
                                                        with bladder cancer. J Clin Oncol 23 (21): 4602-8, 2005.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16034041&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16034041&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.8">Vaishampayan UN, Faulkner JR, Small EJ, et al.: Phase II trial of carboplatin
                                                        and paclitaxel in cisplatin-pretreated advanced transitional cell
                                                        carcinoma: a Southwest Oncology Group study. Cancer 104 (8): 1627-32,
                                                        2005.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16138364&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16138364&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.9">Carles J, Nogué M: Gemcitabine/carboplatin in advanced urothelial cancer.
                                                        Semin Oncol 28 (3 Suppl 10): 19-24, 2001.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11510030&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11510030&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.10">Linardou H, Aravantinos G, Efstathiou E, et al.: Gemcitabine and carboplatin
                                                        combination as first-line treatment in elderly patients and those
                                                        unfit for cisplatin-based chemotherapy with advanced bladder carcinoma:
                                                        Phase II study of the Hellenic Co-operative Oncology Group. Urology
                                                        64 (3): 479-84, 2004.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15351574&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15351574&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.11">De Santis M, Bellmunt J, Mead G, et al.: Randomized phase II/III trial
                                                        assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine
                                                        in patients with advanced urothelial cancer "unfit" for cisplatin-based
                                                        chemotherapy: phase II--results of EORTC study 30986. J Clin Oncol
                                                        27 (33): 5634-9, 2009.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19786668&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19786668&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.12">Sternberg CN, Calabrò F, Pizzocaro G, et al.: Chemotherapy with an every-2-week
                                                        regimen of gemcitabine and paclitaxel in patients with transitional
                                                        cell carcinoma who have received prior cisplatin-based therapy. Cancer
                                                        92 (12): 2993-8, 2001.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11753976&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11753976&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.13">Kaufman DS, Carducci MA, Kuzel TM, et al.: A multi-institutional phase
                                                        II trial of gemcitabine plus paclitaxel in patients with locally
                                                        advanced or metastatic urothelial cancer. Urol Oncol 22 (5): 393-7,
                                                        2004 Sep-Oct.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15464919&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15464919&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.14">Calabrò F, Lorusso V, Rosati G, et al.: Gemcitabine and paclitaxel every
                                                        2 weeks in patients with previously untreated urothelial carcinoma.
                                                        Cancer 115 (12): 2652-9, 2009.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19396817&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19396817&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.15">Stadler WM, Kuzel T, Roth B, et al.: Phase II study of single-agent gemcitabine
                                                        in previously untreated patients with metastatic urothelial cancer.
                                                        J Clin Oncol 15 (11): 3394-8, 1997.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9363871&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9363871&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.16">Lorusso V, Pollera CF, Antimi M, et al.: A phase II study of gemcitabine
                                                        in patients with transitional cell carcinoma of the urinary tract
                                                        previously treated with platinum. Italian Co-operative Group on Bladder
                                                        Cancer. Eur J Cancer 34 (8): 1208-12, 1998.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9849481&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9849481&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.17">Roth BJ, Dreicer R, Einhorn LH, et al.: Significant activity of paclitaxel
                                                        in advanced transitional-cell carcinoma of the urothelium: a phase
                                                        II trial of the Eastern Cooperative Oncology Group. J Clin Oncol
                                                        12 (11): 2264-70, 1994.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7525883&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7525883&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.18">Dreicer R, Gustin DM, See WA, et al.: Paclitaxel in advanced urothelial
                                                        carcinoma: its role in patients with renal insufficiency and as salvage
                                                        therapy. J Urol 156 (5): 1606-8, 1996.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8863548&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8863548&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.19">Vaughn DJ, Broome CM, Hussain M, et al.: Phase II trial of weekly paclitaxel
                                                        in patients with previously treated advanced urothelial cancer. J
                                                        Clin Oncol 20 (4): 937-40, 2002.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11844814&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11844814&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.20">Bellmunt J, Albanell J, Gallego OS, et al.: Carboplatin, methotrexate,
                                                        and vinblastine in patients with bladder cancer who were ineligible
                                                        for cisplatin-based chemotherapy. Cancer 70 (7): 1974-9, 1992.
                                                        <a
                                                            href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1525774&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1525774&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.21">Bellmunt J, Ribas A, Albanell J, et al.: M-CAVI, a neoadjuvant carboplatin-based
                                                        regimen for the treatment of T2-4N0M0 carcinoma of the bladder. Am
                                                        J Clin Oncol 19 (4): 344-8, 1996.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8677901&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8677901&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.22">Skarlos DV, Aravantinos G, Linardou E, et al.: Chemotherapy with methotrexate,
                                                        vinblastine, epirubicin and carboplatin (Carbo-MVE) in transitional
                                                        cell urothelial cancer. A Hellenic Co-Operative Oncology Group study.
                                                        Eur Urol 31 (4): 420-7, 1997.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9187901&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9187901&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.23">Hainsworth JD, Meluch AA, Litchy S, et al.: Paclitaxel, carboplatin,
                                                        and gemcitabine in the treatment of patients with advanced transitional
                                                        cell carcinoma of the urothelium. Cancer 103 (11): 2298-303, 2005.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15856431&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15856431&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.24">Bamias A, Aravantinos G, Deliveliotis C, et al.: Docetaxel and cisplatin
                                                        with granulocyte colony-stimulating factor (G-CSF) versus MVAC with
                                                        G-CSF in advanced urothelial carcinoma: a multicenter, randomized,
                                                        phase III study from the Hellenic Cooperative Oncology Group. J Clin
                                                        Oncol 22 (2): 220-8, 2004.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14665607&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14665607&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.25">Logothetis CJ, Dexeus FH, Finn L, et al.: A prospective randomized trial
                                                        comparing MVAC and CISCA chemotherapy for patients with metastatic
                                                        urothelial tumors. J Clin Oncol 8 (6): 1050-5, 1990.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2189954&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2189954&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.26">Loehrer PJ Sr, Einhorn LH, Elson PJ, et al.: A randomized comparison
                                                        of cisplatin alone or in combination with methotrexate, vinblastine,
                                                        and doxorubicin in patients with metastatic urothelial carcinoma:
                                                        a cooperative group study. J Clin Oncol 10 (7): 1066-73, 1992.
                                                        <a
                                                            href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1607913&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1607913&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.27">Mead GM, Russell M, Clark P, et al.: A randomized trial comparing methotrexate
                                                        and vinblastine (MV) with cisplatin, methotrexate and vinblastine
                                                        (CMV) in advanced transitional cell carcinoma: results and a report
                                                        on prognostic factors in a Medical Research Council study. MRC Advanced
                                                        Bladder Cancer Working Party. Br J Cancer 78 (8): 1067-75, 1998.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9792152&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9792152&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.28">Sternberg CN, de Mulder P, Schornagel JH, et al.: Seven year update of
                                                        an EORTC phase III trial of high-dose intensity M-VAC chemotherapy
                                                        and G-CSF versus classic M-VAC in advanced urothelial tract tumours.
                                                        Eur J Cancer 42 (1): 50-4, 2006.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16330205&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16330205&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.29">von der Maase H, Hansen SW, Roberts JT, et al.: Gemcitabine and cisplatin
                                                        versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced
                                                        or metastatic bladder cancer: results of a large, randomized, multinational,
                                                        multicenter, phase III study. J Clin Oncol 18 (17): 3068-77, 2000.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11001674&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11001674&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.30">Konety BR, Joslyn SA, O'Donnell MA: Extent of pelvic lymphadenectomy
                                                        and its impact on outcome in patients diagnosed with bladder cancer:
                                                        analysis of data from the Surveillance, Epidemiology and End Results
                                                        Program data base. J Urol 169 (3): 946-50, 2003.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12576819&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12576819&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.31">Thrasher JB, Crawford ED: Current management of invasive and metastatic
                                                        transitional cell carcinoma of the bladder. J Urol 149 (5): 957-72,
                                                        1993.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8483247&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8483247&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.32">Grossman HB, Natale RB, Tangen CM, et al.: Neoadjuvant chemotherapy plus
                                                        cystectomy compared with cystectomy alone for locally advanced bladder
                                                        cancer. N Engl J Med 349 (9): 859-66, 2003.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12944571&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12944571&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.33">Jahnson S, Pedersen J, Westman G: Bladder carcinoma--a 20-year review
                                                        of radical irradiation therapy. Radiother Oncol 22 (2): 111-7, 1991.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1957001&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1957001&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.34">Coppin CM, Gospodarowicz MK, James K, et al.: Improved local control
                                                        of invasive bladder cancer by concurrent cisplatin and preoperative
                                                        or definitive radiation. The National Cancer Institute of Canada
                                                        Clinical Trials Group. J Clin Oncol 14 (11): 2901-7, 1996.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8918486&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8918486&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.35">Shipley WU, Winter KA, Kaufman DS, et al.: Phase III trial of neoadjuvant
                                                        chemotherapy in patients with invasive bladder cancer treated with
                                                        selective bladder preservation by combined radiation therapy and
                                                        chemotherapy: initial results of Radiation Therapy Oncology Group
                                                        89-03. J Clin Oncol 16 (11): 3576-83, 1998.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817278&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817278&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.36">James ND, Hussain SA, Hall E, et al.: Radiotherapy with or without chemotherapy
                                                        in muscle-invasive bladder cancer. N Engl J Med 366 (16): 1477-88,
                                                        2012.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22512481&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22512481&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.37">Plimack ER, Bellmunt J, Gupta S, et al.: Safety and activity of pembrolizumab
                                                        in patients with locally advanced or metastatic urothelial cancer
                                                        (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet
                                                        Oncol 18 (2): 212-220, 2017.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28081914&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28081914&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.38">Sharma P, Retz M, Siefker-Radtke A, et al.: Nivolumab in metastatic urothelial
                                                        carcinoma after platinum therapy (CheckMate 275): a multicentre,
                                                        single-arm, phase 2 trial. Lancet Oncol 18 (3): 312-322, 2017.
                                                        <a
                                                            href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28131785&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28131785&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.39">Sharma P, Callahan MK, Bono P, et al.: Nivolumab monotherapy in recurrent
                                                        metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label,
                                                        two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 17 (11): 1590-1598,
                                                        2016.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27733243&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27733243&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.40">Rosenberg JE, Hoffman-Censits J, Powles T, et al.: Atezolizumab in patients
                                                        with locally advanced and metastatic urothelial carcinoma who have
                                                        progressed following treatment with platinum-based chemotherapy:
                                                        a single-arm, multicentre, phase 2 trial. Lancet 387 (10031): 1909-20,
                                                        2016.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26952546&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26952546&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.41">Balar AV, Galsky MD, Rosenberg JE, et al.: Atezolizumab as first-line
                                                        treatment in cisplatin-ineligible patients with locally advanced
                                                        and metastatic urothelial carcinoma: a single-arm, multicentre, phase
                                                        2 trial. Lancet 389 (10064): 67-76, 2017.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27939400&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27939400&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.42">Raghavan D, Huben R: Management of bladder cancer. Curr Probl Cancer
                                                        19 (1): 1-64, 1995 Jan-Feb.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7768113&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7768113&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_8.43">Sweeney CJ, Roth BJ, Kabbinavar FF, et al.: Phase II study of pemetrexed
                                                        for second-line treatment of transitional cell cancer of the urothelium.
                                                        J Clin Oncol 24 (21): 3451-7, 2006.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16849761&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16849761&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                </ol>
                                            </div>
                                        </section>


                                        <section id="_180">
                                            <h2>Recurrent Bladder Cancer Treatment</h2>
                                            <div id="_section_180" class="pdq-sections">
                                                <p id="_181" tabindex="-1">The prognosis for any patient with progressive or recurrent invasive bladder
                                                    cancer is generally poor. Management of recurrence depends on previous
                                                    therapy, sites of recurrence, and individual patient considerations.
                                                    </p>
                                                <section id="_182">
                                                    <h3 id="_182_toc">Treatment Options for Recurrent Bladder Cancer</h3>
                                                    <p id="_183" tabindex="-1">Treatment options for patients with
                                                        <a href="/types/bladder/hp/bladder-treatment-pdq#link/_461">recurrent bladder cancer</a> include the following:</p>
                                                    <div class="pdq-content-list">
                                                        <ol id="_184">
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_185">Combination chemotherapy</a>.</li>
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_521">Immunotherapy</a>.</li>
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_484">Surgery</a> for new superficial or localized tumors.</li>
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_486">Palliative therapy</a>.</li>
                                                            <li>
                                                                <a href="/types/bladder/hp/bladder-treatment-pdq#link/_488">Clinical trials</a>.</li>
                                                        </ol>
                                                    </div>
                                                    <section id="_185">
                                                        <h4 id="_185_toc">Combination chemotherapy</h4>
                                                        <p id="_483" tabindex="-1">Patients who have not received previous chemotherapy for urothelial
                                                            carcinoma should be considered for chemotherapy as described
                                                            above for
                                                            <a href="/types/bladder/hp/bladder-treatment-pdq#link/_174">stage IV disease</a>.</p>
                                                        <p id="_186" tabindex="-1">In patients with recurrent transitional cell carcinoma, combination
                                                            chemotherapy has produced high response rates, with occasional
                                                            complete responses seen.[
                                                            <a href="#cit/section_9.1">1</a>,
                                                            <a href="#cit/section_9.2">2</a>] </p>
                                                        <p id="_244" tabindex="-1">Evidence (combination chemotherapy):</p>
                                                        <div class="pdq-content-list">
                                                            <ol id="_264">
                                                                <li>Results from a randomized trial that compared methotrexate,
                                                                    vinblastine, doxorubicin, and cisplatin (MVAC) with single-agent
                                                                    cisplatin in patients with advanced bladder cancer show
                                                                    a significant advantage with MVAC in both response rate
                                                                    and median survival.[
                                                                    <a href="#cit/section_9.3">3</a>] The overall response rate with MVAC in this cooperative
                                                                    group trial was 39%.</li>
                                                                <li>Results from a randomized trial that compared MVAC with cisplatin,
                                                                    cyclophosphamide, and doxorubicin in 110 patients reported
                                                                    longer overall survival (OS) with MVAC (median survival
                                                                    48.3 weeks vs. 36.1 weeks;
                                                                    <em>P</em> = .0003).[
                                                                    <a href="#cit/section_9.4">4</a>]</li>
                                                                <li>Results from a randomized trial that compared cisplatin,
                                                                    methotrexate, and vinblastine (CMV) with methotrexate
                                                                    plus vinblastine reported longer OS with CMV (median
                                                                    survival 7 months vs. 4.5 months; hazard ratio [HR],
                                                                    0.55; 95% confidence interval [CI], 0.41–0.73;
                                                                    <em>P</em> = .0001).[
                                                                    <a href="#cit/section_9.5">5</a>]</li>
                                                                <li>In a multicenter, randomized, phase III trial that compared
                                                                    the combination of gemcitabine plus cisplatin (GC) with
                                                                    the MVAC regimen in 405 patients with advanced or metastatic
                                                                    bladder cancer, GC yielded response rates, time-to-progression,
                                                                    and OS (HR, 1.04; 95% CI, 0.82–1.32;
                                                                    <em>P</em> = .75) similar to MVAC, but GC had a better safety
                                                                    profile and was better tolerated than MVAC. Although
                                                                    this study was not designed to show the equivalence of
                                                                    the two regimens, the similar efficacy and reduced toxic
                                                                    effects of GC make it a reasonable alternative in patients
                                                                    who may not tolerate the MVAC regimen.[
                                                                    <a href="#cit/section_9.6">6</a>][
                                                                    <a href="/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English"
                                                                        onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>]</li>
                                                                <li>Other chemotherapy regimens that have shown activity in metastatic
                                                                    bladder cancer include single-agent paclitaxel, single-agent
                                                                    gemcitabine, single-agent pemetrexed, carboplatin combined
                                                                    with either gemcitabine or paclitaxel, and gemcitabine
                                                                    combined with paclitaxel. There are no phase III trials
                                                                    demonstrating a survival or quality-of-life benefit from
                                                                    second-line chemotherapy.[
                                                                    <a href="#cit/section_9.7">7</a>-
                                                                    <a href="#cit/section_9.14">14</a>]</li>
                                                            </ol>
                                                        </div>
                                                    </section>
                                                    <section id="_521">
                                                        <h4 id="_521_toc">Immunotherapy</h4>
                                                        <p id="_522" tabindex="-1">Immunotherapy has emerged as a treatment alternative for patients
                                                            with recurrent bladder cancer. Immune checkpoint inhibitors that
                                                            have anti−programmed death-1 (PD-1) or anti−programmed death-ligand
                                                            1 (PD-L1) activity have been shown in clinical trials to have
                                                            activity against urothelial carcinoma in patients who have previously
                                                            been treated with cisplatin-based chemotherapy.[
                                                            <a href="#cit/section_9.15">15</a>-
                                                            <a href="#cit/section_9.19">19</a>]</p>
                                                        <section id="_523">
                                                            <h5 id="_523_toc">Atezolizumab</h5>
                                                            <p id="_524" tabindex="-1">Atezolizumab is a humanized monoclonal antibody that binds to
                                                                PD-L1 and prevents it from binding to its receptors PD-1
                                                                or B7-1. There are no published controlled trials and thus
                                                                no data regarding whether atezolizumab results in longer
                                                                survival or improved quality of life.</p>
                                                            <p id="_525" tabindex="-1">Evidence (atezolizumab):</p>
                                                            <div class="pdq-content-list">
                                                                <ol id="_526">
                                                                    <li>In a multicenter, single-arm trial of atezolizumab (1,200
                                                                        mg intravenously [IV] every 21 days) in 315 patients
                                                                        with inoperable locally advanced or metastatic urothelial
                                                                        carcinoma, the overall response rate was 15%.[
                                                                        <a
                                                                            href="#cit/section_9.18">18</a>][
                                                                            <a href="/Common/PopUps/popDefinition.aspx?id=335135&amp;version=HealthProfessional&amp;language=English"
                                                                                onclick="javascript:popWindow('defbyid','CDR0000335135&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 2iD</a>]
                                                                            <div class="pdq-content-list">
                                                                                <ul id="_527">
                                                                                    <li>With a median follow-up of 11.7 months,
                                                                                        38 of 45 responders (84%) had an
                                                                                        ongoing response. </li>
                                                                                    <li>The response rate was 27% in those with
                                                                                        PD-L1 expression of at least 5%,
                                                                                        10% in those with PD-L1 expression
                                                                                        of 1% to 5%, and 8% in those with
                                                                                        PD-L1 expression of less than 1%.
                                                                                        </li>
                                                                                    <li>Grade 3/4 AEs were reported in 16% of
                                                                                        patients, and high-grade immune-related
                                                                                        adverse events were reported in 5%
                                                                                        of patients.</li>
                                                                                </ul>
                                                                            </div>
                                                                    </li>
                                                                    <li>Similarly, a study of 123 patients with cisplatin-ineligible,
                                                                        locally advanced metastatic urothelial carcinoma
                                                                        who were treated with atezolizumab reported that
                                                                        at 17.2 months' median follow-up, the objective response
                                                                        rate was 23%, and 9% had complete responses.[
                                                                        <a href="#cit/section_9.19">19</a>][
                                                                        <a href="/Common/PopUps/popDefinition.aspx?id=335135&amp;version=HealthProfessional&amp;language=English"
                                                                            onclick="javascript:popWindow('defbyid','CDR0000335135&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 2iD</a>]
                                                                        <div class="pdq-content-list">
                                                                            <ul id="_528">
                                                                                <li>Of the 27 responses, 19 were ongoing at the
                                                                                    time of data analysis. Median OS was
                                                                                    15.9 months. </li>
                                                                                <li>High-grade AEs were reported in 16% of patients,
                                                                                    8% of patients discontinued treatment
                                                                                    because of the AEs, and there was one
                                                                                    treatment-related death.</li>
                                                                            </ul>
                                                                        </div>
                                                                    </li>
                                                                </ol>
                                                            </div>
                                                        </section>
                                                        <section id="_529">
                                                            <h5 id="_529_toc">Nivolumab</h5>
                                                            <p id="_530" tabindex="-1">Nivolumab is a fully human immunoglobulin G4 PD-1 immune checkpoint
                                                                inhibitor antibody that blocks interaction between PD-L1
                                                                and PD-L2 with PD-1. There are no published controlled trials
                                                                and thus no data regarding whether nivolumab results in longer
                                                                survival or improved quality of life.</p>
                                                            <p id="_531" tabindex="-1">Evidence (nivolumab):</p>
                                                            <div class="pdq-content-list">
                                                                <ol id="_532">
                                                                    <li>In a multicenter trial of 86 patients with metastatic
                                                                        urothelial carcinoma whose disease progressed after
                                                                        platinum-based chemotherapy, patients were treated
                                                                        with nivolumab (3 mg/kg IV q 2 wks).[
                                                                        <a href="#cit/section_9.17">17</a>][
                                                                        <a href="/Common/PopUps/popDefinition.aspx?id=335135&amp;version=HealthProfessional&amp;language=English"
                                                                            onclick="javascript:popWindow('defbyid','CDR0000335135&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 2iD</a>]
                                                                        <div class="pdq-content-list">
                                                                            <ul id="_533">
                                                                                <li>With a minimum follow-up of 9 months and
                                                                                    a median follow-up of 15 months, 24%
                                                                                    had an objective response, and 22% had
                                                                                    grade 3 or 4 adverse events.</li>
                                                                                <li>The most common adverse events were elevated
                                                                                    lipase or amylase, fatigue, rash, dyspnea,
                                                                                    lymphopenia, and neutropenia.</li>
                                                                            </ul>
                                                                        </div>
                                                                    </li>
                                                                    <li>Another multicenter study in 270 patients with locally
                                                                        advanced or metastatic urothelial carcinoma that
                                                                        had progressed after treatment with platinum-based
                                                                        chemotherapy reported an objective response rate
                                                                        of 20%.[
                                                                        <a href="#cit/section_9.16">16</a>][
                                                                        <a href="/Common/PopUps/popDefinition.aspx?id=335135&amp;version=HealthProfessional&amp;language=English"
                                                                            onclick="javascript:popWindow('defbyid','CDR0000335135&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 2iD</a>]
                                                                        <div class="pdq-content-list">
                                                                            <ul id="_534">
                                                                                <li>When evaluated by PD-L1 expression, the objective
                                                                                    response rate was 28% in those with PD-L1
                                                                                    expression of 5% or greater; 24% in those
                                                                                    with PD-L1 expression of 1% or greater;
                                                                                    and 16% in those with PD-L1 expression
                                                                                    of less than 1%.</li>
                                                                                <li>Grade 3/4 adverse events were reported in
                                                                                    18% of patients.</li>
                                                                                <li>There were three treatment-related deaths.
                                                                                    </li>
                                                                            </ul>
                                                                        </div>
                                                                    </li>
                                                                </ol>
                                                            </div>
                                                        </section>
                                                    </section>
                                                    <section id="_484">
                                                        <h4 id="_484_toc">Surgery for new superficial or localized tumors</h4>
                                                        <p id="_485" tabindex="-1">Treatment of new superficial or locally invasive tumors that develop
                                                            in the setting of previous conservative therapy for superficial
                                                            bladder neoplasia has been discussed earlier in
                                                            <a href="/types/bladder/hp/bladder-treatment-pdq#link/_66">stage I</a> in this summary. </p>
                                                    </section>
                                                    <section id="_486">
                                                        <h4 id="_486_toc">Palliative therapy</h4>
                                                        <p id="_487" tabindex="-1">Palliative radiation therapy should be considered for patients with
                                                            symptomatic tumors.</p>
                                                    </section>
                                                    <section id="_488">
                                                        <h4 id="_488_toc">Clinical trials</h4>
                                                        <p id="_489" tabindex="-1">Recurrent or progressive disease in distant sites or after definitive
                                                            local therapy has an extremely poor prognosis, and clinical trials
                                                            should be considered whenever possible. </p>
                                                    </section>
                                                </section>
                                                <section id="_TrialSearch_180_sid_9">
                                                    <h3 id="_TrialSearch_180_sid_9_toc">Current Clinical Trials</h3>
                                                    <p id="_TrialSearch_180_22" tabindex="-1">Use our
                                                        <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search"
                                                            title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">advanced clinical trial search</a> to find NCI-supported cancer clinical
                                                        trials that are now enrolling patients. The search can be narrowed
                                                        by location of the trial, type of treatment, name of the drug, and
                                                        other criteria.
                                                        <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/"
                                                            title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/">General information</a> about clinical trials is also available.</p>
                                                </section>
                                                <h6 do-not-show="toc">References</h6>
                                                <ol>
                                                    <li id="section_9.1">Sternberg CN, Yagoda A, Scher HI, et al.: Methotrexate, vinblastine,
                                                        doxorubicin, and cisplatin for advanced transitional cell carcinoma
                                                        of the urothelium. Efficacy and patterns of response and relapse.
                                                        Cancer 64 (12): 2448-58, 1989.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2819654&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2819654&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_9.2">Harker WG, Meyers FJ, Freiha FS, et al.: Cisplatin, methotrexate, and
                                                        vinblastine (CMV): an effective chemotherapy regimen for metastatic
                                                        transitional cell carcinoma of the urinary tract. A Northern California
                                                        Oncology Group study. J Clin Oncol 3 (11): 1463-70, 1985.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4056840&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4056840&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_9.3">Loehrer PJ Sr, Einhorn LH, Elson PJ, et al.: A randomized comparison
                                                        of cisplatin alone or in combination with methotrexate, vinblastine,
                                                        and doxorubicin in patients with metastatic urothelial carcinoma:
                                                        a cooperative group study. J Clin Oncol 10 (7): 1066-73, 1992.
                                                        <a
                                                            href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1607913&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1607913&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_9.4">Logothetis CJ, Dexeus FH, Finn L, et al.: A prospective randomized trial
                                                        comparing MVAC and CISCA chemotherapy for patients with metastatic
                                                        urothelial tumors. J Clin Oncol 8 (6): 1050-5, 1990.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2189954&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2189954&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_9.5">Mead GM, Russell M, Clark P, et al.: A randomized trial comparing methotrexate
                                                        and vinblastine (MV) with cisplatin, methotrexate and vinblastine
                                                        (CMV) in advanced transitional cell carcinoma: results and a report
                                                        on prognostic factors in a Medical Research Council study. MRC Advanced
                                                        Bladder Cancer Working Party. Br J Cancer 78 (8): 1067-75, 1998.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9792152&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9792152&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_9.6">von der Maase H, Hansen SW, Roberts JT, et al.: Gemcitabine and cisplatin
                                                        versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced
                                                        or metastatic bladder cancer: results of a large, randomized, multinational,
                                                        multicenter, phase III study. J Clin Oncol 18 (17): 3068-77, 2000.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11001674&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11001674&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_9.7">Roth BJ: Preliminary experience with paclitaxel in advanced bladder cancer.
                                                        Semin Oncol 22 (3 Suppl 6): 1-5, 1995.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7541150&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7541150&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_9.8">Witte RS, Elson P, Bono B, et al.: Eastern Cooperative Oncology Group
                                                        phase II trial of ifosfamide in the treatment of previously treated
                                                        advanced urothelial carcinoma. J Clin Oncol 15 (2): 589-93, 1997.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9053481&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9053481&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_9.9">Einhorn LH, Roth BJ, Ansari R, et al.: Phase II trial of vinblastine,
                                                        ifosfamide, and gallium combination chemotherapy in metastatic urothelial
                                                        carcinoma. J Clin Oncol 12 (11): 2271-6, 1994.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7525884&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7525884&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_9.10">Pollera CF, Ceribelli A, Crecco M, et al.: Weekly gemcitabine in advanced
                                                        bladder cancer: a preliminary report from a phase I study. Ann Oncol
                                                        5 (2): 182-4, 1994.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8186164&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8186164&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_9.11">Seidman AD, Scher HI, Heinemann MH, et al.: Continuous infusion gallium
                                                        nitrate for patients with advanced refractory urothelial tract tumors.
                                                        Cancer 68 (12): 2561-5, 1991.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1933802&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1933802&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_9.12">Roth BJ: Ifosfamide in the treatment of bladder cancer. Semin Oncol 23
                                                        (3 Suppl 6): 50-5, 1996.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8677450&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8677450&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_9.13">Bajorin DF: Paclitaxel in the treatment of advanced urothelial cancer.
                                                        Oncology (Huntingt) 14 (1): 43-52, 57; discussion 58, 61-2, 2000.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10680149&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10680149&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_9.14">Sweeney CJ, Roth BJ, Kabbinavar FF, et al.: Phase II study of pemetrexed
                                                        for second-line treatment of transitional cell cancer of the urothelium.
                                                        J Clin Oncol 24 (21): 3451-7, 2006.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16849761&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16849761&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_9.15">Plimack ER, Bellmunt J, Gupta S, et al.: Safety and activity of pembrolizumab
                                                        in patients with locally advanced or metastatic urothelial cancer
                                                        (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet
                                                        Oncol 18 (2): 212-220, 2017.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28081914&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28081914&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_9.16">Sharma P, Retz M, Siefker-Radtke A, et al.: Nivolumab in metastatic urothelial
                                                        carcinoma after platinum therapy (CheckMate 275): a multicentre,
                                                        single-arm, phase 2 trial. Lancet Oncol 18 (3): 312-322, 2017.
                                                        <a
                                                            href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28131785&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28131785&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_9.17">Sharma P, Callahan MK, Bono P, et al.: Nivolumab monotherapy in recurrent
                                                        metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label,
                                                        two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 17 (11): 1590-1598,
                                                        2016.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27733243&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27733243&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_9.18">Rosenberg JE, Hoffman-Censits J, Powles T, et al.: Atezolizumab in patients
                                                        with locally advanced and metastatic urothelial carcinoma who have
                                                        progressed following treatment with platinum-based chemotherapy:
                                                        a single-arm, multicentre, phase 2 trial. Lancet 387 (10031): 1909-20,
                                                        2016.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26952546&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26952546&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                    <li id="section_9.19">Balar AV, Galsky MD, Rosenberg JE, et al.: Atezolizumab as first-line
                                                        treatment in cisplatin-ineligible patients with locally advanced
                                                        and metastatic urothelial carcinoma: a single-arm, multicentre, phase
                                                        2 trial. Lancet 389 (10064): 67-76, 2017.
                                                        <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27939400&amp;dopt=Abstract"
                                                            title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27939400&amp;dopt=Abstract">[PUBMED Abstract]</a>
                                                    </li>
                                                </ol>
                                            </div>
                                        </section>


                                        <section id="_4">
                                            <h2>Changes to This Summary (01/18/2018)</h2>
                                            <div id="_section_4" class="pdq-sections">
                                                <p id="_6" tabindex="-1">The PDQ cancer information summaries are reviewed regularly and updated as
                                                    new information becomes available. This section describes the latest
                                                    changes made to this summary as of the date above.</p>
                                                <p id="_559" tabindex="-1">
                                                    <strong>
                                                        <a href="/types/bladder/hp/bladder-treatment-pdq#link/_1">General Information About Bladder Cancer</a>
                                                    </strong>
                                                </p>
                                                <p id="_560" tabindex="-1">Updated
                                                    <a href="/types/bladder/hp/bladder-treatment-pdq#link/_11">statistics</a> with estimated new cases and deaths for 2018 (cited American
                                                    Cancer Society as reference 1).</p>
                                                <p id="_disclaimerHP_3" tabindex="-1">This summary is written and maintained by the
                                                    <a href="http://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment"
                                                        title="http://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</a>, which is editorially independent
                                                    of NCI. The summary reflects an independent review of the literature
                                                    and does not represent a policy statement of NCI or NIH. More information
                                                    about summary policies and the role of the PDQ Editorial Boards in maintaining
                                                    the PDQ summaries can be found on the
                                                    <a href="/types/bladder/hp/bladder-treatment-pdq#link/_AboutThis_1">About This PDQ Summary</a> and
                                                    <a href="http://www.cancer.gov/publications/pdq"
                                                        title="http://www.cancer.gov/publications/pdq">PDQ® - NCI's Comprehensive Cancer Database</a> pages.
                                                </p>
                                            </div>
                                        </section>


                                        <section id="_AboutThis_1">
                                            <h2>About This PDQ Summary</h2>
                                            <div id="_section_AboutThis_1" class="pdq-sections">
                                                <section id="_AboutThis_2">
                                                    <h3 id="_AboutThis_2_toc">Purpose of This Summary</h3>
                                                    <p id="_AboutThis_3" tabindex="-1">This PDQ cancer information summary for health professionals provides
                                                        comprehensive, peer-reviewed, evidence-based information about the
                                                        treatment of bladder cancer. It is intended as a resource to inform
                                                        and assist clinicians who care for cancer patients. It does not provide
                                                        formal guidelines or recommendations for making health care decisions.</p>
                                                </section>
                                                <section id="_AboutThis_4">
                                                    <h3 id="_AboutThis_4_toc">Reviewers and Updates</h3>
                                                    <p id="_AboutThis_5" tabindex="-1">This summary is reviewed regularly and updated as necessary by the
                                                        <a
                                                            href="http://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment"
                                                            title="http://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</a>, which is editorially independent
                                                            of the National Cancer Institute (NCI). The summary reflects
                                                            an independent review of the literature and does not represent
                                                            a policy statement of NCI or the National Institutes of Health
                                                            (NIH).</p>
                                                    <p id="_AboutThis_22" tabindex="-1"> Board members review recently published articles each month to determine
                                                        whether an article should:</p>
                                                    <div class="pdq-content-list">
                                                        <ul id="_AboutThis_6">
                                                            <li>be discussed at a meeting,</li>
                                                            <li>be cited with text, or</li>
                                                            <li>replace or update an existing article that is already cited.</li>
                                                        </ul>
                                                    </div>
                                                    <p id="_AboutThis_7" tabindex="-1">Changes to the summaries are made through a consensus process in which
                                                        Board members evaluate the strength of the evidence in the published
                                                        articles and determine how the article should be included in the
                                                        summary.</p>
                                                    <p id="" tabindex="-1">The lead reviewer for Bladder Cancer Treatment is:</p>
                                                    <div class="pdq-content-list">
                                                        <ul id="">
                                                            <li>Timothy Gilligan, MD (Cleveland Clinic Taussig Cancer Institute)</li>
                                                        </ul>
                                                    </div>
                                                    <p id="_AboutThis_9" tabindex="-1">Any comments or questions about the summary content should be submitted
                                                        to Cancer.gov through the NCI website's
                                                        <a href="https://www.cancer.gov/contact/email-us"
                                                            title="https://www.cancer.gov/contact/email-us">Email Us</a>. Do not contact the individual Board Members with questions
                                                        or comments about the summaries. Board members will not respond to
                                                        individual inquiries.</p>
                                                </section>
                                                <section id="_AboutThis_10">
                                                    <h3 id="_AboutThis_10_toc">Levels of Evidence</h3>
                                                    <p id="_AboutThis_11" tabindex="-1">Some of the reference citations in this summary are accompanied by a
                                                        level-of-evidence designation. These designations are intended to
                                                        help readers assess the strength of the evidence supporting the use
                                                        of specific interventions or approaches. The PDQ Adult Treatment
                                                        Editorial Board uses a
                                                        <a href="">formal evidence ranking system</a> in developing its level-of-evidence
                                                        designations.</p>
                                                </section>
                                                <section id="_AboutThis_12">
                                                    <h3 id="_AboutThis_12_toc">Permission to Use This Summary</h3>
                                                    <p id="_AboutThis_13" tabindex="-1">PDQ is a registered trademark. Although the content of PDQ documents
                                                        can be used freely as text, it cannot be identified as an NCI PDQ
                                                        cancer information summary unless it is presented in its entirety
                                                        and is regularly updated. However, an author would be permitted to
                                                        write a sentence such as “NCI’s PDQ cancer information summary about
                                                        breast cancer prevention states the risks succinctly: [include excerpt
                                                        from the summary].”</p>
                                                    <p id="_AboutThis_14" tabindex="-1">The preferred citation for this PDQ summary is:</p>
                                                    <p id="_AboutThis_15" tabindex="-1">PDQ® Adult Treatment Editorial Board. PDQ Bladder Cancer Treatment. Bethesda,
                                                        MD: National Cancer Institute. Updated &lt;MM/DD/YYYY&gt;. Available
                                                        at:
                                                        <a href="https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq"
                                                            title="https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq">https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq</a>.
                                                        Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389399]</p>
                                                    <p id="_AboutThis_16" tabindex="-1">Images in this summary are used with permission of the author(s), artist,
                                                        and/or publisher for use within the PDQ summaries only. Permission
                                                        to use images outside the context of PDQ information must be obtained
                                                        from the owner(s) and cannot be granted by the National Cancer Institute.
                                                        Information about using the illustrations in this summary, along
                                                        with many other cancer-related images, is available in
                                                        <a href="https://visualsonline.cancer.gov/"
                                                            title="https://visualsonline.cancer.gov/">Visuals Online</a>, a collection of over 2,000 scientific images.

                                                    </p>
                                                </section>
                                                <section id="_AboutThis_17">
                                                    <h3 id="_AboutThis_17_toc">Disclaimer</h3>
                                                    <p id="_AboutThis_18" tabindex="-1">Based on the strength of the available evidence, treatment options may
                                                        be described as either “standard” or “under clinical evaluation.”
                                                        These classifications should not be used as a basis for insurance
                                                        reimbursement determinations. More information on insurance coverage
                                                        is available on Cancer.gov on the
                                                        <a href="https://www.cancer.gov/about-cancer/managing-care"
                                                            title="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</a> page.</p>
                                                </section>
                                                <section id="_AboutThis_20">
                                                    <h3 id="_AboutThis_20_toc">Contact Us</h3>
                                                    <p id="_AboutThis_21" tabindex="-1">More information about contacting us or receiving help with the Cancer.gov
                                                        website can be found on our
                                                        <a href="https://www.cancer.gov/contact"
                                                            title="https://www.cancer.gov/contact">Contact Us for Help</a> page. Questions can also be submitted to
                                                        Cancer.gov through the website’s
                                                        <a href="https://www.cancer.gov/contact/email-us"
                                                            title="https://www.cancer.gov/contact/email-us">Email Us</a>.</p>
                                                </section>
                                            </div>
                                        </section>

                                    </div>

                                </div>
                            </div>

                            <footer class="article-footer">


                                <div id="cgvDate">
                                    <div class="contentid-3394 slot-item only-SI">







                                        <div class="document-dates horizontal">
                                            <ul class="clearfix">
                                                <li>
                                                    <strong>Updated:</strong> January 18, 2018</li>
                                            </ul>
                                        </div>

                                    </div>
                                </div>




                                <div id="nvcgSlPublicUse">
                                    <div class="contentid-911758 slot-item only-SI">
                                        <div class="public-use">
                                            <p id="public-use">
                                                <i>Most text on the National Cancer Institute website may be reproduced or reused
                                                    freely. The National Cancer Institute should be credited as the source
                                                    and a link to this page included, e.g., “Bladder Cancer Treatment (PDQ®)–Health
                                                    Professional Version was originally published by the National Cancer
                                                    Institute.”</i>
                                            </p>

                                            <p id="public-use">Please note that blog posts that are written by individuals from outside the
                                                government may be owned by the writer, and graphics may be owned by their
                                                creator. In such cases, it is necessary to contact the writer, artists, or
                                                publisher to obtain
                                                <a href="/policies/copyright-reuse">permission</a> for reuse.</p>

                                            <p id="comment-policy" class="blog-comment-policy">We welcome your comments on this post. All comments must follow our
                                                <a href="/policies/comments">comment policy</a>.</p>
                                        </div>

                                    </div>
                                </div>
                                <div id="nvcgSlSyndication">
                                    <div class="contentid-911760 slot-item only-SI">
                                        <div class="syndication">
                                            <div class="row collapse-edges">
                                                <div class="large-1 small-2 columns">
                                                    <img alt="" src="/publishedcontent/Images/images/design-elements/icons/syndication.png">
                                                </div>
                                                <div class="large-11 small-10 columns">
                                                    <p style="margin-top: 0;">Want to use this content on your website or other digital platform? Our
                                                        <a href="/syndication">syndication services page</a> shows you how.</p>
                                                </div>
                                            </div>
                                        </div>

                                    </div>
                                </div>

                            </footer>
                    </div>
                    <!-- End resizeable area -->
                    </article>
                    <!-- ********************************* END Page Content ********************************** -->
                </div>
                <!-- END Main -->
            </div>
            <!-- END "row" -->
        </div>
        <!-- END "row general-page-body-container collapse" -->
    </div>
    <!-- End MAIN CONTENT AREA -->

    </div>
    <!-- END Page -->

    <!-- FOOTER -->
    <footer class="site-footer">
        <div id="nvcgSlFooter">
            <div class="contentid-911586 slot-item only-SI">


                <div class="row">
                    <div class="large-12 columns footer-nci">National Cancer Institute
                        <br />
                        <span>at the National Institutes of Health</span>
                    </div>
                </div>
                <div class="row footer-utility">
                    <div class="large-3 columns">
                        <h2>FOLLOW US</h2>
                        <ul class="follow-us clearfix">
                            <li>
                                <a class="facebook icon" onclick="NCIAnalytics.FooterLink(this, 'Facebook');" href="/social-media#facebook">
                                    <span class="hidden">Facebook</span>
                                </a>
                            </li>
                            <li>
                                <a class="twitter icon" onclick="NCIAnalytics.FooterLink(this, 'Twitter');" href="/social-media#twitter">
                                    <span class="hidden">Twitter</span>
                                </a>
                            </li>
                            <li>
                                <a class="instagram icon no-exit-notification" onclick="NCIAnalytics.FooterLink(this, 'Instagram');"
                                    href="http://instagram.com/nationalcancerinstitute">
                                    <span class="hidden">Instagram</span>
                                </a>
                            </li>
                            <li>
                                <a class="youtube icon" onclick="NCIAnalytics.FooterLink(this, 'YouTube');" href="/social-media#youTube">
                                    <span class="hidden">YouTube</span>
                                </a>
                            </li>
                            <li>
                                <a class="googleplus icon" onclick="NCIAnalytics.FooterLink(this, 'Google+');" href="/social-media#google+">
                                    <span class="hidden">Google+</span>
                                </a>
                            </li>
                            <li>
                                <a class="linkedin icon" onclick="NCIAnalytics.FooterLink(this, 'LinkedIn');" href="/social-media#linkedIn">
                                    <span class="hidden">LinkedIn</span>
                                </a>
                            </li>
                        </ul>
                        <ul class="follow-us clearfix">
                            <li>
                                <a class="govdelivery icon" onclick="NCIAnalytics.FooterLink(this, 'GovDelivery');" href="https://public.govdelivery.com/accounts/USNIHNCI/subscriber/new ">
                                    <span class="hidden">GovDelivery</span>
                                </a>
                            </li>
                            <li>
                                <a class="rss icon" onclick="NCIAnalytics.FooterLink(this, 'RSS');" href="/syndication/rss">
                                    <span class="hidden">RSS</span>
                                </a>
                            </li>
                        </ul>
                    </div>
                    <div class="large-3 columns">
                        <h2>CONTACT INFORMATION</h2>
                        <ul>
                            <li>
                                <a onclick="NCIAnalytics.FooterLink(this, 'Contact Us');" href="/contact">Contact Us</a>
                            </li>
                            <li>
                                <a onclick="NCIAnalytics.FooterLink(this, 'LiveHelp Chat'); window.open('https://livehelp.cancer.gov', 'LiveHelp','scrollbars=yes,resizable=yes,menubar=yes,toolbar=yes,location=yes,width=650,height=600'); return false;"
                                    href="https://livehelp.cancer.gov">LiveHelp Online Chat</a>
                            </li>
                        </ul>
                    </div>
                    <div class="large-3 columns">
                        <h2>MORE INFORMATION</h2>
                        <ul>
                            <li>
                                <a onclick="NCIAnalytics.FooterLink(this, 'About Website');" href="/about-website">About This Website</a>
                            </li>
                            <li>
                                <a onclick="NCIAnalytics.FooterLink(this, 'Cancer.gov en Espanol');" href="/espanol">Cancer.gov en espa&ntilde;ol</a>
                            </li>
                            <li>
                                <a onclick="NCIAnalytics.FooterLink(this, 'Multimedia');" href="/multimedia">Multimedia</a>
                            </li>
                            <li>
                                <a onclick="NCIAnalytics.FooterLink(this, 'Publications');" href="/publications">Publications</a>
                            </li>
                            <li>
                                <a onclick="NCIAnalytics.FooterLink(this, 'Site Map');" href="/about-website/sitemap">Site Map</a>
                            </li>
                            <li>
                                <a onclick="NCIAnalytics.FooterLink(this, 'Digital Standards');" href="/digital-standards">Digital Standards for NCI Websites</a>
                            </li>
                        </ul>
                    </div>
                    <div class="large-3 columns">
                        <h2>POLICIES</h2>
                        <ul>
                            <li>
                                <a onclick="NCIAnalytics.FooterLink(this, 'Accessibility');" href="/policies/accessibility">Accessibility</a>
                            </li>
                            <li>
                                <a onclick="NCIAnalytics.FooterLink(this, 'Comments');" href="/policies/comments">Comment Policy</a>
                            </li>
                            <li>
                                <a onclick="NCIAnalytics.FooterLink(this, 'Disclaimer');" href="/policies/disclaimer">Disclaimer</a>
                            </li>
                            <li>
                                <a onclick="NCIAnalytics.FooterLink(this, 'FOIA');" href="/policies/foia">FOIA</a>
                            </li>
                            <li>
                                <a onclick="NCIAnalytics.FooterLink(this, 'Privacy and Security');" href="/policies/privacy-security">Privacy &amp; Security</a>
                            </li>
                            <li>
                                <a onclick="NCIAnalytics.FooterLink(this, 'Reuse');" href="/policies/copyright-reuse">Reuse &amp; Copyright</a>
                            </li>
                            <li>
                                <a onclick="NCIAnalytics.FooterLink(this, 'Syndication');" href="/syndication">Syndication Services</a>
                            </li>
                            <li>
                                <a onclick="NCIAnalytics.FooterLink(this, 'Linking');" href="/policies/linking">Website Linking</a>
                            </li>
                        </ul>
                    </div>
                </div>
                <div class="row">
                    <div class="large-12 small-centered columns agencies">
                        <ul>
                            <li>
                                <a onclick="NCIAnalytics.FooterLink(this, 'HHS');" href="http://www.hhs.gov/">U.S. Department of Health and Human Services</a>
                            </li>
                            <li>
                                <a onclick="NCIAnalytics.FooterLink(this, 'NIH');" href="http://www.nih.gov">National Institutes of Health</a>
                            </li>
                            <li>
                                <a onclick="NCIAnalytics.FooterLink(this, 'NCI');" href="/">National Cancer Institute</a>
                            </li>
                            <li class="last">
                                <a onclick="NCIAnalytics.FooterLink(this, 'USA.gov');" href="http://usa.gov">USA.gov</a>
                            </li>
                        </ul>
                    </div>
                </div>
                <div class="row">
                    <div class="large-12 small-centered columns tagline">NIH ... Turning Discovery Into Health
                        <sup>&reg;</sup>
                    </div>
                </div>
                <a class="back-to-top" href="#top">TOP</a>
            </div>
        </div>
    </footer>
    <!-- END FOOTER -->

    <script id="_fed_an_ua_tag" src="https://dap.digitalgov.gov/Universal-Federated-Analytics-Min.js?agency=HHS&subagency=NCI"
        async></script>

    <!-- TO INSERT WEB ANALYTICS CODE. Every template should have this
        control else Web analytics scripts will not show up in the HTML-->

    <!-- ***** NCI Web Analytics - DO NOT ALTER ***** -->
    <script language="JavaScript" type="text/javascript" src="//static.cancer.gov/webanalytics/wcms/wa_wcms_pre.js"></script>
    <script language="JavaScript" type="text/javascript">
            < !--
var s_account = AnalyticsMapping.GetSuites("nciglobal,ncienterprise");
        -->
    </script>
    <script language="JavaScript" type="text/javascript" src="//static.cancer.gov/webanalytics/wcms/NCIAnalyticsFunctions.js"></script>
    <script language="JavaScript" type="text/javascript" src="//static.cancer.gov/webanalytics/wcms/s_code.js"></script>
    <script language="JavaScript" type="text/javascript">
< !--
            s.channel='Cancer Types';
        s.prop3 = '/types/bladder/hp/bladder-treatment-pdq';
        s.prop6 = 'Bladder Cancer Treatment';
        s.prop8 = 'english';
        s.prop10 = document.title;
        s.prop25 = '01/01/1980';
        s.prop44 = 'Cancer Types Landing Page';
        s.eVar2 = 'english';
        s.eVar44 = 'Cancer Types Landing Page';
        s.events = 'event1';

        var s_code = s.t();
        if (s_code)
            document.write(s_code);
        -->
    </script>
    <!-- ***** End NCI Web Analytics ***** -->


    <script type="text/javascript">_satellite.pageBottom();</script>
</body>

</html>